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The Schnitzler Syndrome (SchS) is a rare, autoinflammatory condition with an unknown 
pathological mechanism, but treatment with IL-1 inhibition provides remarkable efficacy.  
Exhibiting two main defining features: (1) an urticarial rash and (2) an IgM gammopathy, this 
IL-1 mediated disease phenotypically bears stark resemblance to NLRP3-associated 
inflammatory disease. The latter monogenic entity is known to show gain-of-function and 
pathological mutations in the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) 
inflammasome. Furthermore, 20% of SchS patients go on to develop overt lymphoproliferative 
diseases, namely Waldenström's Macroglobulinaemia (WM). This condition presents with a 
specific mutation in the Myeloid Differentiation Primary Response (MYD88) gene in over 90% 
of patients. Against the backdrop of these imperative findings, the work presented in this thesis 
therefore examines the role of these immunological constituents in SchS, via the assessment 
of mutations in NLRP3 and MYD88 alongside a panel of genes frequently mutated in 
haematological malignancies. Identification of a causative gene would not only improve 
molecular diagnosis, but allows for potential unearthing of genotype-phenotype correlations. 
Since the identification of this condition in 1972, the features and consequences of the IgM 
gammopathy has remained elusive. In a bid to delineate the latter, examination of the heavy 
chain of the immunoglobulin repertoire would therefore indicate aspects of the adaptive 
immune response integral to formation of the monoclonal component. A biased repertoire 
would therefore indicate the existence of a clonal B-cell population. Additionally, isolation of 
SchS-IgM and interrogation of a protein array comprising of over 15,700 human proteins 
further indicates whether this element causes pathological effects.  
Exploration of the genetic and molecular components did not expose a common mechanism 
through which SchS manifests, ruling out the notion that NLRP3, MYD88 and other associated 
genes are universally causative of this enigmatic disease. Assessment of the IgH repertoire 
indicated that SchS patients show evidence of expanded B-cell populations, and together with 
protein array analysis demonstrating the preference of IgM binding to nuclear antigens, this 
study supports the theory that SchS is a clonal disorder. The breadth and depth of these 
findings broadens the currently limited scientific knowledge pertaining to SchS, forming the 
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Chapter 1: Introduction 
Systemic Auto-inflammatory Disorders 
Characteristically distinguished by recurrent outbreaks of sterile systemic inflammation, 
‘Systemic Auto-inflammatory Disorders’ (SAIDs) are referred to as conditions of the innate 
immune system (1). The presence of high titre antibodies (Abs) or antigen-specific T cells 
characteristic of an adaptive immune response is absent in SAIDs. More particularly over the 
last decade and since the advent of Next Generation Sequencing (NGS), the SAIDs spectrum 
is broadening and included in this overarching term are Periodic Fever Syndromes (PFS), 
bearing a monogenetic basis. Being of a recurrent nature, the periodic fevers seen within PFS 
have no infectious basis (2). A majority of PFS have undergone comprehensive genetic and 
functional delineation, attributable to novel gene and mutation discovery. The NLRP3-
associated autoinflammatory disease spectrum (NLRP3-AID); Familial Mediterranean Fever 
(FMF); and Tumour Necrosis Factor Associated Periodic Syndrome (TRAPS) form the more 
well-studied hereditary PFS.  
Diagnosis of such hereditary PFS was entirely dependent upon the assessment of clinical 
manifestations and laboratory findings, up until the 1990’s. Mutations within exon 10 of MEFV, 
encoding the inflammasome associated protein, pyrin, was deemed causative of FMF (3). This 
novel finding was closely followed by the discovery of TNF-receptor associated mutations 
causal of TRAPS (1). Alongside the Mendelian mode of inheritance and significant progression 
in genetic mapping techniques, identification of many monogenic forms of SAIDs ensued. 
(Table 1). The pathogenesis of these PFS can be attributed to the aberrant IL-1β release due 
to inappropriate caspase 1 activation. Likewise, a large proportion of these conditions are 






General pathway Disease Gene Affected protein MOI 
Age of 
onset Key clinical features Treatment 
Inflammasomopathies 
FMF MEFV1 Pyrin AR/AD 0-20 yrs Peritonitis, joint attacks and joint pain Colchicine/anti-IL1 






















NLRP31 NLRP3  AD* Variable
2 Conjunctivitis, general malaise, headaches, rash, joint pain Anti-IL-1 
NLRP12-AID NLRP12 Monarch-1 protein AD Infancy 
Skin rash, lymphadenopathy, aphthous 
ulcers, abdominal complaint Anti-IL-1 /corticosteroids 
NLRC4-AID NLRC4 NLRC4 AD Infancy Infantile enterocolitis Macrophage activation syndrome Anti-IL-1/anti-IL18 



































Proteasome AR Infancy  













Vasculopathy, skin lesions (leading to 
ulcers and necrosis), Raynaud 
phenomenon 
JAK inhibition 



















N/A Infancy Early-onset inflammatory bowel disease, and progressive polyarthritis 














AR Infancy  
Amylopectinosis, increased 





















AR Variable Mottled rash (livedo reticularis) anaemia, joint pain, fatigue 





























AD* Infancy-childhood   
Granulomatous dermatitis, arthritis, 
uveitis Anti-TNF 




Aside from apparent high fever, other key clinical features are stated in Table 1 which was 
constructed using information from references (5-12).  
CANDLE: Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated 
Temperature Syndrome; CAMPS: CARD14-Mediated Pustular Psoriasis; DADA2: Deficiency 
of Adenosine Deaminase 2; FMF: Familial Mediterranean Fever; DIRA: Deficiency Of 
Interleukin-1 Receptor Antagonist; DITRA: Deficiency of the IL-36 Receptor Antagonist; 
FCAS2: Familial Cold Autoinflammatory Syndrome 2; HSCT: Haematopoietic Stem Cell 
Transplantation; LUBAC: Linear Ubiquitin Chain Assembly Complex; MKD: Mevalonate 
Kinase Deficiency; ORAS: Otulin-Related Autoinflammatory Syndrome; NLRC4-AID: NLRC4 
Associated Inflammatory Disease; NLRP3-AID: NLRP3 Associated Inflammatory Disease; 
PAAND: Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis; PAPA: pyogenic 
arthritis, pyoderma gangrenosum, and acne syndrome; SAVI: Sting-Associated Vasculopathy 
With Onset In Infancy; TRAPS: TNF-associated Periodic Fever Syndrome.  
AD: Autosomal Dominant; AID: Associated Inflammatory Disease; AR: Autosomal Recessive; 
MOI: Mode of inheritance; NSAIDs: Nonsteroidal Anti-Inflammatory Drugs.  
1 Genes that have been investigated in this study.           
2 Age of onset depends on disease severity. 
* Reports of sporadic cases as well.  





















1.1.1 Broadening the spectrum of SAIDs and PFS 
Description of new clinical phenotypes alongside utilisation of Next Generation Sequencing 
(NGS) for causative gene discovery within increasing numbers of patients worldwide, has 
inevitably expanded the spectrum of PFS (2). Since the primary genetic basis of FMF and 
TRAPS was established, the focus of genetic testing in SAIDS has successfully rendered 
identification of several new PFS. Nevertheless, there are still an estimated 50-60% of patients 
testing negative for germline mutations in genes associated with such monogenic conditions 
(13). This is markedly relevant as there are growing numbers of sporadic cases recognised in 
the clinic where patients were not determined to carry such mutations. However, upon further 
examination facilitated through NGS technology, some of these cases were determined to 
carry somatic mutations of low frequency in SAID-associated genes, initially arising from the 
haematopoietic stem cell (HSC) lineage within the bone marrow (14-17). The first indication 
of this phenomenon was described in a Japanese patient 2005, initially presenting with the 
more severe NLRP3-AID entity known as Chronic Infantile Neurological, Cutaneous, and 
Articular Syndrome (CINCA). Sanger sequencing of genomic DNA (gDNA) derived from total 
peripheral blood mononuclear cells (PBMCs) and also sorted cells (i.e. neutrophils and T cells) 
revealed the NLRP3 Y570C mutation appearing at around 20% in each of these subsets. 
Further cloning experiments established this variant alone to be ‘potent in inducing ASC 
(apoptosis associated speck-like protein containing a CARD) dependent NF-κB activation’, 
sufficient to cause disease at low percentages (18). Since the publication of this study, several 
reports utilising NGS have indicated the occurrence of somatic mutations and somatic 
mosaicism within patients diagnosed with NLRP3-AID, TRAPS and FMF (14-17), where the 
genetic component was not initially apparent. Another example of a lesser known PFS where 
this concept was also hypothesised is the Schnitzler Syndrome (SchS). In 2015, de Koning et 
al employed NGS to carry out whole exome sequencing upon gDNA and further granulocytes 
and monocytes in 11 SchS patients (19), revealing pathological NLRP3 mutations (F523L and 
K435E detected at less than 30%) in two SchS patients. Thus, novel insights into the genetics 
and pathology of these rare conditions through such investigations has not only confirmed 
appropriate treatment options (i.e. anti-IL-1 therapy for NLRP3 mutation based conditions), 








1.2 The Schnitzler Syndrome 
The Schnitzler Syndrome (SchS) is a rare, systemic disease bearing similarities with the 
monogenic SAID and PFS: NLRP3-AID (mainly Muckle Wells Syndrome (MWS)). The 
relatively late onset of SchS (presenting in the fifth decade of life) and the lack of positive 
family history portrays this as an acquired entity. Its main clinical features comprise of a 
chronic urticarial rash, periodic fevers, bone, joint and/or muscle pain and lymphadenopathy. 
With regards to biological indicators, a monoclonal immunoglobulin M (IgM) gammopathy is 
the hallmark of this condition. Prior to the introduction of the IL-1 antagonist anakinra with 
remarkable success, SchS was conventionally treated with anti-histamines for the chronic 
urticaria, with systemic and immunosuppressive agents for the systemic manifestations with 
limited effectiveness.  Near to 20% of SchS patients develop overt lymphoproliferative 
diseases such as Waldenström's Macrogobulinaemia (WM) and Monoclonal Gammopathy of 
Undetermined Significance (MGUS), with both of the latter conditions presenting with a spike 
in the monoclonal component.  Clinician unfamiliarity alongside the relatively unspecific 
phenotype of the condition renders SchS as an underdiagnosed entity (20).   
 
 
1.2.1 Differential Diagnosis and Diagnostic Criteria 
The rarity of the SchS combined with the absence of a biological or other confirmative 
assessment necessitates an extensive and differential diagnosis. Retrospective studies 
determined that obtaining a definite diagnosis of SchS takes an average of five years; 
attributed to the rarity of the disease combined with the absence of a biological or other 
confirmative assessment (21, 22). Given the overlapping features of autoimmune and 
autoinflammatory disorders with SchS (Table 1), exclusion of haematological, infectious and 
other immunological conditions, covering both acquired and inherited entities is advised prior 
to such diagnosis (23) (Table 2). The original diagnostic criteria were first developed by Lipsker 
et al., in 2001 (24). Over the past decade there have been increased reports of SchS cases, 
especially beyond Europe where this condition was first documented. Such outcomes indicate 
that SchS is more common than previously considered (24), and better recognition may be 
attributed to the revised ‘Strasbourg’ criteria published in 2013 (Table 3). The notion that SchS 
is under-diagnosed in the clinic is further highlighted by the retrospective study carried out at 
Mayo Clinic USA, where 46 undiagnosed patients were identified to fulfil SchS criteria, by 
cross referencing chronic urticarial and dysproteinaemia databases (25). Notably, this 
identified cohort was originally stratified from 4,000 patients who presented with monoclonal 
















The above conditions must be excluded before a clinical diagnosis of SchS can be made. This 
table was constructed using information from: Dingli et al., and de Koning et al. (20, 23). 
 
Lipsker 2001 guidelines Strasbourg 2013 guidelines 
Obligate criteria: Obligate criteria: 
• Urticarial rash  
• IgM component  
• Chronic urticarial rash  
• Monoclonal IgM or IgG  
With at least two of the following: With at least two of the following: 
• Arthralgia or arthritis 
• Abnormal bone morphology 
• Bone pain 
• Elevated ESR 
• Fever 
• Leucocytosis 
• Liver or spleen enlargement 
• Palpable lymph nodes 
• Abnormal bone remodelling with or 
without bone pain  
(As assessed by bone scintigraphy, MRI, or elevation 
of bone alkaline phosphatase) 
• Leucocytosis and/or elevated CRP  
(Neutrophils >10,000/mm3 and/or CRP >30 mg/L) 
• Neutrophilic dermal infiltrate on skin 
biopsy 
(Corresponding to the entity described as “neutrophilic 
urticarial dermatosis”: absence of fibrinoid necrosis and 
significant dermal oedema) 
• Recurrent fever 
(Must be >38 °C and otherwise unexplained. Occurs 
usually—but not obligatory—together with the skin 
rash) 
Table 3: Comparison of the SchS diagnostic criteria. 
 
Periodic Fever syndromes 
• NLRP3 autoinflammatory disease spectrum (NLRP3-AID) 
• TNFRS1 receptor associated periodic syndrome (TRAPS) 
• Hyper-IgD syndrome 
Immunological disorders  
• Adult Onset Still’s disease (AOSD) 
• Systemic Lupus Erythematosus (SLE) 
Haematological Disorders 
• Monoclonal Gammopathy of unknown significance (MGUS) 
• Waldenström’s macroglobulinemia (WM) 
• Multiple Myeloma (MM) 
• POEMS syndrome 
Infectious diseases 
• Hepatitis (B,C) 
• Chronic meningococcemia 
Other 
• Chronic idiopathic urticaria 
• Mastocytosis 
• Cryoglobulinaemia  
• Erdheim-Chester disease 




The Lipsker 2001 diagnostic criteria (24) were revised by Simon et al in 2013 (22). A patient 
is diagnosed with SchS if they fulfil both of the obligate criteria and at least 2 of the minor 
criteria; however preceding this, a differential diagnosis must be made to exclude the more 
frequent disorders (Table 2).The obligate criteria were amended to denote the urticarial rash 
as ‘chronic’ and include the Immunoglobulin G (IgG) gammopathy occurring in approximately 
10% of patients (known as variant type SchS). Three minor criteria from the Lipsker 
recommendations were further detailed (abnormal bone remodelling, leucocytosis/elevated 
CRP and recurrent fever), with the inclusion of a new guideline based on evaluation of 196 
cases with 76% of these demonstrating a neutrophilic dermal infiltrate (Table 4). Nonetheless, 
the 2001 minor criterion not enlisted in the 2013 guidelines (i.e. palpable lymph nodes) is still 












Published by Simon et al in 2013 (22), Table 4 provides a summary of the clinical and 
biological findings in 196 patients with SchS. These findings, in association with the Lipsker 
2001 diagnostic guidelines, formed the basis of the Strasbourg criteria which are currently 






Finding Percentage of SchS patients (%) 
Urticarial rash 100 
Elevated ESR 95 
Fever 93 
Monoclonal IgM gammopathy 89 
Kappa light chain 89 
Arthralgia/Arthritis 77 
Neutrophilic leucocytosis 76 
Bone pain 68 
Abnormal bone morphology 62 
Palpable lymph nodes 47 
Pruritus 45 
Liver and/or spleen enlargement 34 





Despite sharing many common symptoms with inherited autoinflammatory diseases, the lack 
of familial clustering and later age of onset renders SchS as an acquired syndrome (26). There 
have been no genetic studies carried out prior to the brief report published in 2015 by Koning 
et al revealing NLRP3 mutations restricted to the myeloid population of cells in two out of 
seven patients with SchS (19). Further, two SchS patients were found to have a non-
pathological variant in NLRP3, although since healthy family members also presented with the 
same mutation, it is unlikely that this is significant in the context of disease (23, 27) 
1.2.3 Clinical Findings 
As described, the fundamental clinical symptom of SchS is the chronic urticarial rash, 
accompanied by intermittent fevers; bone, muscle and joint pain; lymphadenopathy and 
hepatosplenomegaly. Exhaustion, fatigue and general malaise are also commonly reported. 
The following section describes the prevalence of SchS and further details the aforementioned 
observations. 
1.2.3.1 Epidemiology 
Since the initial description of an SchS patient in 1972 (later published as a single report in 
1974 by Liliane Schnitzler (28, 29)), around 300 cases have been reported in literature until 
date. Though the early cases were European - largely attributable to the enhanced knowledge 
of the condition in this continent. The past two decades have seen SchS patients originating 
from the USA (30) to Japan (31) and Australia (32). Notably, SchS doesn’t exhibit ethnic 
preferentiality unlike FMF where approximately a fifth of the Mediterranean and Middle Eastern 
populations are predicted to be carriers of the disease (4).  
Although one SchS patient reported that their urticarial symptoms started at 13 years of age, 
no paediatric case has been reported until date. The average age of SchS onset is 55 years, 
with a slight bias of this condition among males, marking parallels with WM where males are 
affected 50% more than females (33, 34). However the SchS male bias is contrasted to 
autoimmune disorders which generally follow a female preponderance (35).   
1.2.3.2 Chronic urticarial rash  
Usually, the recurrent, urticarial rash is the primary clinical indication of SchS. Manifesting 
mainly on the trunk and limbs, this exanthema presents as rose pink or red macules, with 
slightly raised papules with a pruritic tendency (36, 37). A similar type of rash can be seen in 
other autoinflammatory conditions such as Adult-Onset Stills Disease (AOSD) and NLRP3-




is a highly likely designation (37, 38). Occasionally, vasoconstriction and dermographism can 
be seen (39). Although common in urticarial disorders, angioedema is a rare finding, likewise 
to other PFS (40) and autoimmune conditions such as Systemic Lupus Erythematosus (SLE) 
(41). Similar to the fever, the eruptions can be aggravated by stress and usually last around 
24 to 48 hours. Interestingly, the lesions show a ‘daytime dynamic’, most ‘pronounced’ the 
evening (37, 40), comparable to non-SchS patients presenting with Neutrophilic Urticarial 
Dermatosis (NUD) and systemic inflammation (42). Appearance of the rash greatly varies 
individually. For example, the study by Gusdorf et al reported that within a 32 SchS patient 
cohort the rash appeared: daily (n=19), more than once a week (n=4), weekly (n=2) and 
monthly (n=1) (36). Without treatment, these skin flares tend to resolve under less than a 
month, though an immediate and ‘dramatic’ amelioration in the severity of the rash is 
witnessed within 48 hours upon administration of the IL-1 receptor (IL-1R) antagonist, anakinra 








(A) Prior to anti-IL-1 therapy and (B) 48 hours after daily subcutaneous administration of 
100mg anakinra showing rapid clearance of the rash. Image taken from Volz et al, 2012 (45).  
Imperatively, the histopathological analysis of a skin biopsy of a recent lesion is usually carried 
out to also search for evidence of neutrophilic urticarial dermatosis (NUD) - one of the newly 
included minor criteria in the revised Strasbourg 2013 guidelines (Table 3). The group of 
‘neutrophilic urticaria’ has never been properly defined, with literature generally referring to 
this condition as a neutrophilic aseptic disease. In a bid to avoid confusion with NUD, Kieffer 
et al (46) delineated NUD as a separate entity from neutrophilic urticaria on the basis of two 
distinct histopathological patterns. Where the latter condition is exhibited as a perivascular 
neutrophilic and eosinophilic infiltrate with dermal edema not associated with systemic 
disease, NUD is defined as a perivascular and interstitial infiltrate of neutrophils, accompanied 
by leucocytoclasia but with the absence of vasculitis and edema strongly associated with 
systemic disease (36, 46).  
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Figure 2 (A&B) shows histopathological images of a patient affected with SchS demonstrating 
characteristic NUD patterns. (A) Principally neutrophilic perivascular and interstitial 
inflammation with evidence of leucocytoclasia and (B) mononuclear cell perivascular 
inflammation. Images A and B have been taken from Sokumbi et al, 2012 (21) and are stained 
with haematoxylin-eosin stain at a 20x magnification. 
 
1.2.3.3 Fever 
Nearly all SchS patients develop intermittent fever above 39°C, though the duration of the 
episodes varies per individual (24-48 hours) (33), akin to other PFS such as FMF (47) and 
NLRP3-AID (48).  Interestingly, AOSD commonly reports elevated temperatures from the mid-
afternoon to the evening (49) indicating unknown endogenous or external triggers, but an 
equivalent observation has not been recorded in SchS. Though, environmental and biological 
factors such as cold exposure, stress and infection can exacerbate fever flares and are 
commonly accompanied with fatigue (26). Out of 174 SchS patients presenting with urticaria 
as the predominant SchS symptom, 16 appeared to have this symptom three years prior to 
fever, with one case described as having fever a year before urticaria. The other 157 patients 
demonstrated both symptoms occurring simultaneously (20), thus, the onset of fever is usually 
concurrent with the dermal manifestations of the disease. 
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Aside from the characteristic dermal manifestations, physical examination of SchS patients 
can also show abnormal organ enlargements. Evaluation of 281 cases by de Koning et al 
determined lymphadenopathy in a third of patients, with hepatomegaly and splenomegaly less 
common at around 10% (20). These swollen, palpable lymph nodes are largely in the axillary 
and inguinal regions, and can be permanently enlarged up to several centimetres presenting 
non-specific inflammation (23, 26, 37). 
 
1.2.3.5 Kidney involvement 
Five cases have been published where kidney involvement was presented alongside the SchS 
symptoms. O’Hare et al described the first known patient with renal insufficiency as measured 
by serum creatinine, followed by a kidney biopsy revealing tubulointerstitial nephritis 
associated with light chain deposition (50). This initial report was followed up by four more 
studies stating membranous nephropathy and membranoproliferative glomerulonephritis (51-
54). The described renal issues were largely resolved upon treatment with either NSAIDs or 
IL-1 inhibition.  Intriguingly, the study subjects were exclusively males and whether this is due 
to the male preponderance of the disease (39) or whether they are predisposed to renal 
ramifications in the context of SchS, is an observation yet to be examined. Nevertheless, 
reports of serum amyloidosis complications facilitates the recommendation of close kidney 
function monitoring as well, despite the infrequency of SchS kidney involvement (55). 
 
1.2.4 Biological Findings 
One of the two defining criteria of SchS is the existence of an IgM monoclonal component, 
alongside increased levels of inflammatory markers such as C - Reactive Protein (CRP), 
Erythrocyte Sedimentation Rate (ESR) and a raised neutrophilic count.  
1.2.4.1 Monoclonal Component  
The monoclonal IgM paraproteinaemia is a crucial feature of the syndrome, though in 10% of 
cases, an IgG component has been reported (24, 56). Generally, the IgM is associated with a 
kappa light chain in over 90% of patients and on primary diagnosis, the levels of this 
component can be present at trace amounts or at higher levels up to 41g/L (36). Such high 
levels (i.e. >10g/L raises suspicion of LPLs) and levels of the monoclonal component tend to 




SchS has been diagnosed without the gammopathy but have fulfilled the major and minor 
criteria for a diagnosis (57-60). As the presence of the aforementioned biological component 
is central to SchS, the nomenclature of ‘variant-type Schnitzler Syndrome’, denotes the IgG 
harbouring individuals.  
A quarter of SchS patients have lowered levels of IgA and IgG (24), though one case report 
showed a polyclonal increase in the latter antibodies (61). Upon initial identification of the 
disease, bone marrow (BM) examination is usually normal in over 80% of patients, with the 
remaining individuals exhibiting unspecific or plasmocytic infiltrates (37).  
Largely unaddressed experimentally, the query remains as to whether the paraproteinaemia 
seen is a consequence of continuous antigenic stimulation or is ‘primitive in nature’ (26) and 
is thus a by-product of the condition through unidentified mechanisms. In 2009, the clinical 
trial entitled ‘Clinical Study, Physiopathological and Search for Genetic Factors’ was launched 
in France and Italy, with the recruitment of 52 SchS patients led by Dan Lipsker (62). The 
study included the hypothesis that the monoclonal component ‘fixes’ IL-1 and lowers its 
clearance, however no results were posted or published and the trial was closed in 2017 (26, 
62). There have been two cases where treatment of the underlying gammopathy was 
beneficial, substantiating the former stance (63, 64).  No substantial change in IgM levels upon 
IL-1 inhibition is observed and could allude to the additional therapeutic capacity to halt clonal 
B cell growth – although not able to induce complete cessation (20).  
 
 
1.2.4.2 Other Biological Observations 
Inflammatory indicators CRP levels above 30mg/L (normal levels below 3mg/L) and an 
elevated ESR rate at 30 or above (healthy range between 0-20mm/hr) are frequent findings 
in over 95% of SchS patients (Table 4, (22)). Persistent neutrophilic leucocytosis 
(>10,000mm3, normal range between 1,500 to 8,000/mm3) in the absence of any therapy 
appears in over two thirds of SchS affected individuals, providing clinical relevance through 
the lack of this occurrence in autoimmune diseases such as urticarial vasculitis and 
cyroglobulinaemia . Thus, the neutrophilia observed can be considered as a discriminating 
factor between this autoinflammatory disorder and support an autoimmune differential 
diagnosis (26).  
Complement factor levels (C3 and C4) tend to be normal or raised, though a 1977 report 
alluded to two SchS patients harbouring genetic C4a deficiency (65), thus other associated 




considered when complement levels found to be low. Other findings observed in less than 
50% of SchS patients have included thrombocytosis, inflammatory anaemia and the presence 
of Bence-Jones proteins. More recently, biological indicators of abnormal bone remodelling 
and VEGF have also been observed with the latter component suggested to be included as a 
minor criterion for diagnosis of SchS (section 1.2.2.5, (66)).  
1.2.5 Unique Findings 
In 1991, Saurat et al discovered IgG antibodies directed at IL-1α in six out of nine SchS 
patients tested (67), suggested by de Koning et al to prolong the half-life of IL-1 and sustain 
the systemic effects of this cytokine (68). However, these autoantibodies were not detected in 
subsequent studies, nor were serum levels of IL-1β or IL-1Ra increased (68-72). Other auto 
antibody findings include anti phospholipid antibodies (73), IgG3 against microvascular 
endothelial and mast cells (74) and IgG2 directed against the high-affinity IgE receptor alpha 
(FcεRIα) – though not mediating histamine release (74).  
Also a manifestation of the NLRP3-AID entities - MWS and CINCA, hearing loss observed in 
one SchS patient was successfully resolved with the commencement of anakinra (33), further 
highlighting the similarities seen between SchS and NLRP3-AID. There have been several 
reports of individual cases describing disease features unique to the affected SchS patient. 
These have included eye pain (75), aortitis (76), intercostal neuralgia (77) and pancreatitis 
(78), which were all resolved upon IL-1 blocking treatment. Hence, it is highly probable that 
this collateral damage is a consequence of IL-1β dysregulation and its broad capacity to evoke 
inflammation through recruitment of additional proinflammatory mediators (79).  
1.2.6 Disease Course and Complications  
Besides a single case of spontaneous remission (80), SchS is a life-long, chronic disease with 
its complications largely attributable to existence of the monoclonal component. Prognosis of 
the condition depends on the potential advancement to lymphoproliferative disorders (LPDs), 
as those patients without LPDs have an ‘unrestricted’ life expectancy (37). Given the absence 
of a predictive marker to LPD evolution, it is thus challenging to specify the prognostic timeline 
of SchS. WM is acquired in approximately 20% of patients, with a median onset of eight years 
subsequent to the first signs of SchS. Progression to other lymphoproliferative disorders 
(LPDs) such as Chronic Lymphocytic Leukaemia (CLL) (0.1%), Lymphoplasmacytic 
Lymphoma (LPL) (3%) and Multiple Myeloma (MM) (0.5%) have also been detailed (20).  
Literature development of serum amyloidosis (AA subtype) in seven cases (20, 81-85), with 
one of these patients dying of renal failure complications prior to anakinra therapy (85).  In 




developing amyloidosis. Interestingly, there have been no reports of immunoglobulin (Ig) light 




Many SchS features are shared with both genetically determined and acquired 
autoinflammatory syndromes and also rare haematological malignancies. The NLRP3-AID 
spectrum exhibits specific characteristics such as such as chronic urticaria (namely NUD), 
neutrophilia and with the ‘dramatic response to IL-1 inhibition’ strongly highlighting NLRP3 
inflammasome involvement (26), these entities exhibit the most resemblances with SchS. 
However, a monoclonal component is not detected in NLRP3-AID, unlike in WM, LPL and 
polyneuropathy, organomegaly, endocrinopathy, myeloma protein, and skin changes 
(POEMS) where the gammopathy is a biological characteristic of the condition (86, 87), akin 
to SchS.   
Mutations in the IL-1β and IL-18 processing platform, NLRP3, were hypothesised to be the 
genetic determinant of this acquired disease, analogous to both hereditary and acquired forms 
of NLRP3-AID. Initially, de Koning et al reported the presence somatic NLRP3 mutations in 
the myeloid lineage two subjects with variant type SchS (19). However it is the prerogative of 
experts in the field that these two cases should be considered as NLRP3-AID entities (39). 
Further investigation into the mutational status of this inflammasome is presented in Results 
Chapter 2 of this thesis.   
1.2.7.1 IL-1 
Deriving similarities to monogenic SAIDs such as NLRP3-AID, IL-1β is the key inflammatory 
mediator in SchS, with previous research largely reporting increased levels of circulating IL-6 
and IL-18 (88, 89). Gene expression of PBMCs taken during the symptomatic phase of SchS 
has demonstrated high levels of both IL-1β and IL-6 mRNA transcripts, with IL-6 protein levels 
also high in sera (88). Quantification of IL-1β remains challenging due to its short half-life (2 
hours), though the central role IL-1β plays in the pathophysiology of SchS is further reinforced 
by the high efficacy of anti-IL-1 treatment and subsequent suppression of the inflammatory 
response (85, 88). Migliorini et al established that there were raised levels of IL-18 in the serum 
of two SchS patients, despite low gene expression levels in monocytes (89). The latter findings 
also support the widely accepted concept that the IL-1β/IL-18 producing inflammasome, 
NLRP3, is pivotal to the inflammatory manifestations of SchS (Figure 3).  
Regulation of IL-1 is tightly controlled given the potential potent effects of this family of 




and a few decoy receptors and soluble antagonists exist to support the regulation of both IL-
1α and IL-1β (90). Both the latter cytokines bind to IL-1R1, which in turn forms a complex with 
the IL-1R3 accessory chain, initiating downstream signalling (91). The key antagonist, IL-1Ra, 
binds to IL-1R1 and blocks the formation of the complex required to initiating of IL-1 induced 
inflammatory activation. Whilst IL-1R2 is another IL-1 binding receptor, this essentially acts as 
a decoy receptor as binding to this receptor does not result in IL-1 mediated signalling (92). 
Interestingly, the extracellular domains of IL-1R1 and IL-1R2 can be soluble, with the ability to 
capture IL-1 cytokines in circulation (90, 93).  
1.2.7.2 IL-6 and IL-18  
The other two cytokines involved in SchS pathology are IL-6 and the NLRP3-inflammasome 
generated IL-18. The former is an acute phase reactant and is known to correlate with SchS 
disease activity (94), therefore its involvement maybe anticipated during systemic disease 
(26). However, given its additional role as an essential plasma cell growth factor (20, 95), it is 
highly likely that elevated amounts of this cytokine amplifies B cell growth in SchS and could 
be a factor promoting the underlying paraproteinaemia. Although successful remission of three 
SchS patients with anti-IL-6 therapy has been observed, high levels of the monoclonal 
component remained, but long-term follow up is required to confirm these findings (96). Raised 
levels of circulating IL-18 underscores the role of the overactive inflammasome in SchS, 
marking parallels to hereditary autoinflammatory diseases such as FMF (97) and NLRC4-AID 
(98). Thus, deducing that the systemic and autoinflammatory phenotype of SchS is largely 
due to the aberrant production of proinflammatory mediators based on the described data are 
the most relevant pathophysiological indications with regards to SchS. Nevertheless, the 
precise mechanisms underlying these defective pathways remain to be further investigated.   
1.2.7.3 TNF- α 
Aside from IL-1β, other pro and anti-inflammatory cytokines have also been implicated within 
pathophysiology of SchS. The key role of TNF-α in monocyte proliferation and release of IL-
1β and IL-6, renders this effector molecule of interest in SchS pathology. Generally, TNF-α 
levels have not been widely described in SchS literature, though one 2007 report indicated 
significantly higher levels of TNF-α upon LPS stimulation of SchS PBMCs compared to HC 
(99). However, conflicting reports on the efficacy of TNF-α blockade further proves that its role 
in SchS is largely unclear. The 2010 report by Aikawa et al showed evidence of symptom 
amelioration with anti-TNF therapy (100), whereas this was conflicted with the 2007 report 
demonstrating disease exacerbation (101). Intriguingly, both reports used Adalimumab 
therefore the inconsistency observed could indicate TNF-α as a by-product of the 





Released by cells from both the innate and adaptive branches of the immune system (i.e. 
macrophages and B-cells), IL-10 is predominantly an anti-inflammatory cytokine with multiple 
effects. Where IL-10 enhances B-cell survival and antibody production (102), this molecule 
demonstrates inhibitory activity through the prevention of TNF-α release from macrophages 
(103). As SchS also involves the adaptive branch of the immune system through excessive 
IgM production, higher levels of IL-10 could be indicative of its potential contribution to the 
paraproteinaemia seen.  
1.2.7.5 IFN-γ 
IFN-γ is the vital mediator in two autoinflammatory syndromes: Haemophagocytic 
Lymphohistiocytosis (HLH) and Macrophage Activation Syndrome (MAS) and is produced by 
both the innate and adaptive immune systems (Natural Killer cells and T cells respectively) 
(104). This cytokine has also been implicated in the pathophysiology of several autoimmune 
conditions such as SLE, Sjögren’s syndrome and polymyositis (105). Therefore, investigating 
levels of IFN-γ will indicate whether this cytokine plays a role in SchS pathophysiology. 
1.2.7.6 IL-8 
Although increased levels of IL-8 have not been documented previously in NUD, probing for 
this neutrophilic chemoattractant could partially explain the neutrophilic dermal infiltration. IL-
8 primarily attracts neutrophils to sites of infection, with the secretion of this chemokine 
induced by TLR activation (more specifically TLR2 and TLR5) (106). Increased amounts of IL-
1β is noted to induce IL-8 transcription through NF-	κB activation, therefore probing for thus 
cytokine is of great relevance to this work (107).  
1.2.7.7 IL-17 
IL-17 is chiefly produced by T helper 17 (Th-17) cells and is recognised as a cause of chronic 
inflammation through its stimulation of IL-1β, IL-6, IL-8 and TNF-α production (108, 109). 
Although limited research has shown IL-17 levels not significantly raised in TH17 cells, in 
comparison to healthy controls (HCs) (109), another report stated its significance in the 
keratinocytes of one SchS patient with variant type SchS (IgG instead of IgM) (110).   
 
1.2.7.8 IL-12 
Secretion of IL-12 has been associated with both innate and adaptive immunity, inducing IFN-
γ production (111). Primarily produced by monocytes, macrophages and dendritic cells, IL-




linked (111). Aside from IL-1β, IL-6, IL-18 and TNF-α, levels of the other described cytokines 
have not been investigated before in the context of SchS and each of their presented roles 
within an inflammatory environment rationalises their investigation in the following research. 
 
1.2.8 Treatment  
Since the primary report of SchS, several treatment options have been outlined in literature. 
Prior to the introduction of successful amelioration of inflammatory manifestations in 
hereditary and autoinflammatory diseases with IL-1 blockade (112, 113), SchS patients were 
subject to an array of anti-inflammatory and immune-suppressing agents. Therapies such 
as alkylating agents, colchicine and cyclooxygenase inhibitors have been only partially 
effective (33, 55), with slight improvement in periodic fevers, ESR and CRP levels.  Steroid 
administration has been ‘highly’ or ‘partially’ efficient in 64% of patients, though long-term 
management of SchS via this therapy is followed by adverse effects such as hypertension 
and osteoporosis and is therefore not indicated (20, 33, 39, 68).  The largely non-pruritic 
urticarial eruption was typically resistant to such indications, and even antihistamines and 
ultraviolet therapy failed to resolve this manifestation, suggesting a ‘histamine independent 
aetiology’ (33). Nonetheless, the aforementioned drugs can be utilised in concert with IL-1 
inhibition as a ‘supportive’ agent (37).  
Given the inadequacy and safety concerns of the above-described treatments, the notion 
that alternative and systemic proinflammatory mediators were responsible for the 
characteristic manifestations of SchS was reinforced through the studies of both Hawkins et 
al in 2003 and 2004 (112, 113) and Hoffman et al in 2004 (114). Successful disease 
refraction in three MWS and four Familial Cold Autoinflammatory Syndrome (FCAS) patients 
using the IL-1 receptor antagonist (IL-1Ra), anakinra, underscored the imperative role of IL-
1β in NLRP3-AID pathophysiology. Following these revolutionary findings, administration IL-
1Ra in an SchS patient yielding ‘dramatic’ remission (115), subsequently paved the way for 
IL-1 inhibition becoming the mainstay SchS therapeutic choice. Other IL-1 inhibitory agents 
utilised in SchS subjects include canakinumab, rilonacept and gevokizumab (39, 55, 116).  
Worldwide, a majority of SchS patients rely on off-label treatment or depend on the inclusion 
in clinical trials as there is no approved SchS indication (55). Though in the UK, anakinra 
was commissioned for SchS therapy in 2018 based on two retrospective studies (43, 117) 
highlighting the remarkable efficacy of IL-1Ra in a total of 38 SchS patients (118). In view of 
novel treatments for SchS, there are currently two alternative compounds being tested in 




ITF2357 – an oral histone deacetylase inhibitor (Clinical Trial ID: NCT00442182). Whilst the 
former drug is in the pilot stage in ten SchS patients and ideally abrogates release of active 
IL-1β and IL-18, the latter compound is in phase two comprising of 20 subjects with 
autoinflammatory diseases, including SchS patients. ITF2357 is hypothesised to decrease 
gene expression of the acute phase response genes (IL-1β, IL-6 and TNFα) and thus aid 
the reduction of disease severity (119).  
1.2.8.1 Anakinra (Kineret®) 
Human IL-1Ra is expressed systemically by a wide variety cells including immune (120, 121), 
skin keratinocytes (122) hepatocytes (123), and even by intestinal epithelial cells where IL-1β 
was shown not to be secreted (124). The latter findings highlight the pivotal role of endogenous 
IL-1Ra, attempting to balance the proinflammatory effects of its competitive ligands, IL-1α and 
IL-1β. The pharmaceutical company Amgen generated the first non-glycosylated homologue 
of recombinant human IL-1Ra in 1993, known as ‘anakinra’ (Kineret®) in 1993, and in the same 
year trialled within RA patients (125). First approved for European use in March 2002, this 
antagonist competitively inhibits binding of the IL-1 receptor type 1 (IL-1R1) to both IL-1α and 
IL-1β (125). The recommended anakinra dosage is a once daily, subcutaneous administration 
of 100mg (22, 118), analogous to the suggested quantity for RA patients (113, 126). A few 
publications have demonstrated the safety and tolerability of the ‘modestly effective’ anakinra 
in RA (113) and the ‘remarkable sustained efficacy’ of anakinra in SchS (43). The first 
evaluative study of 472 RA patients in 1998 confirmed both the safety and moderate efficacy 
of the drug in question over a 24 week period (127) and subsequently followed by assessment 
of its long term over a longer duration of 76 weeks (128). Neel et al emulated the same in 29 
SchS subjects, over the mean course of nine years and reported ‘no loss of effectiveness’ with 
a ‘favourable tolerance profile’ (43) and a recent account by de Koning and Krause determined 
a 95% efficacy of this drug in a further 94 cases (55). These clinical findings have also been 
mirrored ex-vivo, where increased IL-1β secretion by SchS PBMCs were normalised by 
anakinra (99, 129). In spite of the clinical proficiency of this antagonist, an isolated case report 
in 2016 outlined the development of RA in concurrence with IL-1Ra treatment in one SchS 
patient suffering for nearly two decades (130). The initial response to anakinra was ‘immediate’ 
and ‘spectacular’ and was on this therapy eight years, prior to complaints of pain within hands, 
wrists and knees – but no appearance of a dermal rash (130). Whether the progression to 
autoimmunity was causally related or is a coincidental occurrence is yet to be determined, with 





The rash and fever subside within the first few hours following the primary injection (30, 43, 
68), with leucocyte counts and systemic markers of inflammation such as CRP generally 
returning to normal values within 48 hours (45).  Common adverse effects of anakinra 
administration include neutropenia, upper respiratory tract infections and an erythematous 
reaction at the injection site (20). The 2014 follow up study reported the occurrence of the 
latter side effect in five patients, in whom four achieved complete remission. Three cases 
developed neutropenia, whilst a further five developed pneumonia and one complained of a 
severe sore throat. Of note, the latter six patients were all steroid dependent prior to 
commencement of anakinra and two of these patients had already developed chronic 
obstructive pulmonary disease (COPD). Therefore, it is likely that the aforementioned factors 
predisposed these patients to developing such infections. Nonetheless, all but one patient 
continued on IL-1Ra, with the researchers concluding the ‘impressive clinical benefits’ 
evidently outweighing the ‘restrictive nature’ of the regular injection regimen (43). Although 
anakinra monotherapy results in the effective clinical alleviation of SchS symptoms, long term 
remission from the disease itself is an extremely rare observation. There are two documented 
patients where spontaneous resolution of SchS symptoms occurred (26, 80), including the 
complete disappearance of the IgM component in one (80). Such unexplained remissions 
have also been reported in the NLRP3-AID entity, MWS (131).  
 
1.2.8.1.1 Canakinumab (Ilaris®) 
Despite the tremendous response to anakinra, the ‘burden of painful daily injections’ warrants 
the need of a longer acting agent (132). Originally developed by Novartis as a potential asthma 
treatment but later contraindicated, (133), this biologic has been trialled in many studies aside 
from SchS, looking at NLRP3-AID (134-136), MVK, TRAPS and colchicine resistant FMF 
(137). The largest clinical trial entitled ‘CANTOS’ assessed the therapeutic potential of 
canakinumab in 10,061 patients suffering from atherosclerotic disease, therefore the 
therapeutic potential of this drug has been assessed in approximately 10,400 patients 
worldwide (138). These trials generally reported the reasonable capacity of this treatment in 
successfully controlling and preventing disease flares and reducing the ‘persistent 
proinflammatory response’ as evaluated by CRP levels (138).  
The evidence that IL-1β was central to the pathophysiology of SchS was further underscored 
by two European clinical trials assessing the effects of canakinumab within a total of 28 
patients (all previously on anakinra therapy) (132, 139, 140), a Russian study comprising of 
four patients (three on canakinumab) (141) and a further two patients in the USA (142). The 




dependent upon the recurrence of clinical symptoms), with all four studies reporting the 
alleviation of symptoms within hours of the first injection and high clinical and laboratory 
efficiency as measured by CRP, Serum Amyloid A levels (SAA) and Quality of Life (QoL) 
assessments. The most common adverse side effect documented was ‘mild’ upper respiratory 
infections reported in a total of 15 patients from the two clinical trials (139, 140) and whether 
these were entirely as a consequence of treatment is more challenging to decipher. Requiring 
less injections, the 28 day half-life of canakinumab in comparison to anakinra (four to six 
hours) and rilonacept (seven days) is a key advantage of canakinumab. Conversely, the major 
drawback of prescribing canakinumab is its stark price in comparison to the other IL-1 
inhibiting options. Where one dose of anakinra (100mg,	 Swedish Orphan Biovitrum AB) 
approximately costs £30, this mAb costs £9927.80 for one injection (150mg, Novartis) (143, 
144).   
The average time of relapsing symptoms in the trial by Krause et al was three months (139), 
whereas interestingly, de Koning et al reported the eight month, long-term remission in two 
patients after treatment discontinuation (140). SchS duration and indicators of disease activity 
for both these patients were similar to the other six patients included in the trial, therefore 
presuming that these particular individuals would be predisposed to sustaining longer 
remission periods could not have been anticipated. The ‘vicious’ autocrine IL-1β generating 
cycle was clearly intercepted, though the mechanism behind this sustained efficacy remains 
elusive and such findings have not been discerned in the other therapeutic alternatives used 
for this ultra-rare condition (140). Although the paucity of data requires expansion with regards 
to long term ramifications of this drug in SchS, the decent safety and efficacy profile of 
canakinumab as indicated by the aforesaid studies, renders this treatment as a promising 
candidate for SchS therapy. 
 
1.2.8.1.2 Rilonacept (Arcalyst®) 
Several autoinflammatory and autoimmune disease based clinical trials have reported the 
general efficacy of rilonacept in ameliorating the symptoms associated with excessive IL-1 
generation (145-149). In 2008, the orphan designation status was granted for the NLRP3-AID 
entities by the Food and Drug Administration (FDA) but was later withdrawn from the European 
market.  Structurally resembling an antibody, rilonacept consists of the extracellular ligand 
binding domains of the human IL-1 receptor with the IL-1 receptor accessory protein fused to 
the Fragment Crystallisable Region (Fc) fragment of humanised IgG. Thus, this recombinant 
fusion protein enables the capture of both IL-1α and IL-1β blocking the downstream effects of 




eight participants, where an initial subcutaneous injection of 320mg was followed by weekly 
administrations of 160mg (147). The ‘effective, well tolerated’ and ‘safe’ concluding remarks 
by Krause and co-workers outweighed the ‘mild’ and ‘moderate’ adverse events, none of which 
were considered related to rilonacept administration. Such findings were emulated in the 2018 
study assessing the pharmokinetics of this drug in six DIRA patients (145), with Hoffman et al 
establishing injection site reaction as the most frequent adverse event within 47 NLRP3-AID 
cohort (149).   
Akin to canakinumab, the benefits and drawbacks of this drug lie within its half-life and cost. 
The weekly injections (as opposed to daily with anakinra) is attributed to the seven day half-
life of rilonacept, thus reducing the need for injections and consequently decreasing the 
chance of injection site reactions and increasing QoL. However, the approximate cost of £4000 
per 80mg (150) and relative lack of clinical data in comparison to both anakinra and 
canakinumab largely explains the infrequent use of rilonacept in SchS. 
 
1.2.8.1.3 Gevokizumab 
Since the introduction of this compound in 2008 (XOMA/Novartis), limited trials of this mAb 
have been carried out in cancer (151), autoimmune (152, 153) and autoinflammatory settings 
(116), mainly yielding efficacious results. A French initiated study of gevokizumab in three 
SchS patients (one male, two females) over a two year period with a subcutaneous dosing 
strategy of 60mg each fortnight. The investigators reported ‘markedly improved’ global 
assessment of SchS disease activity as evaluated through clinical and biological parameters 
such as a 50% decrease in CRP levels prior to gevokizumab administration (116). Two of the 
SchS subjects were stated to develop diarrhoea, although this has not been documented as 
a side effect in the other studies (152, 153). Intriguingly, the results from the SchS trial are yet 
to be published and therefore this drug is not indicated for this autoinflammatory entity. 
1.2.8.2 Alternative treatments 
A handful of reports have reported benefit with tocilizumab (mAb against the IL-6 receptor) 
(96), B-cell depletion or modulatory agents such as rituximab (63, 154) and ibrutinib (64) and 
the antibiotic, pefloxacin (155, 156). These latter therapies are further detailed in the following 
sub-sections. 
1.2.8.2.1 Tocilizumab (RoActemra®) 
The particular success of IL-1 inhibition has rendered this line of therapy to be the mainstay 
treatment of SchS, however there have been a handful of cases where IL-1 inhibition has been 




SchS patients were reported to achieve complete remission with tocilizumab monotherapy 
within three months of the initial intravenous infusion (96). Largely indicated for RA and 
Systemic Juvenile Idiopathic Arthritis (SJIA) in concurrence with other immunosuppressants 
such as methotrexate, tocilizumab competitively binds to both the soluble and membrane 
bound IL-6 receptor alpha chain (157), thereby preventing IL-6 signal transduction and 
diminishing the proinflammatory, acute-phase response. The three aforementioned SchS 
subjects were subject to a monthly dosing strategy of 8mg/kg, analogous to the effective dose 
in RA and SJIA (55, 157). Common side effects of this IL-6 mAb include abnormal liver function 
and neutropenia (157, 158), but these have not been stated in SchS tocilizumab research 
(96).  Noted by the investigators of the latter study, the clinical parameters such as age at 
disease onset and duration of single dermatological lesions were comparable amongst those 
patients who responded to IL-1 inhibition and the trio responding to IL-6 inhibition. Therefore, 
these findings not only identify a sub-set of anti-IL-6 responding SchS patients, but highlights 
the imperative role of this acute-phase reactant in the pathogenesis of this rare condition. 
Interestingly, elevated circulating levels of IL-18 in SchS compared to healthy individuals is 
not only an indicator of inflammasome dysregulation (89, 93), but may also emphasise a 
treatment direction for those patients unresponsive to recommended SchS therapy. The 
success status of anti-IL-18 therapy autoinflammatory entities such as NLRP3-AID (159), 
accordingly warrants delineation of its role in SchS. However, such hypotheses are yet to be 
evaluated assessed in the setting of SchS. 
 
1.2.8.2.2 Pefloxacin 
Descriptions of antibiotics as a largely successful therapy in a handful of patients have 
emerged within the last two decades. The reports by Asli et al and Kastritis et al totalled 12 
SchS patients on an oral, daily pefloxcin mesylate 800mg regime (155, 156).  Antibiotic 
therapy was administered alongside other drugs such as antihistamines and NSAIDs, but not 
IL-1 inhibitory agents and concluded ‘dramatic’ and ‘sustained’ improvements in the symptoms 
(155, 156). The reasonable success of this treatment in 11 out of 12 patients underscores the 
immunomodulatory role of pefloxacin against the backdrop of sterile inflammation in 
autoinflammatory disease. It is likely that this quinolone therapeutic modified the inflammatory 
response through mRNA regulation for the IL-1 cytokine superfamily and IL-6 (155, 160). The 
case report by Kastritis et al observed a significant reduction in both the osteogenesis marker 
OPN and the angiogenesis-related VEGF (156), alluding to the musculoskeletal 
manifestations of SchS and indeed the role of these markers in autoinflammatory disease. 
These findings were emulated in 13 SchS patients assessed pre and post anakinra therapy a 




patient compliance with the agent, pefloxacin has not shown similar success in other cases. 
Thus, comparable to alternative therapies outlined, these cases may signify a subgroup of 
patients who respond well to antibiotics. 
 
1.2.8.2.3 B cell depletion agents 
In haematological diseases where the role of monoclonal gammopathy is also elusive but not 
associated with systemic inflammation, eradication of the plasma cell producing IgM 
population is highly effective (64). In 2013, SchS experts opposed the direction of treatment 
towards underlying gammopathy and highly recommended the focus to be on the 
autoinflammatory symptomatic alleviation (22). Nevertheless, a small number cases have 
been successfully treated with B cell modulatory agents such as the small molecule inhibitor, 
Ibrutinib and the mAb, rituximab (63, 64, 154, 161). The former agent is an irreversible Bruton’s 
tyrosine kinase inhibitor (BTK) and an indicated therapy for WM and CLL – both of which are 
associated with the presence of plasma cells generating the IgM monoclonal component (64). 
Ibrutinib proved effective in the treatment of an 86 year old SchS patient, leading to ‘resolution 
of existing lesions’ and ‘fewer new onset lesions’, signifying the sole case employing anti-BTK 
therapy thus far (64). Targeting the CD20 antigen on both normal and malignant cells, 
ritixumab was also an effective therapy in a few cases (63, 154, 161), but such favourable 
findings have been contradicted by other studies reporting the failure of this treatment using 
the same 375mg weekly dosing regimen (162, 163). Notably, IL-1 blockade later proved 
efficacious in these patients (162, 163). Taking the aforementioned evidence into 
consideration, the conflicting evidence and inconsistency of these atypical treatment options 
renders B-cell depleting therapies as less favoured in treating this heterogeneous syndrome.  
 
 
1.2.8.3 Treatment effects on the Monoclonal Gammopathy  
Elevated levels of the monoclonal IgM are one of the two main diagnostic criteria for SchS, a 
phenomenon also occurring in haematological malignancies such as CLL, WM and IgM-
MGUS. The observation that SchS IgM paraprotein levels tend to increase by 0.5 to 1g/L per 
year (26), suggests that the SchS mainstay IL-1 inhibition therapy is unlikely to affect levels of 
the monoclonal component. The 10 year follow up study by Neel et al, demonstrating no 
significant difference seen upon IgM levels in 10 SchS patients treated with anakinra (43). 
These findings are corroborated in literature, aside from an isolated case where treatment with 




alternative immunosuppressive agents (canakinumab, rilonacept, tocilizumab) and antibiotic 
therapy (pefloxacin) has demonstrated no significant effect upon the levels of the monoclonal 
component in each of the SchS cases presented (96, 139, 140, 147, 155, 156). Therefore 
based on this evidence, it is highly unlikely that the success of B-cell modulating agents in a 
limited number of cases is simply due to the removal of the monoclonal component. Rather, 
the favourable outcome may be attributed to the abrogation of IL-1β mediated IL-6 
upregulation within B cells (91) . A similar occurrence was initially documented in the 2017 
study looking at patients with NLRP3-AID (MWS) and X-linked agammaglobulinaemia (XLA), 
noting that PBMCs showed a markedly reduced release of IL-1β upon BTK ablation (165).   
 
1.3 The NLRP3 Inflammasome  
Despite the rarity of SchS, there is significant emphasis on a more streamlined diagnosis as 
appropriate treatment dramatically improves QoL (section 1.2.7) (39, 55). The evidence that 
over 90% of SchS patients exhibit remarkable response to IL-1 blockade supports the 
involvement of the IL-1β generating, NLRP3 inflammasome in SchS (20). Likewise, both 
inherited and acquired NLRP3-AID patients respond well to such blockade and present with 
either germline or somatic mutations in the NLRP3 gene (2). The phenotypic similiarity of SchS 
and NLRP3-AID raises the question as to whether the genetic findings in the latter entities are 
emulated in SchS. This line of enquiry in SchS was initially fuelled by the success of IL-1 
antagonism (112, 113) and cases of late-onset, acquired NLRP3-AID (14, 166, 167). Saito et 
al first demonstrated somatic mutations in exon 3 of NLRP3 in both the lymphoid and myeloid 
lineages in one CINCA patient (18). Subsequently, the advent of NGS coincided with several 
researchers investigating the prevalence of somatic mutations in those NLRP3-AID patients 
negative for mutations within the causative gene (166, 167), based on the initial discovery by 
Saito and colleagues (18). Such findings were later emulated in two SchS patients 
demonstrating myeloid cell-restricted somatic mosaicism in NLRP3 (19). Notably, the other 
nine patients included in the SchS study were negative for NLRP3 mutations (19) with other 
reports disclosing the same in a limited number of SchS cases (20). Moreover, mutations 
within this inflammasome are present in around five percent of the healthy population (168), 
therefore in this regard and in view of the NLRP3 negative SchS patients (19, 20), it is highly 
plausible that pathogenic and somatic NLRP3 mutations may not be discovered. 
Nevertheless, continuing the search within an increased number of SchS patients would 
ascertain or disprove the aforesaid phenomenon in this autoinflammatory entity. The variants 
sought may be universally present and even the limited presence in a subset of cases may 




Abundant research establishes the inflammasome as the source of IL-1β (91), therefore the 
augmented levels of this cytokine renders NLRP3 as a pivotal component in SchS disease 
pathophysiology. Exploring the involvement of other acute phase reactants such as IL-6 and 
TNF-α, and other (but not limited to) pro and anti-inflammatory cytokines such as IL-8, IL-10 
and IFN-γ, provides comprehensive insight into the dynamics of the systemic inflammatory 
response. Furthermore, seeking proof of NLRP3 components extracellularly (i.e. Apoptosis-
associated speck-like protein containing a CARD (ASC) specks) is not only indicative of 
autoinflammatory cell death (pyroptosis), but further explains high IL-1β levels as such 
domains exhibit the capability of activating this cytokine outside the cell (169). Limited 
research has denoted the augmented circulating levels of IL-6, IL-18 and TNF-α largely in-
vitro (88, 89, 99) but broad assessment of a large number of inflammatory mediators has not 
been investigated within the serum of active SchS. Irrespective of the genetic investigation, 
obtaining both direct and indirect evidence of upregulated inflammasome activity would 
reinforce its involvement in the disease and potentially reveal other pathological mediators in 
SchS. Thus, the work presented in the subsequent chapter investigates the extent of 
inflammasome dysregulation, interrogating both genetic and molecular aspects of the NLRP3 
inflammasome within SchS patients.  
 
1.4 The Connection between Autoinflammation and Clonal 
Haematopoiesis 
Clonal Haematopoiesis (CH) is outlined as the preferential expansion of a population of blood 
cells originating from a single haematopoietic stem cell (HSC) lineage (170). The existence of 
these cells can be evidenced through the presence of somatic mutations in genes conferring 
selective growth and survival advantages, and can also be determined by X-chromosome 
inactivation (XCI) - in females only (171). Whilst CH is a ‘relatively benign’ phenomenon, its 
existence can be a precursory factor to the development of Myelodysplastic Syndromes (MDS) 
and subsequently Acute Myeloid Leukaemia (AML) (170). Although both disorders 
predominantly affect the myeloid lineage, MDS is considered to be a heterogeneous group of 
haematological disorders largely characterised by peripheral blood cytopenias (172). Whereas 
the abundant proliferation of immature myeloid cells in the bone marrow is emblematic of AML 
(172).  
Emerging literature highlights the prevalence of autoinflammatory features present within a 
subset of MDS patients such as fever and a skin rash (173-175), with a further 10% of MDS 
cases being associated with autoinflammatory conditions, namely Sweet’s Syndrome (176). 




investigators recommending the initiation of IL-1 blockade amongst MDS patients against the 
backdrop of preclinical studies indicating the pathogenic role of IL-1β in haematological 
disease (176-178).  
In addition to autoinflammatory diseases, extensive research has detailed the pathological 
consequences of NLRP3 inflammasome dysregulation in the context of haematological 
abnormalities (179, 180). The importance of these comprehensive investigations resides 
within establishing the inflammasome as a focus for therapeutic intervention. For example, 
inhibition of the enzyme BTK in CLL patients resulted in a significant reduction of NLRP3 
activity, as assessed through quantification of IL-1β in comparison to healthy controls (165). 
Use of this BTK inhibitor (ibrutinib) has also yielded a reduction in SchS disease activity, 
although only trialled in a single patient (Section 1.2.7.2) (64), thus demonstrating that NLRP3 
is ‘targetable’ through this therapy. 
In 2016, Basiorka et al reported the incidence somatic variants in epigenetic modifying genes 
resulting in NLRP3 activation due to excessive Reactive Oxygen Species (ROS) production 
(179, 180), thus provoking unwarranted stimulation of the inflammasome. These discoveries 
were verified through assessment of NLRP3 components such as extracellular ASC specks 
and pyroptosis with these elements being frequent findings in patients with autoinflammatory 
disease (181). Analogous to MDS, SchS is also an acquired, late onset and heterogeneous 
disease, therefore acquisition of somatic mutations in the bone marrow during both the ageing 
and disease processes may predispose and/or amplify the proinflammatory consequences 
perpetuated through NLRP3 over-activity.   
 
1.5 Schnitzler Syndrome and Lymphoproliferative Disorders 
Though the role of the monoclonal component in SchS pathogenesis remains unclear, twenty 
percent of patients go on to develop WM (section 1.2.5), an LPD also presenting with IgM 
gammopathy - of unknown significance (MGUS) (182). Whole Exome Sequencing (WES) by 
Treon et al in 2012 revealed a somatic mutation in the Myeloid-Differentiation Primary 
Response 88 (MYD88) gene in 91% of WM patients sequenced (n=54) (182), with these 
findings paralleled a year later within a different WM cohort (183). MYD88 is an adaptor 
protein, relaying signals from the Toll/IL-1 Receptor (TIR), ultimately leading to nuclear NF- 
κB activation. The somatic mutation detailed is a single nucleotide variation (SNV) at 
chromosomal position 3:38182641 in exon 5, resulting in the leucine to proline substitution at 
position 265 (L265P) (184). Located in the TIR domain of the MYD88 protein, this gain-of-




promote NF-κB and JAK-STAT3 signalling to boost cell survival (184, 185). Other 
haematological malignancies such as activated B cell Diffuse Large B-cell Lymphoma (ABC-
DLBCL) and IgM-MGUS also bear this mutation at frequencies of 29% and 50% within these 
patient cohorts respectively (185).  
Granted that WM is not associated with systemic inflammation despite the universal 
occurrence of the aforesaid IL-1 facilitating mutation, acquisition of this somatic variant in the 
context of autoinflammation could represent a subset of those SchS patients who develop this 
LPD. Determination of the latter would also rationalise why those negative for NLRP3 
mutations are successfully treated with IL-1 inhibition. Uniting the concepts presented in 1.4 
and this section, the work presented in the second results chapter questions the role of the 
ageing haematological compartment within the setting of SchS and assesses the presence of 
certain predisposing mutations which would theoretically endorse the evolution of SchS to WM 
and other LPDs.  
 
 
1.6 Binding Capacities of the Monoclonal Component  
	
The IgM monoclonal component is one of the two main criteria required for the diagnosis of 
SchS (section 1.2.1), yet the nature of the disease association remains unclear, akin to the 
aforesaid haematological malignancies. One case reported the onset of IgM paraprotein 
occurring four years after clinical symptom presentation (186), though there is insufficient data 
to determine whether this component precedes or follows the clinical signs. Hence, 
overproduction of this Ig could either be responsible for disease onset, or its establishment 
could be a result of the heightened inflammatory response. Either supposition renders IgM 
directly or indirectly perpetuating SchS disease manifestations through activation of the 
adaptive immune system and therefore supporting a proinflammatory milieu.  
The theory of an underlying connection connecting B-cell neoplasms and potential antigenic 
stimulants have been proposed widely in literature (187, 188), therefore identification of the 
latter could reveal its effects upon disease manifestations. For example, the autoimmune Cold 
Agglutinins Disease (CAD) features mainly IgM autoantibodies directed at self-antigens 
present on red blood cells (RBCs) and subsequently causing their lysis (189). Conversely, the 
pathological function of the monoclonal component is dubious in haematological malignancies 
where B-cell neoplasms are a central trait of the condition. On the whole, research indicates 




and MM ‘unlikely’ (188), with no universal antigenic target discovered in WM (190). Also 
accounting the heterogeneity of the few targets detected in a small percentage of patients, the 
conclusions obtained are in spite of the elevated levels of the monoclonal component (188, 
190). Nevertheless, identification of potential antigenic stimuli in SchS warrants investigation 
using an unbiased target approach.  
Development of protein microarray technology has enabled the extensive detection of protein-
protein interactions. This technology has been employed in the delineation of numerous 
disease pathophysiologies, including the widespread identification of autoantibody targets in 
autoimmune diseases (191, 192). For example in SLE and RA, anti-dsDNA and anti-
citrullinated protein antibodies are a common finding (193, 194). Taking the aforementioned 
into consideration, probing the SchS-IgM protein interactions may provide clues to a potential 
antigenic target or group of related targets. Such experiments can be facilitated via the 
isolation of SchS IgM and subsequent application onto a protein microarray comprising of 
thousands of human antigens. Also supporting the genetic search for antigenic stimulation in 
SchS as explored in Results Chapter 4, execution of the protein microarray functionally 
addresses this concept through determining the binding capacity of SchS-IgM.  
1.7 B-cell Repertoire Sequencing 
The outcome of the adaptive immune response is influenced by the pool of available 
lymphocyte antigen receptors that constitute the immune repertoire. Understanding the 
composition and dynamics of immune repertoires is hence of relevance to characterising 
immunological and physiological processes, as well as understanding disease pathogenesis. 
In the context of SchS, the distinguishing paraproteinaemia of SchS highlights the role of the 
adaptive immune system in this autoinflammatory disorder, marking a very rare situation. The 
clonal expansion of B-cells is therefore implicated in the generation of the monoclonal 
component, akin to other conditions such as WM and ABC-DLBCL (182, 185). Largely of an 
IgM kappa (IgMκ) subtype, this element hence raises the query as to whether there is a 
predominant recombination pattern within the Ig genes of these patients. Biased usage of 
these Ig genes would not only indicate the existence of a clonal B cell population, but further 
questions the role of antigenic stimulation in the proliferation of a subset of SchS B cells.  
A majority of the diversity lies within the IgH region, given the two rearrangement steps and 
non-templated additions and deletions within the junctional regions. Thus, analysis of the Ig 
heavy chain (IgH) region proves the most informative for the identification of B cell clones 
(195). The unique arrangement of V (Variable), D (Diversity) and J (Junctional) - (VDJ) 
segments enables the production of diverse sets of antibodies (196), with the amino acid (aa) 




light chains, mostly determining the specificity of an antibody. While repertoire sequencing has 
not been carried out before in this autoinflammatory disorder, SchS experts have 
recommended that ‘immunoglobulin gene rearrangement study’ should be carried out where 
a diagnosis is uncertain (22). The hypothesis that SchS is in fact a B-cell clonal disorder can 
be addressed via VDJ rearrangement and CDR3 analysis. The experiments performed in 
Results Chapter 5 therefore pertain to the aforementioned suppositions.  
 
1.8 Novelty of this PhD 
The rarity combined with the heterogeneity of this condition, renders many disparities within 
SchS pathology. The studies presented in this work pertain to uncovering the genetic and 
pathophysiological mechanisms through which SchS is established. Facilitated by the access 
to samples from a tenth of the total cases worldwide and the advent of novel scientific 
technology, the investigations shown in this work have addressed both new and original 
theories that were previously unachievable due to limited resources.   
The first and second results chapters probe the mutational status of over 60 genes associated 
with autoinflammation, MDS and other haematological disorders in 30 SchS patients. Whilst 
previous work has questioned the genetic and functional role of the NLRP3 inflammasome in 
SchS, large scale genetic sequencing has not included the aforementioned categories. 
Likewise, analysis of 10 cytokines plus markers associated with the activated inflammasome 
has not been carried out previously in a relatively large cohort. 
The third and fourth results chapters address the underlying monoclonal component. Central 
to the diagnosis of SchS, the notion that the underlying IgM gammopathy plays a role in SchS 
pathophysiology has been previously surmised but not examined. Isolation of IgM followed by 
application onto a protein microarray comprising of over 15,700 human proteins thus 
addresses if SchS derived IgM binds preferentially to a particular antigen and could therefore 
be implicated in SchS disease manifestations. To supplement these findings, comprehensive 
assessment of the IgH region seeks to detect if there are indications of clonality, hypothetically 
supporting the generation of the aforesaid component. Via the assessment of VDJ 
recombination and CDR3 aa sequences, determining whether there are indications of a 
monoclonal B-cell population, hence bridges the link between the innate and adaptive immune 
networks in SchS. The outcomes shown in each of the four results chapters not only adds to 
the limited literature on SchS and are informative for clinicians and research scientists alike, 





1.9 Hypotheses of this PhD 
The work presented in this thesis endeavours to address concepts related to the pathogenesis 
of SchS. suggested through previous research of this condition and observations in other 
related IL-1 mediated monogenic autoinflammatory diseases such as NLRP3-AID and 
haematological entities where paraproteinaemia is a central feature of the condition, such as 
Waldenstroms Macroglobulinaemia.  
 
(1) SchS patients have mutations in the IL-1β /IL-18 molecular processing platform 
known as the NLRP3 inflammasome. 
The central role of IL-1β in SchS has been highlighted through the efficacious and remarkable 
response of SchS patients to IL-1 inhibition (22). Two somatic gain of function mutations in 
this gene have been detected in two patients with SchS leading to increased IL-1β release 
(19). On this basis, the hypothesis was formed that somatic mutations within the NLRP3 
inflammasome may be instigating increased levels of IL-1β. 
 
(2) A proportion of SchS patients have the MYD88 L265P gain-of-function mutation. 
Waldenstroms Macroglobulinaemia (WM) is a type of lymphoproliferative disease, of which 
20% of SchS patients go onto develop. Over 90% of WM patients were discovered to have 
the single nucleotide variation (T>C) at position 38182641 at 3p22.2 within exon 5 of MYD88, 
resulting in the L265P mutation (182). Based on these findings, the second hypothesis 
addresses if this variant is indeed present in SchS patients.  
 
(3) Oligoclonal Haematopoiesis (OH) is a feature of SchS, evident through the presence 
of additional ‘passenger’ mutations associated with myelodysplastic syndromes 
(MDS).  
Recently, upregulation of the NLRP3 inflammasome has been implicated in the pathology of 
MDS (179, 180). This latter condition is known to bear mutations in a set of genes associated 
with OH. Given the central role of IL-1 in this condition and therefore involvement of NLRP3 
in SchS, the notion that further mutations in genes frequently mutated in conditions where 





Whilst the first three hypotheses address the genetic aspect of SchS, the further two 
hypotheses focus on the characteristics of the IgM paraproteinaemia. 
 
(4) Serum derived SchS IgM binds a common antigen. 
One previous study demonstrated the infiltration of IgM in the skin lesions of three SchS 
patients (197). However, since this study, the potential pathological role of IgM generated by 
SchS patients is yet to be addressed. In other haematological and autoimmune diseases, the 
paraproteinemia may be directed towards a specific antigen. For example, in Cold Agglutinin 
Disease (CAD), the IgM generated binds a specific component of red blood cells. In a similar 
manner, it is possible that SchS derived IgM binds a common antigen or set of antigens that 
are different to other disease entities.  
 
(5) SchS bears characteristics of a clonal B cell disorder. 
Given the generation of IgM from B cells, it is considerable that there is a defect within these 
cells responsible for the paraproteinaemia. Although the paraproteinaemia seen with WM is 
not known to be pathological, there is a bias in the usage of genes used for the generation of 
antibodies (IgH region). This usage bias is indicative that the antibody repertoire of these WM 
patients are skewed towards producing antibodies generated from specific V, D and J genes 
(198). Likewise, it is possible that such bias is seen in SchS, indicating a preponderance of 


















2.1.1 Periodic Fever Syndromes 
PFS are a group of disorders characterised by recurrent episodic fevers accompanied by 
systemic or organ-specific sterile inflammation, encompassed by the umbrella term ‘Systemic 
Autoinflammatory Disorders’ (SAIDs). The clearly identifiable PFS include the NLRP3-AID 
associated FCAS, MWS;  FMF, and TRAPS (Table 1) (199). The pathogenesis of such PFS 
can be ascribed to the release of IL-1β due to inappropriate caspase 1 activation (200), with 
a large proportion of monogenic and polygenic SAIDs effectively treated with anti-IL-1 
blockade (2). The diagnostic process of PFS relied wholly upon laboratory findings and clinical 
manifestations of the disease, until the assignment of MEFV mutations causative of FMF in 
1997 (3). The Mendelian mode of inheritance of such diseases permitted the identification of 
additional monogenic SAIDs (5), allowing for a more ‘definite diagnosis’ (6). SchS is classified 
as a periodic fever, given the recurrent episodes of fever and sterile inflammation ascribable 
to IL-1β mediated pathology (22, 26) . 
 
2.1.2 The Inflammatory Response of Schnitzler Syndrome 
Aside from fevers of a periodic nature, the diagnosis of SchS relies on the fulfilment of two 
main components: NUD and IgM paraproteinaemia, in accordance with the SchS Strasbourg 
criteria (Table 3, Introduction) (22). Other symptoms of this adult-onset condition usually 
include arthralgia, myalgia and ostealgia with clinical findings comprising of elevated CRP, 
leucocytosis and lymphadenopathy (22). The imperative role of IL-1β upon manifestations of 
this condition has been widely corroborated, though whether this proinflammatory cytokine 
has effects on the IgM paraproteinaemia remains elusive. Quantification of this IL-1β 
alongside nine other cytokines (IL-6, IL-18, TNF-a, IL-10, IFN-y, IL-8, IL-17 and IL-12) 







2.1.3 The role of the NLRP3 inflammasome in autoinflammatory disease 
Constituents of the NLRP3 (Nod-like receptor – NLR) inflammasome are phylogenetically 
conserved molecules and play an important role in the recognition and subsequent response 
to danger within innate immunity (201). Unlike Toll-like receptors (TLRs), NLRs are 
intracellular sensors, forming macromolecular complexes termed ‘inflammasomes’, eventually 
mediating the maturation and release of IL-1β and IL-18 via caspase 1 (201). Under normal, 
healthy conditions, the NLRP3 inflammasome requires both a ‘priming signal’, which can be 
Pathogen-Associated Molecular Patterns (PAMPs) or endogenous cytokines such as IL-1β or 
TNF-α , followed by an ‘activation’ signal, provided by a wide range of reported stimuli such 
as ATP or particulate matter (202). Gain-of function mutations within NLRP3 lead to 
spontaneous assembly of the inflammasome (203, 204). For example, mutations in the NLRP3 
gene in NLRP3-AID constitutively activates the inflammasome which has been shown to 
spontaneously oligomerise, providing a platform for pro - IL-1β processing, due to increased 
activity of caspases 1 and 5 (13, 203) (Figure 3). Non germline mutations have also been 
reported in NLR domains and pyrin domains of NLRP3, thus causing ‘acquired NLRP3-AID’ 
(15, 17). Additionally, several reports of both the NLRP3 inflammasome and the pyrin and 
CARD domains (together forming the macromolecule ASC) have been detected in serum of 
NLRP3-AID and FMF patients (169, 205, 206). Not only is this indicative of pyroptosis (auto-
inflammatory cell death) (207), but could also serve as a biomarker of NLRP3 activation within 



















This inflammasome consists of the NLRP3 sensor molecule, the adaptor ASC (comprising of 
the Pyrin and CARD domains) and the effector molecule, pro-caspase 1. The assembly of this 
inflammasome results in the formation of active caspase-1 further cleaving proinflammatory 
cytokines such as IL-1β and IL-18 (not shown) into their mature forms. 
 
Figure 3 created with information from: Rubartelli, 2012 (208), Eitel et al., 2010 (209), Tschopp 











2.1.3.1 Somatic mosaicism in NLRP3 
Initially reported in 2005, a patient with CINCA (Chronic Infantile Neurologic Cutaneous 
Articular syndrome), the most severe phenotype of the NLRP3-AID spectrum, presented with 
negative family history for this condition.  Further evaluation by sub-cloning and subsequent 
Sanger sequencing revealed the presence of a disease-causing NLRP3 variant in 16.7% of 
whole blood derived DNA (18), though such precise quantification is debatable given the 
difficulty of detecting lower frequency mutations (especially below 20%) with this technique 
(211, 212) . Evidently this variant, even in a lower percentage of cells was sufficient to cause 
the disease phenotype (18). Following this, a case-control study on the same condition, 
comprising of 26 patients was published, showing 70% of probands harbouring NLRP3 
mutations with high grade mosaicism; which were completely absent in the healthy controls 
(15). The aforementioned study carried out deep amplicon sequencing of gDNA; where the 
mutations were all present at varying degrees. Contrastingly, in 2015, Zhou et al. carried out 
NLRP3 sequencing from the myeloid and lymphoid lineages of a suspected MWS patient 
(NLRP3-AID spectrum), who initially was reported as NLRP3 mutation negative via Sanger 
sequencing (14). Using targeted deep sequencing, these researchers identified a somatic 
mutation which was present in 15% of the myeloid lineage, underscoring the significance of 
deep sequencing as a diagnostic method in auto-inflammatory conditions (14).  
Reports of this genetic concept in auto-inflammatory disease is not limited to NLRP3-AID. 
Recently, Shinar et al reported the first case of ‘acquired’ FMF, usually an inherited disorder, 
with again the somatic variant present in 27% of the myeloid lineage (17). Interestingly, this 
R652H mutation in the FMF disease causative gene pyrin [an integral part of the 
inflammasome (Figure 3)], was present at ‘negligible’ levels prior to disease commencement; 
however after the onset of fever, the mutant allele was present at a 46% percent frequency in 
gDNA. This study also emphasised the mutated cell-dosage effect whereby the increasing 
number of cells harbouring the mutant allele correlated with disease activity (17). In line with 
these findings, 47 patients suffering from FMF who were mutation negative in pyrin by Sanger 
sequencing, were reported to have a milder phenotype than those patients harbouring the 
pyrin mutations (213). The mutation-negative patients showed milder acute and chronic 
manifestations with requiring a reduction in Colchicine therapy, as compared to mutation 
positive patients, indicating a marginal difference in phenotype.  It is likely that there are in 
fact, mutations in pyrin but only present in a subset of small cells (likely the myeloid cells), 






2.1.3.2 ASC specks 
Inflammasome sensors such as NLRP3 comprise of a pyrin domain (PYD) and a CARD 
domain, together forming the apoptosis-associated speck like protein containing a caspase 
recruitment domain (henceforth known as ASC specks) (169). Detection of danger signals or 
microbes (i.e. ATP, Nigericin) by inflammasome sensors induces the rapid polymerisation of 
PYD and CARD into a speck, which in turn activates pro-caspase-1; stimulating the latter’s 
autoproteolysis into mature caspase 1 (214). The enzymatic activity of active caspase-1 is 
employed through the cleavage of IL-1β and IL-18 from their immature forms to their active 
structures. Thus, ASC specks provide a platform by which caspase-1 is recruited, thereby 
facilitating the inflammatory response (214). Aside from NLRP3, six other inflammasomes 
(AIM2, IFI-16, Pyrin, NLRC4 and NLRP1 and RIG1) can facilitate the assembly of an ASC 
speck (169, 214, 215).  
In the context of autoinflammation, cellular release of ASC specks upon pyroptosis augments 
the inflammatory response through dissemination of these adaptor molecules through the 
extracellular environment. ASC specks demonstrated their ability to facilitate the cleavage of 
pro-IL-1β to activated IL-1β in the cell-free supernatant of NLRP3 primed and activated 
macrophages (169). Franklin et al further revealed that these extracellular specks were taken 
up by other surrounding macrophages into their phagolysosomal compartments, where ASC 
remained stable for over several hours. Baroja-Mazo et al corroborated these findings, 
detecting ASC specks in sera obtained from 18 NLRP3-AID patients with active disease and 
CRP levels over 10mg/l. In comparison to six healthy controls, levels of these specks were 
deemed significant in NLRP3-AID patients during active disease, but not significant during 
non-flare periods in these patients (214). Since the release of these papers, several 
publications have suggested the use of extracellular inflammasome components as 
biomarkers for traumatic brain injury (216), Multiple Sclerosis (217) and MDS (218). 
Accordingly, quantifying levels of ASC in sera and extracellular fluids can be an indicator of 











2.1.4 Chapter aims 
Supporting the concept of SchS as an autoinflammatory disease, assessment of the SchS 
inflammatory milieu through measurements of cytokines and ASC specks serve as additional 
markers of inflammasome activation and NLRP3 involvement respectively. Emulating 
previous experimental strategies based on NLRP3-AID, utilising NGS technology to search 
for somatic NLRP3 mutations in PB derived DNA. Therefore, the aims of this chapter are as 
follows: 
A. Deep sequencing of NLRP3 in 32 patients 
B. Detection of ASC specks present in serum as an additional marker of NLRP3 activation 
C. Serum quantification of ten interleukins associated with the NLRP3 inflammasome and 






















2.2.1 Patients and ethical approval  
Informed and written consent was obtained from all participants included in this thesis and 
subsequent published research papers. Samples were collected from three centres: St James’ 
University Hospital, Leeds, UK; The National Amyloidosis Centre - University College London 
and Department of Dermatology and Allergy - Universitätsmedizin Berlin, Germany. Samples 
were also taken from healthy donors working in the department with informed consent, to 
serve as controls for this project. Ethical approval was granted by the Leeds (East) Research 
Ethics Committee (04/Q1206/107), Royal Free Hospital and University College Medical 
School Research Ethics (06/Q0501/42) and the Universitäts-medizin Berlin ethics committee 
(EA4/005/15, EA1/007/17).  
 
2.2.2 Cytokine Detection 
The Meso Scale Discovery (MSD) platform was utilised to detect the following cytokines in 
their active form: IL-1β, TNF-α, IFN-γ, IL-6, IL-8, IL-10, IL-12p40, IL-12p70, and IL-17α. MSD 
platform allows for the detection of nine separate cytokines within a single well of a 96-well 
plate, combining both electrochemiluminscence and spatial gridding technology. Subsequent 
detection of cytokines was achieved by the addition of an MSD ECL molecule (Sulfo-Tag™), 
which requires electrical stimulation for the activation of its chemiluminescence properties. 
Imaging of the resulting light signal was measured using the MSD Sector Imager instrument.  
 
2.2.3 IL-18 ELISA 
IL-18 levels were measured using ELISA: Human IL-18 Matched Antibody Kit (Catalogue no. 
BMS267-2MST, Thermo Fisher Scientific, UK). Ninety-six well plates were pre-coated with 
human monoclonal IL-18 antibody and incubated overnight at 4°C. Both the coating antibody 
and detection antibody detect the cleaved, mature form of IL-18. Serum samples and 
standards were added to the wells, followed by the addition of IL-18 antibodies labelled with 
biotin, in combination with Streptavidin-HRP in order to form immune complexes. Unbound 
material was washed away, with Chromogen solution added until the transformation of the 
colourless solution to blue. The latter steps were carried out at room temperature. The 
fluorescence was then measured using the Multiskan microplate reader (Thermo Fisher 





2.2.4 Statistical analysis 
Statistical analysis was performed using GraphPad Prism software 8.0. The Shapiro-Wilks 
normality test was used to determine whether the resulting data was parametric or non-
parametric. The Kruskal-Wallis one-way analysis of variance (ANOVA) test was used to derive 
significances between the non-parametric data obtained for comparing more than two 
datasets. If significance was determined across the groups, comparison between individual 
pairings and correction for multiple comparisons was carried out using the Dunn’s multiple 
comparison test. A significant result was defined with a P value equal to or less than 0.05.  
 
 
2.2.5 DNA extraction 
Extraction of DNA was performed on 1 million PBMCs derived from lymphoprep (the latter 
carried from UCL and Berlin – not carried out at St James’ Hospital). Based on column 
purification, the QIAmp DNA Mini Kit (Qiagen, Germany) was utilised according to the 
manufacturer’s instructions. Purified DNA was eluted in 100µl of DNase free water 
(ThermoFisher, UK), with subsequent quantification and quality assessed using the Nanodrop 
spectrophotometer.  
 
2.2.6 PCR and agarose-gel electrophoresis 
The primary polymerase chain reaction (PCR) amplified NLRP3 from leucocyte DNA derived 
from the previous section (2.2.5), including the untranslated regions according to the following 
method. The final PCR volume of 20μL consisted of 10 picomoles of each primer (section 
7.7.1, appendix), 10μl of Phusion Green Hot Start II High-Fidelity DNA Polymerase master 
mix (Thermo-Fisher Scientific, USA) with 10-150ng of the DNA template. The reactions were 
carried out for 35 cycles: denaturation at 98°C for 10 seconds, annealing at 65°C for 5 seconds 
and elongation at 72°C for 4 minutes and 30 seconds, with 20μl of each PCR product plus 1μl 
of Midori Green Direct (Nippon Genetics, Germany), run on a 1% agarose gel in Tris-acetate-
EDTA at 90 volts for 45 minutes. The gel was visualised using gel green and the GelDoc 
system, and Quantity-One software (BioRad, USA). Bands corresponding to the correct 
fragment sizes were excised and purified using the Zymogen Gel Recovery kit (Zymogen, 
USA) according to the manufacturer’s protocol. DNA concentration was determined using the 






Library preparations were performed using the NEBNext DNA Library Prep Kit for Illumina 
(NEB, USA), according to manufacturer’s instructions. Equal amounts (20ng) of PCR products 
were pooled together. Purified amplicons were sonicated using the Bioruptor instrument 
(Diagnode, Belgium) with 0.25% SDS, at 4°C for 15 minutes using 1.5ml Eppendorf tubes, in 
order to fragment DNA as input for the following step. This was followed by column based 
purification method (Clean and Concentrate, Zymogen, UK), and the fragmented DNA eluted 
in 20µl of DNase free water (Thermo-Fisher, UK).  
 
 
2.2.6.2 End repair and dA tailing 
End repair and dA tailing was performed as a single reaction at room temperature for 30 
minutes, then 65°C for a further 30 minutes to denature the enzymes and stop the reaction. 
End repair is necessary to fill in the blunt ended overhangs generated via the sonication step, 
containing 5’ phosphate and 3’ hydroxyl groups. For the ligation of IIlumina sequencing 
adaptors, end repaired fragments require inclusion of a 5’ deoxyadenosine, but also allowing 
for ligation with complementary adaptor dT overhangs (219). As DNA input was less than 
100ng, index tagged adaptor ligation was carried out using a 1:10 dilution of the adaptor 
(originally at 15 µM) to prevent adaptor dimer formation; followed by the addition of the Ligation 
Master Mix and Ligation enhancer to the end-repaired and dA tailed amplicons from the 
previous step. Each tag was composed of a specific indexed primer sequence to enable 
identification of the patient.  
2.2.6.3 Size selection  
Due to the lower amounts of DNA derived from the initial PCR step, size selection and clean-
up of adaptor ligated DNA was performed as one step prior to PCR enrichment. DNA size 
selection is imperative for successful sequencing, as surplus lower molecular weight 
fragments such as adaptor dimers and primer dimers can interfere with the sequencing run, 
essentially preventing reads on desired DNA fragments (219). The DNA products were purified 
using AxyPrep™ bead selection procedure (Axygen, CA, USA) in a 96 well plate. 0.9x 
AxyPrep beads were added to the adaptor ligation mix, preceded by an incubation time of 5 
minutes, followed by placement onto a magnetic stand to allow for separation for a further 5 




fragment length (250bp in this work), the lower the AxyPrep™ bead ratio to DNA ratio, the 
larger the eluted DNA fragments are. Addition of Polyethene-glycol (PEG) to DNA solution 
causes the DNA to form random coiled structures (220), with the addition of sodium chloride 
enabling DNA aggregation and adhesion to other molecules in the near vicinity, including the 
beads coated with carboxyl groups. With the addition of water, hydrating the DNA, the carboxyl 
groups on the beads repel the DNA, allowing for supernatant extraction.  
2.2.6.4 PCR enrichment 
The size-selected products were then subject to enrichment using NEBNext Q5 Master Mix 
and Universal Primer. PCR is carried out to amplify DNA fragments with 2 primers, one 
annealing to the ligated adaptor, and the other ‘universal’ primer ligating to the other end of 
the adaptor ligated DNA fragment. With fragments comprising of unique adaptor sequences 
at one end, this permits the first run within the flow cell to sequence the forward strand of the 
DNA, then synthesis of the reverse. The number of PCR cycles are limited to minimise 
generation of errors, and the PCR conditions were as follows: 98°C for 1 second, 65°C for 5 
seconds and 72°C for 10 seconds, for a total of 6 cycles.  A 250bp based 'size selection' 
procedure was additionally carried out before the final enrichment step. Figure 4 provides a 
summary of the DNA library preparation workflow.  
2.2.6.5 Quality control and pooling 
The size distribution of the resultant index tagged DNA libraries was measured using the 
Agilent 2200 TapeStation system and corresponding software; using 1μl of the DNA library 
and 3μl of the D1K buffer run on D1K screen tape (Agilent Technologies, UK).  
Equal amounts of each library were pooled prior to the DNA library construction step, and for 
the final mix of all the uniquely tagged samples for loading onto the MiSeq was carried out 
following quantification by the Quant-iT™ dsDNA Assay Kit (Invitrogen, USA), which was 
utilised according to the manufacturer’s instructions. Briefly, 2μl aliquots of each PCR product 
(or the final DNA libraries), were transferred into black Costar 96-well fluorimetry plates (to 
minimise background and absorb light) (Corning, USA), alongside 2μl of the manufacturer 
supplied standard curve. Quant-it dsBR reagent was diluted (1:200) using Quant-iT dsBR 
buffer (working solution), with 198μl of this transferred into each well containing the 
samples/standards. 20μl of each standard was transferred into a corresponding well, with 
another 180μl of working solution added to these wells to give a 1/10 standard curve. The 
PicoGreen probe within this working solution is fluorescent, binding double-stranded DNA and 
forming a highly fluorescent complex in comparison to dye in solution. Fluorescence was 
measured using the FluoStar plate reader, with comparison to the 2 standard curves 

















Step 1 - DNA is first fragmented to around 250bp-300bp. Step 2 - end repair and dA tailing is 
carried out. Step 3 - adaptors are ligated to the end repaired and dA tailed fragments. Step 4 
- fragments are then size-selected and purified with AxyPrep TM beads. 5. PCR enrichment 
allows for increased DNA yields and accurate amplification using a high fidelity master mix. 
Following the above steps, the amplicons are subject to pooling and QC as described in 
section 2.2.6.5.  

















2.2.6.6 MiSeq run 
Sequencing was carried out by the NGS facility within the Leeds Institute of Medical Research 
at St James. Sequencing was performed on an Illumina MiSeq™ instrument, with a 2 x 150 
bp paired end run. The sequencing result itself generating over 3 million reads, with the depth 
of sequencing average at 5000 reads per sample.  
2.2.7 Galaxy  
Using the Galaxy platform bioinformatics interface www.usegalaxy.org (222), the sequencing 



















Each step in Figure 5 shows the file format, analysis step and tools used to analyse the data. 
























Briefly, the paired end fastq files were subject to quality control analysis using fastqc. The 
‘Trimmomatic’ tool was used to low quality data, as well as remove adaptors. Quality control 
checks on raw sequence data provided quality scores across all bases, where Q30 was 
deemed as ‘good’ based on a 1 in 1000 error probability. The Burrows Wheeler Alignment 
(BWA) allows for the alignment of short sequences less 400 nucleotides long to the selected 
reference genome (HG19). SAM files were converted to their binary format as BAM files and 
the conversion of SAM files to BAM files was required for the use of the downstream 
programme ‘GATK’. Step 3 determined the percentage of aligned reads and coverage of target 
regions, step 4 involved variant calling using GATK to minimise false positives, and to call 
SNVs & short indels. Variant annotation was step 5, and determined the potential biological 
action of SNVs and small indels; i.e. variant location, variant effect, phenotype and disease 
association. The final step was gene annotation, involving the examination of the biological 
function of the list of genes containing the SNPs and short indels obtained from the previous 
step. DAVID is an online database for analysing groups of genes. 
 
2.2.8 ASC specks  
200μl of healthy control (HC) or patient serum were incubated with 5μl of PE anti-ASC (TMS-
1) antibody (Cat. Number 653904, Biolegend, UK) for 1 hour, and subsequently analysed on 
the LSRII flow cytometer instrument (BD Biosciences, UK). Non-fluorescent 1μm 
microspheres (Cat. Number F13838 Thermo-Fisher Scientific, UK) were used as a guide to 
gate around the 1μm ASC specks. ASC speck events were reported as total events in the set 






2.3.1 Cytokine data  
Nine pro-inflammatory and anti-inflammatory cytokines were measured within sera using the MSD platform, with IL-18 levels measured using an 
ELISA. All graphs are representative of healthy controls (n=12), SchS patients (n=19) and NLRP3-AID patients (n=7), except for IL-18, where 21 
healthy controls were included in the experiment.  The Kruskal-Wallis one way ANOVA test was used to derive significances between the non-











A – IL-1β levels no significant differences observed. B - IL- 6 levels. Significant difference observed between the HC and SchS groups (***p= 
0.0005) and between HC and NLRP3-AID groups (**p = 0.0016). 





















































A – IL- 8, no differences observed between the three groups. B – IL-10, significant difference was observed between the HC and SchS groups 
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A – IL-17α, significant difference was observed between the HC and SchS groups (****p=0.0001). B – IL-18, significant difference observed 
between HC and NLRP3-AID patients (***p = <0.0003), and between HC and SchS patients (****p = <0.0001). C – IFN-γ, significant difference 
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Previously investigated cytokines in SchS have included IL-6, IL-18 and TNF-α, though these 
studies were limited to between three to ten patients. In this work, 19 SchS patients were 
subject to their serum being probed for the following ten cytokines: IL-1β, IL-6, IL-8, IL-10, IL-
12p40, IL-12p70, IL-18, IFN-γ and TNF-α. Conferring statistical power, this in contrast to 
previous studies where access to large SchS cohorts was not possible. No significant 
differences were determined between HC, SchS and the NLRP3-AID cohorts with IL-1β, IL-
8, IL-12p40, IL-12p70 and TNF-α.  
The median concentration of IL-6 in HC, SchS and NLRP3-AID groups were: 0.3 pg/ml (range 
0.2-0.8), 4 pg/ml (range 1-97) and 3.7pg/ml (range 1.8-52.6) respectively. Significant 
difference was observed between HC and SchS (***p= 0.0005) and between HC and NLRP3-
AID (**p = 0.0016) patients, but no significant difference of IL-6 was observed between the 
SchS and NLRP3-AID patients.  
 
The median concentration of IL-10 in HC, SchS and NLRP3-AID groups were 0.19pg/ml 
(range 0-0.41), 0.75pg/ml (range: 0.14 to 6.3) and 0.16pg/ml (range: 0.08-4.0) respectively. 
Significant difference was observed between the HC and SchS groups (**p=0.0016) and also 
between the SchS and NLRP3-AID patients (*p=0.0254). No significant difference was 
observed between the HC and NLRP3-AID groups.  
The median concentration of IL-17α in HC, SchS and NLRP3-AID groups were 1.07pg/ml 
(range: 0.6 – 2.46), 0.15pg/ml (range 0.05 – 0.72) and 0.27pg/ml (range: 0.12-1.9) 
respectively. Significant difference was observed between the HC and SchS groups 
(****p=0.0001), but not between the SchS and NLRP3-AID patients, or between the HC and 
NLRP3-AID groups.  
IL-18 levels were measured in healthy controls (HC, n=21), SchS patients (n=19) and NLRP3-
AID patients (n=7). The median concentration of IL-18 in these three groups were: 119 pg/ml 
(range 23-278), 750 pg/ml (range 371-1852); and 688 pg/ml (range 411-1141) respectively. 
The levels of IL-18 were similar between SchS and NLRP3-AID patients, with no significant 
difference observed between these two cohorts. However, both SchS and NLRP3-AID had 
significantly higher levels in comparison to HC.  
The median concentration of IFN-γ in HC, SchS and NLRP3-AID groups were 3.9pg/ml 
(range: 2.7-6.9), 11.2pg/ml (range: 3.3-74.5) and 7.0pg/ml (1.4-498p). Significant difference 
was observed between the HC and SchS groups (*p=0.016), but not seen between HC and 





2.3.2 PCR and agarose-gel electrophoresis 
The initial aim was to generate amplicons from PB DNA, with the primers used corresponding 
fragment length are shown in section 7.7.1, Appendix. PCR optimisation was carried out 
previously for each primer pair to determine the best PCR composition and thermocycling 
conditions in order to generate a clear, defined band. Amplicon size and primer coverage of 
the gene are further described below in the figure legends.  
 




NLRP3 is located on the long arm of chromosome one (base pairs 247,416,156 to 
247,449,108). Primers were designed to encompass each of the nine exons of this gene. The 














Figure 9: Schematic of the NLRP3 gene and primer coverage.  




Figure 10 - A,B,C & D are representative gel electrophoresis images showing the PCR 
products obtained for NLRP3 amplification run on a 1% gel . The products were run on 0.5% 
agarose gel to allow for better resolution for the larger sized amplicons. Four sets of PCR 
primers for NLRP3 were designed.  Lane 1 on images A, B C and D correspond to the 1kb 
ladder used. (A): Primer set 1 amplified NLRP3 from the 5’ UTR to the end of exon 2 – 3121bp 
product (lanes 2 and 3).  (B): Primer set 2 amplified NLRP3 from the end of exon 2 to the 
beginning of exon 4 – 2725bp product (lanes 2 and 3). (C): Primer set 3 amplified NLRP3 from 
the beginning of exon 4 to the end of exon 8 – 6918bp product (lanes 2 and 3). (D): Primer 


























2.3.3 Sample QC and pooling 
Prior to pooling the samples for MiSeq loading, two QC steps were carried out in order to 
quantitate and assess the purity of the indexed libraries: (1) TapeStation analysis to determine 









Figure 11 depicts a representative bioanalyser trace demonstrating the average size and 
distribution of the indexed library constructed from the steps described (Figure 4). 
The above trace was acquired using the Agilent D1000 DNA screen tape assay in conjunction 
with Agilent 2200 Tapestation system (Agilent Technologies, UK). Figure 11 shows the size 
fragment distribution of an indexed library for NLRP3 sequencing. The X axis refers to the size 
in base pairs of the DNA library, with the Sample Intensity (normalised fluorescence units) on 
the Y axis. The lower marker (left peak) and the upper marker (rightmost peak) correspond to 
the size markers of 25bp and 1500bp respectively. The average size of the library was 280bp, 
thus this broad peak is expected to cover the sonicated gene fragments with the adaptors 
ligated onto the DNA. The absence of other peaks (i.e. primer dimer at 50bp) within the 
sample, indicates there are no other artefacts which would interfere with the sequencing of 
the library. 




2.3.3.2 Quant it™ PicoGreen assay 
The purpose of carrying out Quant-iT™ assay was to accurately assess the amount of the 
DNA library per sample, in order to ultimately pool together the samples for sequencing in 
equimolar amounts.  
 
Figure 12 demonstrates the 8 point standard curve obtained with the assay (0-100ng/ml). The 
X-axis demonstrates the concentration of DNA in ng/ml with relative fluorescence units on the 
Y-axis (arbitrary).  
The samples were excited at 480nm with the fluorescence emission intensity measured at 
520nm. Per DNA library, equimolar amounts of each sample were pooled to generate a 
combined library with equal amounts of DNA for sequencing to prevent disproportionate 






































2.3.4 Sequencing results 
In the context of this thesis, targeted NLRP3 amplicon sequencing was carried out from the 
PB DNA of 32 SchS patients. No pathological variants were found in NLRP3 of 32 SchS 
patients. Eighteen SchS patients were also subject to additional sequencing against a genetic 
panel comprised of autoinflammatory associated genes, carried out at UCL (85) section 7.3, 
Appendix).  
2.3.4.1 Sequencing Coverage, QC and Alignment 
The number of unique reads covering a given DNA base is referred to as the ‘sequencing 
coverage’, and deep sequencing aims to generate a substantial number of individual reads 
for a given DNA sequence.  In the data obtained for this chapter, the number of unique reads 
varied from 0 to 7340 per sample. The QC step assessed the quality of these unique reads 
obtained (Galaxy). Alignment to the reference Human Genome, GRCh37, permitted detection 
of potential variants in the genes analysed. This latter step was carried out by BWA and 
visualised using Integrated Genome Viewer (IGV) (Figure 15).  
 








Schematic showing the sequencing coverage and alignment of the amplicon sequencing 
carried out in this chapter. Yellow (indices), blue (DNA fragment). Employment of paired end 
sequencing enabled both ends of the input DNA fragment to be sequenced. As the distance 
between each end was known (250bp-300bp), alignment to the reference sequence was more 

























Box plots are generated by Galaxy for each sample, indicating the quality scores across the 
bases. The yellow boxes represent the 25th to 75th percentiles, with the upper and lower 
whiskers demonstrating the 10th and 90th percentiles respectively. The Y-axis refers to the 
Phred quality scores, with the X-axis showing the results in correlation to the position in the 
read (1-150). A Phred score of 30 implies that the probability of an incorrect base call is 1 in 
1000, and a 99.99% base call accuracy. Whereas a decreased Phred quality score of 20 
implies the probability of an incorrect base call is 1 in 100, with a 99% base call accuracy. In 
this sample, all QC scores are above a Phred score of 20, therefore indicative of a 99% to 





















Figure 15 is a representative snapshot of sequencing analysis from Integrated Genome 
Viewer (IGV - Broad Institute, Boston, USA). The image portrays the sequencing results 
obtained first two exons of NLRP3 (position 1:247,585,750 to 1:247,590,451 for SchS sample 
one, aligned against the reference genome: GRCh37. The portion of the chromosome 
displayed is shown in the top box, the read coverage is shown by the track in the second box 
and the third box specifically indicates the coverage across the exonic and intronic regions of 
the gene being analysed. Here, NLRP3 exons one and two are shown. The fourth box shows 
a grey bar which is representative of an individual read, with the sizes of the inserts varying 
from 200bp to 300bp in the sample shown.  These grey bars change colour if there are 20% 
of the nucleotide reads in the sequenced sample that differ to the reference nucleotide. 










2.3.4.2 Additional sequencing panel at UCL 
These negative genetic results were further strengthened by the simultaneous findings of 18 
SchS patients (patient 12 - 28, 32, Table 5), involving the sequencing of hot spots within genes 
associated with autoinflammatory disease. The aim to identify a common genetic susceptibility 
factor to SchS was pursued by Rowzcenio and colleagues at UCL. The panel comprised of 
genes such NLRC4, NOD2 and TNFRSF1A, (section 7.3 Appendix), but failed to identify any 
unifying variants causative of SchS. These outcomes, alongside the results of this chapter 
were published as a regular article in Blood (85). 
2.3.5 ASC specks are elevated in autoinflammatory diseases   
Upon their activation, inflammasome forming receptors nucleate ASC molecules, instigating a 
prion-like aggregation event, forming ASC ‘specks’. These specks are 1µm in diameter, 
enabling the subsequent activation of caspase-1 (223). High levels of these specks have been 
previously identified in NLRP3-AID patients, thus determination of levels of ASC in 16 SchS 












Extracellular ASC protein aggregates and cytokines levels were measured in the serum 
collected from 16 SchS patients, 7 NLRP3-AID patients who had germline mutations in the 
NLRP3 gene and 11 HC, before administration of IL-1 blocking therapy. Significance was 
determined between HC and SchS (*p = 0.0069) and also between HC and NLRP3-AID (*p = 
0.0309) No significant difference was observed between the NLRP3-AID and SchS cohorts.  




2.3.6 Clinical Data summary of the SchS patients 
Patient	
number	










1	 M	 62.0	 IgMk	 6	 Y	 complete	 79.6	 ND	 	
2	 W	 43.5	 IgMk	 17	 Y	 good	 60.9	 ND	 	
3	 M	 51.5	 IgMk	 8	 Y	 good	 44.0	 ND	 	
4	 M	 67.0	 IgMk	 8	 Y	 complete	 8.0	 ND	 	
5	 W	 54.5	 IgMk	 3	 Y	 good	 254.0	 ND	 	
6	 W	 72.5	 IgMk	 11	 Y	 complete	 86.0	 ND	 	
7	 W	 55.5	 IgMk	 5	 Y	 complete	 92.5	 ND	 	
8	 W	 53.0	 IgMk	 5	 Y	 complete	 12.0	 ND	 	
9	 W	 60.0	 IgGk	 N/A	 Y	 good	 70.0	 ND	 	
10	 W	 72.5	 IgMk	 3	 Y	 good	 14.0	 ND	 Q703K**	
11	 M	 62.0	 IgMk	 3	 Y	 good	 26.0	 ND	 	
12*±	 M	 36.8	 IgMk	 3	 Y	 Partial	 40.0	 49.3	 	
13*±	 F	 37.9	 IgMk	 3	 Y	 complete	 257.0	 24.4	 	
14*±	 M	 43.9	 IgGλ	 N/A	 Y	 complete	 60.0	 376.2	 	
15*±	 F	 44.8	 IgMk	 1	 Y	 complete	 120.0	 247.2	 	
16*±	 F	 49.6	 IgMk	 4	 Y	 complete	 89.0	 460.6	 	
17*±	 M	 49.9	 IgMk	 9	 Y	 complete	 19.0	 ND	 	
18*±	 M	 52.8	 IgMλ	(IF)	 N/A	 Y	 complete	 45.0	 309.3	 	
19*±	 M	 57.1	 IgMk	 7	 Y	 complete	 18.0	 430.6	 V198M**	
20*±	 M	 58.1	 IgMk	 3	 Y	 complete	 49.0	 87.5	 	
21*±	 M	 59.6	 IgMλ	 7	 Y	 died	before	treatment	 79.0	 544.7	 	
22*±	 M	 61.7	 IgMk	 5	 Y	 complete	 40.0	 ND	 	
23*±	 F	 60.7	 IgMk	 9	 Y	 complete	 112.0	 897.2	 	
24*±	 F	 68.4	 IgMk	 8	 Y	 complete	 140.0	 398.8	 	
25*±	 M	 78.9	 IgMk	 7	 Y	 complete	 143.0	 659.5	 	
26*±	 F	 39.7	 IgMk	 16	 Y	 complete	 26.0	 ND	 	
27*±	 M	 40.7	 IgMk	 4	 Y	 complete	 20.0	 558.1	 	
28*±	 M	 61.2	 IgMk	 8	 Y	 complete	 80.0	 104.2	 	
29±	 M	 43.6	 IgMk	 6	 Y	 complete	 75.2	 394.1	 	
30±	 F	 59.0	 IgMk	 5	 Y	 complete	 110.0	 100.2	 	
31	 F	 51.0	 IgMk	 14	 Y	 complete	 ND	 ND	 	
32*	 M	 41.9	 IgMk	 12	 Y	 complete	 18.0	 ND	 	
Table 5: Clinical Data Summary of SchS patients.
Table 5 indicates the clinical data obtained for the SchS patients included in this chapter, alongside ASC speck levels and NLRP3 status. 
±Patients included in the cytokine analysis using the MESO platform and IL-18 ELISA. *These patients underwent further sequencing at UCL.  
ND: Not done.  **common non-pathogenic NLRP3 variants unlikely to be disease causative and have shown to be present in healthy individuals. 





The purpose of the work undertaken in this chapter was to assess the inflammatory milieu of 
SchS patients and investigate the presence of somatic mosaicism in two genes imperative to 
inflammasome functioning. The MSD platform was employed to detect cytokine levels and use 
of flow cytometry enabled quantification of ASC speck levels. For the genetics part of this 
chapter, NGS was used to assess if the phenomenon of somatic mosaicism was applicable to 
the cohort of SchS patients included in this research. 
 
To summarise, the main findings in this chapter were: 
i. IL-6 and IL-10 levels were significantly raised in 19 SchS patients 
ii. IL-18 levels were also significantly elevated in 19 SchS patients 
iii. No causative NLRP3 variants identified in 32 SchS patients 
iv. ASC specks detected in the serum of 16 SchS patients are significantly elevated 
in comparison to healthy controls, and similar in values to those in NLRP3-AID 
patients  
 
2.4.1 Cytokine data 
The cytokine profiles obtained from 19 SchS patients, prior to the commencement of IL-1 
blocking therapy, supports the concept of SchS as an autoinflammatory disease. Though the 
complete remission of SchS through inhibition of IL-1 strongly supports the role of IL-1 in the 
pathophysiology of this disease, assessing endogenous levels of the latter cytokine has 
proved challenging. For example, IL-1β was virtually undetectable in seven patients with active 
NLRP3-AID (135), in part owing to its short half-life of two hours. Further, unlike TNF-α or IL-
6, large amounts of the inactive, pro-IL-1β remains within the cell. Once released, active IL-
1β binds to large carrier proteins such α2 macroglobulin (720kDa) and can therefore escape 
detection (224). Thus, the lack of significance seen with IL-1β in this work rather pertains to 
the difficulties in cytokine quantification. 
Contrastingly, IL-6 and IL-18 and can be regarded as biomarkers of disease severity given 
that elevated levels of these cytokines have been previously established in SchS (89, 225), 
RA (226) and other autoinflammatory disorders such as AOSD (227). In this work, levels of 




quantities to those found in NLRP3-AID. Similar to IL-1β, IL-18 undergoes caspase-1 
processing for biological activation, whilst IL-6 production is under the strict control of IL-1β.  
Although TNF-α may contribute to the inflammatory status of SchS, its lack of significance 
indicates that it does not play a central role and could support the little evidence in literature 
indicating the limited efficacy of anti-TNF therapy (100) .  
Deficiency of IL-10 and lack of IL-10 receptor mediated signalling causes proinflammatory 
disease (i.e. severe early-onset enterocolitis) (228), thus high levels of this cytokine 
documented in SchS patients prior to inflammatory resolution, indicates its anti-inflammatory 
role within the immune system. Inferring that the insignificant amounts of TNF-α seen in this 
data is in support of previous findings demonstrating IL-10 mediated suppression of TNF-α 
and IL-17 secretion from macrophages and T cells (103, 229). Moreover, as referred to in 
section 2.1.2 - raised levels of IL-10 could be maintained through its active role in B-cell 
proliferation and its autocrine release from these cells (102). 
Although no significance was seen between the three groups, seven SchS patients alongside 
three NLRP3-AID patients demonstrated increased levels of IL-8 in comparison to HCs. The 
production of this neutrophilic chemoattractant from macrophages is understood to be 
stimulated by IL-1β and TNF-α (107).  
Interestingly, IL-17 levels were significantly lower in SchS in comparison to the HCs, but 
demonstrated similar values to NLRP3-AID. Though IL-17 was found elevated in the 
keratinocytes of one SchS patient (110), assessment of this cytokine in a larger group of SchS 
patients rendered no significant values whilst assessing TH17 secretions (109). The patient 
mentioned in the former paper was a variant IgG type SchS patient and thus more SchS 
patients (IgM type) are necessary to strengthen and corroborate these findings. Further, the 
significantly high amounts of IL-10 within these patients could explain the IL-17 results. 
Literature has shown macrophage-producing IL-10 negatively regulating IL-17 generation 
through suppression of the Th-17 promoter and transcription factor: RAR-related orphan 
receptor gamma (RORγt) (229).  
 
2.4.2 NGS of the NLRP3 gene 
The emergence of SAIDs with a genetic basis rationalised the experimental approach taken 
in this section. Implication of the NLRP3 inflammasome in SchS pathophysiology through 
detection of its elevated components in serum and cytokine analysis, validated searching for 
variants within its gene. The emergence of aNLRP3-AID demonstrated that low level somatic 




apparent case for SchS. Sequencing the entire NLRP3 gene excluded the notion that NLRP3 
mutations are responsible for SchS pathology within a total cohort of 32 SchS patients (Table 
5). The prospect that aNLRP3-AID may be attributed to somatic NLRP3 mutations with its 
close clinical similarity to SchS, raised the likelihood of somatic NLRP3 mosaicism as a 
potential contributor or cause of SchS disease manifestations. This hypothesis was originally 
investigated by de Koning et al in 2015, reporting that two out of seven SchS patients 
harboured two different NLRP3 mutations, F523L and K435E, restricted to the myeloid lineage 
only (19). This hypothesis has proved incorrect in this presented work, although the disparity 
between these findings could be due to the fact that the patients involved in the 2015 report 
had variant IgG, whereas this cohort of patients largely present with the typical IgM 
gammopathy seen with SchS. Nevertheless, no link has been made with NLRP3 mutations 
and gammopathy in published literature as yet.   
 
2.4.2.1 UCL panel 
Forming a panel of genes associated with auto-inflammatory disease not only statistically 
increases the chances of finding a causative mutation with all types of sequencing, but 
association of the clinical findings with genetic status can enable focused treatment (230, 231). 
Taking the latter into consideration, further research by Rowczenio et al (85) revealed that 18 
SchS patients (patients 12-28, 32, Table 5), did not harbour disease-causing mutations within 
hotspots of 32 genes associated with the inflammasome and inherited autoinflammatory 
diseases. The complete list of the 32 gene hotspots are outlined in section 7.3 within the 
Appendix. 
2.4.3 ASC specks  
Activation of the inflammasome ultimately leads to caspase-1 activation through the action of 
nucleated ASC specks around 1µm in diameter. Activation of caspase-1 enables the 
proteolytic cleavage of the proinflammatory cytokines (IL-1β and IL-18) into their active form, 
as well as facilitating pyroptosis (232). ASC specks are believed to be released into the cellular 
milieu through the aforementioned form of regulated cell death, though its recruitment of 
caspase 8 and subsequent apoptotic cell death has been noted (233).  
Quantitative assessment of ASC specks in the sera of 16 SchS patients prior to the 
commencement of IL-1 blocking therapy demonstrated significantly elevated levels of this 
component in comparison to 11 HC’s, but similar amounts to 7 NLRP3-AID patients. Thus, 
acquisition of indirect evidence that SchS is associated with upregulated inflammasome 




In 2014, Baroja-Mazo et al published data showing that ASC specks found in the sera of 
NLRP3-AID patients were significantly high in comparison to healthy controls (214). Building 
upon this work, high levels of ASC specks were reported within the serum of 6 untreated 
NLRP3-AID patients harbouring germline or somatic NLRP3 mutations as opposed to 3 
healthy volunteers (167). In the latter paper, follow up of ASC specks during the course of a 
year showed a gradual decrease in those patients whose CRP remained in the reference 
range (i.e. below 3g/l), with previous research demonstrating values of ASC comparable to 
those seen in HCs during remission periods (214). Although the ASC data shown in this work 
do not appear to correlate with CRP levels (Figure 17), further quantification before, during 
and after a disease flare with the corresponding CRP levels may reveal a correlation. Should 
the latter notion prove correct, this would strengthen the value of ASC as a biomarker of SchS 











There are several limitations for the determination of ASC specks, thus the results shown are 
not conclusive, but are rather considered as another indicator of inflammasome activation. 
One such limitation is the absence of data pertaining to the long term stability of ASC specks 
in frozen sera samples. There is a likelihood that degradation occurred during the storage 
period and thus ASC speck levels could be higher when utilising this assay on freshly obtained 
sera, although this speculation remains clarification. 
Elevated ASC speck levels are unlikely to be characteristic of either SchS or NLRP3-AID 
alone, or where inflammasome activation is integral to the pathophysiology of a given condition 
(i.e. Gout). Though discrimination in view of SchS/NLRP3-AID versus other autoinflammatory 
disorders may be possible, as both FMF and TRAPS have demonstrated very low amounts of 























2.4.4 Chapter conclusions 
In summary, levels of IL-6, IL-10, IL-18 and IFN-γ were significantly raised in SchS, with similar 
levels of IL-6 and IL-18 observed in the NLRP3-AID control group. IL-17 was significantly 
decreased, with levels of IL-8, IL-12p40, IL-12p70 and TNF-α comparable to HCs. Comparison 
of these cytokines during periods of inflammatory flares versus remission would further 
indicate the interplay between these that have not been reported in literature. Likewise, in view 
of ASC specks, comparisons of levels between flare and non-flare periods would demonstrate 
the levels of these inflammasome components released likely due to auto-inflammatory cell 
death (pyroptosis), thereby contributing to the augmented inflammatory phenotype. 
Though the sequencing results of this chapter indicate the absence of NLRP3 variants in 32 
SchS patients and absence of somatic mosaicism in the NLRP3 and MEFV gene within 2 
SchS patients whom were subject to cellular sorting, indirect evidence of inflammasome 
activation was sought through the detection of extracellular ASC specks. Notably, DNA and 
serum samples were obtained from SchS patients prior to starting therapy with anakinra, thus 
the results obtained in this chapter are representative of a disease state (cytokine and ASC 
analyses). The novelty of the research presented in this chapter is largely attributed to the 
access to the relatively large cohort of SchS patient samples, given the rarity of this condition 

















Chapter 3 Exploring the role of Clonal Haematopoiesis in Schnitzler 
Syndrome 
3.1 Introduction  
3.1.1 The MYD88 L265P mutation 
The Myeloid Differentiation Primary Response 88 gene (MYD88) codes for the critical adaptor 
protein required for the downstream signalling of the Toll-like receptors (TLRs) and IL-1 
superfamily within immune cells (234). Initially described as a protein integral to terminal 
differentiation of myeloid cells upon IL-6 induction (235), this adaptor has since been 
documented to play a key role in early haematopoiesis. TLR exposure to PAMPs results in 
MYD88 dependent signalling (Figure 18 below), leading to proliferation of HSCs and precursor 
myeloid and lymphoid cells (236). Besides the latter, TLR/MYD88 is found in mesenchymal 
stem cells (MSCs), giving rise to several cell types including osteocytes and fibroblasts (236). 
MYD88 signalling directly and indirectly influences the development of both HSC and non-
HSC lineages. Upon receptor stimulation by microbes or viral proteins for example, the MYD88 
protein subsequently phosphorylates downstream proteins, ultimately leading to nuclear 
factor-kappa-B (NF-κB) mediated transcription (Figure 18, below).  Regulating the activity of 











Following IL-1R or TLR stimulation, MYD88 forms complexes with IRAK4, together 
phosphorylating IRAK1 and IRAK2 (denoted by ‘P’ in Figure 18). Phosphorylated IRAK1 
interacts with tumour necrosis factor receptor–associated factor 6 (TRAF6) leading to IKK 
phosphorylation and subsequent activation of the transcription factor, NF-κB activation (239). 
Figure 18: MYD88 dependent pathway. 
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Alterations in MYD88 activity are associated with both haematopoietic and non-
haematopoietic conditions. For example, MYD88 was shown to be fundamental to tumour 
development during skin carcinogenesis (240). Conversely, genetic variants in MYD88 are 
also found in a subset of patients with B-cell LPDs such as ABC-DBCL and IgM-MGUS (185). 
Although several mutations in MYD88 have been identified (184), the leucine to proline 
substitution at position 265 of MYD88 due to a single nucleotide variation (SNV) in exon 5 
(38182641 at 3p22.2) is of particular clinical significance. Situated in the Toll receptor/IL-1 
interaction domain (TIR domain) (Figure 19, below), the substitution triggers the spontaneous 
formation of the MYD88-IRAK complex, leading to enhanced NF-κB signalling and has shown 
to encourage cell survival (184, 185) . Hence, this mutation is referred to as ‘gain-of-function’ 
(182, 241).  
 
MYD88 has a death domain (DD), an intermediary death domain (ID) and a TIR domain. The 
L265P variant sits within the TIR (approximate position indicated by red arrows) and affects IL-1 
signalling.  
 
3.1.2 Waldenström’s Macroglobulinaemia 
As mentioned previously (Section 1.2.5), 20% of SchS patients develop Waldenström’s 
macroglobulinaemia (WM), a type of non-Hodgkin lymphoma characterised by IgM 
gammopathy due to uncontrolled proliferation of B cell progeny (182). Over 90% of WM 
patients carry the L265P gain-of-function mutation in MYD88 (182, 242), though the 
consequence of this variant in WM is yet to be fully delineated in terms of the associated IgM 
paraproteinemia (182, 243). WM cell lines harbouring the L265P variant show increased 
activation of the NF-κB pathway, ultimately leading to elevated production of proinflammatory 
cytokines such as IL-1β (Figure 20) (244). Therefore, presence of this mutation could be 
explanatory of the elevated IL-1β release witnessed in SchS patients, also rationalising why 
those negative for NLRP3 mutations are successfully treated with IL-1 inhibitors. This notion 
has also been previously addressed in the review by de Koning et al in 2014, proposing that 
the aforementioned mutation might be present in a subset of SchS patients, hence contributing 
to the IL-1β-dependent character of SchS (20). 























Figure 20 illustrates the proposed mechanism by which the mutant MYD88 L265P augments 
the inflammatory milieu of SchS. Activation of mutant MYD88 can cause constitutive 
downstream signalling, resulting in the increased translocation of NF-κB to the nucleus and 
subsequent transcription of components of the inflammasome, as well as the inactive forms 
of the proinflammatory cytokines, IL-1β and IL-18. Upon signalling (requiring two hits), 
inflammasome assembly and subsequent activation causes release of the active forms of the 
aforesaid cytokines and also ASC specks.  
Probing for this mutation in a non-HSC derived cell population would confirm whether this 
somatic mutation is confined to the HSC lineage or not. Given the varied proinflammatory and 
cell survival effects of this mutation in HSC derived cells, its presence in fibroblasts could 

































DNA from lymphoid and myeloid progenitors, and fibroblasts were sequenced in the following 
work for the MYD88 L265P mutation in 30 SchS patients.  
 
3.1.3 MDS and autoinflammatory disease  
An altered HSC compartment is a feature of the ageing bone marrow and an increased 
incidence of myeloid malignancies is a common finding after the 5th decade of life (170). 
Analogous to autoinflammatory disease, activation of the NLRP3 inflammasome and TLR 
upregulation has been implicated in the pathology of myelodysplastic syndromes (MDS) (179, 
180). Research has shown that MDS-related somatic mutations in TET-2 and U2AF1, genes 
encoding for transcription and splicing factors respectively, stimulate the generation of reactive 
oxygen species (245). In turn, this triggers NLRP3 inflammasome formation and caspase-1 
activation, as evaluated by the presence of ASC specks and consequential pyroptosis.  
The preferential growth of the myeloid lineage can be substantiated by the clonal expansion 
of myeloid-biased HSCs, the latter largely due to the accumulation of somatic mutations within 
certain genes involved with growth and differentiation of these cells (246). On average, MDS 
tends to present in the 6th decade of life with symptoms of SchS tending to establish a decade 
earlier (55, 246). Therefore, it is reasonable to consider that mutations driving the MDS 












Figure 21: The development of haematopoietic and mesenchymal 




3.1.4 X inactivation  
An altered HSC compartment has already been established as the leading feature of the 
ageing haematopoietic system, with analyses of large populations demonstrating that somatic 
mutations in HSCs, leading to expansion of a subset of cells (referred to as clonal 
haematopoiesis, CH), are commonly acquired during ageing (247). A clonally restricted 
haematopoietic compartment is associated with increased prevalence of myeloid or lymphoid 
malignancies and such malignancies can be associated with X chromosome inactivation 
(XCI). Though only relevant in females, such assessment of XCI has identified skewing as an 
age-related occurrence, particularly prominent in the myeloid compartment (248).  
The X chromosome is approximately 150MB in size, harbouring over 1250 genes such as 
Bruton’s Tyrosine Kinase, (BTK - crucial role in B-cell development) and NEMO (downstream 
signalling protein in the MYD88 pathway) (249). Primarily hypothesised by Mary Lyon in 1961 
(250), XCI is an event occurring early in embryogenesis, where one of the two X chromosomes 
in each cell is subjected to specific modifications. Ultimately, this epigenetic phenomenon 
results in the dosage compensation of X-linked proteins between males and females through 
the random silencing of one X chromosome in females (249). Non-random silencing, either 
caused by chance or directed by genetics, can lead to the under or overrepresentation of 
genes. For example, tumour suppressor genes (i.e. FOXP3) located on the X chromosome 
maybe subject to under or overexpression dependent upon the XCI status (251). 
Hypothetically, the presence of XCI could then predispose or diminish the chance of 
developing malignancy. 
Particular genes located on the X chromosome (i.e. G6PD and HUMARA), are highly 
polymorphic amongst individuals and molecular analysis techniques permit resolution of these 
alleles (252). Recent data from five studies have suggested employing the HUMARA assay 
alongside use of NGS sequencing within frequently mutated genes associated with CH, may 
aid the identification of those at higher risk of haematological malignancy (171, 248, 253-255). 
Therefore, application of the HUMARA assay to determine the XCI status is alternative way to 

















Normal female somatic cells comprise of one maternal (M) chromosome and one paternal (P) derived 
chromosome (XP/XM). During embryogenesis, one X chromosome is randomly inactivated, leaving one 
active X chromosome (XP or XM). The pattern of inactivation is then passed onto the cell populations 
derived from the originating cell. Hence, females are heterozygous for the polymorphic X chromosome.  
 
3.1.5 The Role of CH in SchS 
A handful of research papers have explored the possibility of variants within certain genes  
involved within SchS pathology (19, 85). Despite the identification of mutations likely to be 
disease contributing, no universal mutation has been found within autoinflammatory gene 
panels. Finding a causative gene will not only be extremely indicative of downstream SchS 
pathology, but would also facilitate reducing the average time of diagnosis, currently around 5 
years (20, 33).  Therefore, the research in this chapter largely focuses on further investigations 
into the genetics behind this intriguing condition in search for a common genetic component 
unifying all 30 SchS patients included in this work. Taking the detailed concepts (Sections 
3.1.1, 3.1.3 and 3.1.4) into consideration, the hypothesis was formed that SchS patients may 
harbour the MYD88 L265P mutation, whilst demonstrating evidence of clonality in the form of 
MDS associated mutations, as a consequence of a shrinking pool of HSC’s. Therefore, the 
aims of this chapter are as follows: 
 
A. Deep sequencing of 28 MDS related genes in 30 SchS patients   
B. Detection of the MYD88 L265P mutation via ASO-PCR in 30 SchS patients  
C. Investigate the status of XCI to determine if this is a feature of female SchS patients 
 





3.2.1 Primary fibroblast explant culture 
Under aseptic conditions, fresh skin punch biopsies were transferred into PBS supplemented 
with antibiotics (penicillin/streptomycin). Using forceps, the dermis was separated from the 
epidermis and cut into 1mm diameter fragments using surgical blades and placed into T25 
flasks. The fragments were left for 10 minutes to allow for flask adherence before addition of 
5mls of DMEM supplemented with 10% fetal calf serum and antibiotics (ThermoFisher, UK). 
The culture was maintained at 37°C, 5% CO2 in a humidified incubator, with media changes 
every 7 days. Cultured fibroblasts were then trypsinised and further lysed for the purposes of 
allelic variation detection (ASO PCR method, carried out by HMDS), 4 weeks after the initial 
culture set-up to allow for optimal fibroblast expansion for DNA extraction (Results Chapter 2, 
section 2.2.5).  
  
3.2.2 Genetic investigation into MYD88 
Genomic DNA samples from 30 SchS patients and five NLRP3-AID patients with acquired 
mutations (aNLRP3-AID), and fibroblast DNA samples from two SchS patients were 
investigated for the presence of the MYD88 L265P mutation by allele-specific PCR (ASO-
PCR). Two forward primers were utilised to discriminate between the wild-type allele (T) and 
the mutant allele (C), with a common reverse primer (Section 7.2.1, appendix). PCR was 
performed with a final volume of 28μl. The reactions were carried out for 35 cycles: 
denaturation at 95°C for 30 seconds, annealing at 59.5°C for 30 seconds and elongation at 
72°C for 30 seconds. The final extension step was carried out at 72°C for 7 mins. The resulting 
PCR products plus 1μl of Midori Green Direct (Nippon Genetics, Germany), were run on a 2% 
agarose gel, 75 volts for 45 minutes. The gel was visualised using the GelDoc system and 
Quantity-One software (BioRad, USA). This technique is commonly used for the diagnostic 











3.2.3 MDS sequencing 
Sequencing was outsourced to the Haematological Malignancy Diagnostic Service (HMDS), 
a laboratory serving a population of over 6 million across the UK. For each patient, DNA was 
extracted as outlined in Section 2.2.5. Amplicons were designed using the D3™ Assay Design 
service (Fluidigm®, San Francisco, USA), with DNA libraries constructed using Fluidigm® 
technology. Forty-eight barcoded patient samples were pooled and subjected to 150bp paired-
end sequencing. Both library preparation and sequencing were performed as per the 
manufacturer’s instructions. Sequencing of the DNA libraries were performed on MiSeq 
(Illumina, UK), with an average read depth of 1500x. The panel of 28 genes, associated with 
myeloid malignancies, are listed within Section 7.2.2 (Appendix), alongside exon coverage 
and the reference sequences utilised for primer design.  
3.2.4 X inactivation 
The HUMARA assay was used to identify X-allelic skewing in female patients. The first exon 
of the HUMARA gene contains highly polymorphic ‘CAG’ repeats, and within 100bp from the 
start of this gene and the CAG repeats lies a site of differential methylation between the 
inactive and active X chromosome. Within this methylation area are two restriction sites for 
the methylation sensitive endonucleases (258). The enzyme HpaII is one such restriction 
endonuclease, cleaving unmethylated, active X alleles. Therefore, within this assay, a PCR 
product is only generated from the inactive X chromosome. In a mixed population of cells, the 
maternal and paternal X inactivated alleles, will both be amplified, thus two peaks are 
visualised on gene scanning software. Whereas for those cells arising from a single, common 
progenitor cell, only the maternal or paternal X inactivated allele PCR product will generated, 
giving rise to a single peak (258). Whilst the aforementioned is applicable to females, it should 
be noted that performance of this assay on a male derived sample will yield no peaks due to 
the existence of only one, active X chromosome.  
The techniques stated below used to determine X inactivation were originally based on the 
methodologies published by Allen et al in 1992 (259). However, these were modified to 
enhance the quality of results obtained. Genomic DNA was utilised for this part of the study 
from 14 female SchS patients and 3 female aNLRP3-AID patients, at a starting concentration 









3.2.4.1 Restriction enzyme digestion 
Reaction A (undigested DNA), and reaction B (restriction enzyme digested DNA) were 
prepared from each subject according to the following table (Table 6). The reactions were then 
subject to incubation in a thermocycler at for 2 hours to destroy the unmethylated HUMARA 








Table 6 descripts the compositions of reactions A and B, with a final volume adjusted to 20µL, 
using nuclease free water. 
3.2.4.2 PCR amplification of the HUMARA gene 
The AccuPrime™ Taq DNA Polymerase High Fidelity Kit (Invitrogen, Loughborough, UK), was 
used for the primary PCR amplification of the HUMARA gene. The forward primer was labelled 









Using the stated composition, the following thermocycling conditions for AR gene amplification 
were used: denaturation at 94°C, annealing at 56°C and extension at 68°C for a total of 34 cycles. 
 
 
REACTION A REACTION B 
50ng genomic DNA 50ng genomic DNA 
2µl of Buffer a 2µl of Buffer A 
0.2µl acetylated bsa 0.2µl acetylated BSA 
 0.5µl HpaII restriction 
enzyme digestion 
Table 6: The composition of the restriction enzyme digestion. 
Undigested or digested DNA 5µl 
10X AccuPrime™ PCR Buffer II 5µl 
Molecular-grade water 37.8µl 
10 µmol/l fluorescein amidite (FAM)-labeled forward primer  
FAM 5′ TCC AGA ATC TGT TCC AGA GCG TGC 3′ 
1µl 
10 µmol/l reverse primer  
5′ GCT GTG AAG GTT GCT GTT CCT CAT 3’ 
1µl 




3.2.4.3 Capillary reaction  
Succeeding the previous steps, reactions were diluted in molecular-grade water, at a 1:50 
ratio. Plated out in a 96 well plate, 8.5µl of Hi-Di formamide and 0.5µl of GeneScan™ 600 
LIZ® dye Size Standard v2.0 (Life Technologies, UK), was added to 1µl of the diluted reaction. 
These PCR products were further subject to a denaturation cycle for 5 minutes at 95°C before 
subject to testing on the ABI 3100 DNA analyser (Applied Biosystems, UK). 
3.2.4.4 Determination of X-skewing ratios 
The resulting FSA files generated by the DNA analyser in the previous step were subject to 
evaluation using GeneMapper software version 2.0). Although the exact sizes (base pairs) of 
the peaks differ between individuals, two peaks were sought to appear close together (around 
a 20bp proximity). Assessing area under the curve (AUC) from both the HpaII digested and 
undigested reactions, facilitated the generation of ratios of X-inactivation. (A) Undigested 
reaction - left peak; (B) undigested reaction - right peak; (C) digested reaction - left peak; (D) 
digested reaction - right peak. XCI was thus determined by the following calculation: 
(C/A)/((C/A)+(D/B))*100%. The values for the HpaII digested samples were normalised by 
assessing values of the undigested samples, thus accounting for preferential allele 
amplification (260). Percentages equal to or above 80% were deemed indicative of skewing. 
3.3 Results 
3.3.1 The MYD88 L265P mutation 
Since the somatic MYD88 L265P mutation is present in over 90% WM patients (182) and in 
over 50% of IgM-MGUS patients (261), the following work explored the possibility that this 
mutation was present within gDNA of 30 SchS patients and in the fibroblasts of two patients. 
Within the PCR setup, a mixture of the wild-type (WT) primer binding to the WT allele, 
alongside a mutant primer, binding to the mutant allele produces two different sized bands. 
This MYD88 mutation can be detected in DNA dilutions down to a mutant clone size of 0.1-










3.3.1.1 ASO-PCR  
As a preliminary screening, the aim of undertaking ASO-PCR assay was to determine if the 
L265P mutation within MYD88 was present within 30 patients with SchS. This assay was 













Wells 1, 14 and 28 are 100bp ladders, wells 2-13; 15-27 and 29-35 correspond to SchS 
patients (results summarised in Table 9). The wild type allele – normal 400bp product whereas 
the mutant product has a size of around 200bp. Negative controls and positive controls were 









Wells 2-6 – negative for the MYD88 L265P mutation. Lane 1: 100bp ladder, 2-6 aNLRP3-AID 
samples, positive & negative controls were also included in the experimental setup. 
Figure 23: ASO-PCR results of 30 SchS patients. 
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3.3.2 Primary fibroblast explant culture & ASO PCR 
The aim of obtaining skin biopsies and culturing fibroblasts was to obtain DNA and carry out 















Primary fibroblasts were cultured for SchS patients 29 and 30 in this study, followed by ASO 
PCR for MYD88 L265P mutant detection. (A and B) Skin biopsies (1mm diameter) were 
cultured for 4 weeks using DMEM prior to DNA extraction and ASO PCR. Images are shown 
at x40 magnification. The two SchS patients showed absence of the mutant PCR band 
(~200bp) but presence of the normal band (~400bp). Lanes 3, 6-11 correspond to patients not 










































































































Using the MYD88 reference sequence NM_001172567.1, employing the ASO-PCR technique 
permitted identification of the SNV at chromosomal location 3:38141150. The allelic change 
from T to C results in the leucine to proline substitution at position 265 of MYD88, producing 
a ‘gain-of-function’ protein.  Significantly, this variant was detected in nine out of the 30 SchS 
patients included in this work, a novel genetic finding with regards to the condition.  
No aNLRP3-AID patients harboured the T>C change, eliminating the prospect of MYD88 
bearing influence on this NLRP3 mediated disease. Though this SNV was present in subset 
of SchS patients, the former outcome further discriminates SchS as a separate entity from 
aNLRP3-AID. Despite several shared features such as late disease onset and inflammasome 
involvement (Results Chapter 2) between the diseases, absence of this mutation in aNLRP3-
AID reinforces that there is an alternative genetic component in SchS. Absence of the mutant 
band for the alternative germ layer derived fibroblasts demonstrates that the somatic 
pathogenic variant was generated after commitment of stem cells to the haematopoietic 




3.3.3 HMDS Sequencing panel  
The average age of symptom onset for the sequenced set of patients is 56.2 years, with SchS 
patients averaging at 55.2 years and aNLRP3-AID patients averaging at 61 years. The male-
to-female ratio of the entire 36 patients was 1:1.5, identical for the SchS cohort. The aNLRP3-










Genes and their corresponding functional pathways are shown in Table 8. Associated with the 
initiation and development of MDS, sequencing of 28 frequently mutated genes was carried 
out at the HMDS facility, using PB derived DNA from 30 SchS patients and 6 aNLRP3-AID  
patients. The latter cohort were included as disease controls, since they carry somatic 
mutations in NLRP3. The panel (Table 8) comprised of epigenetic modifiers, transcription 
factors, signalling and other genes known to play a role in MDS progression. The panel was 
designed by HMDS to detect somatic mutations and is consequently not suitable for inherited 
variants.  
Solely one male SchS patient (20) had a nonsense mutation in the cohesion complex STAG2 
(c.559C>T p.Gln187), with a low variant allele fraction (VAF) of 0.081. This male patient was 
negative for both the presence of NLRP3 variants and the MYD88 L265P mutation, however 
BM histology examination showed LPL. Of the aNLRP3-AID cases, however, one female 
patient (3) had three pathogenic variants in 2 genes pertaining to DNA methylation: one 
mutation in DNMT3-A (c.2645G>A p.Arg882His), with two mutations in TET-2 (c.4585C>T 
p.Gln1529; p.Gln1699*), all with a significant VAF (0.407, 0.388 and 0.402 respectively). This 
patient doesn’t harbour the MYD88 mutation, though bears the somatic A352T NLRP3 
mutation. Both of the aforementioned patients demonstrate a complete symptomatic response 
to IL-1 inhibition, thus these discovered mutations are more likely to be age-related findings. 
 
Functional Pathway Gene 
Chromatin Modification ASXL1, EZH2 
Cohesin Complex STAG2 
DNA Methylation DNMT3A, IDH1, IDH2, TET2 
Signalling CBL, cKIT, CSF3R, FLT3, JAK2, KRAS, 
MPL, NRAS, STAT3 
Splicing SF3B1, SRSF2, U2AF1, ZRSR2 
Transcription Factors BCOR, NPM1, RUNX1, TP53, WT1 
Other CALR, SETBP1, RHOA 




3.3.4 XCI patterns at the HUMARA locus  
The average age of symptom onset for the SchS female cohort (n=13) subject to the HUMARA 
assay was 53.7 years with a range between 37.9 years to 72.5 years. The aNLRP3-AID  
female cohort (n=3) included in the HUMARA assay had an average age of disease onset of 
58.6 years ranging between 47 years to 67 years. Building upon the notion that MDS mutations 
may be a contributor to SchS disease manifestations, examination of the HUMARA gene to 
explored the possibility of XCI in 13 female SchS patients. 
 














Figure 26 (A and B) are chromatograms showing the results for male control DNA probed with 
the HUMARA assay.  (A) – Prior to digestion, the allelic peak at 274bp shown corresponds to 
the active X chromosome. (B) – Following digestion, the same allele is absent, indicating the 
active status of the male’s one X chromosome. The absence of the peak in 23B also 
strengthens the data by excluding assay bias resultant of incomplete enzymatic digestion by 
HpaII.   
 
 
















Figure 27 A and B show chromatograms of the female healthy control probed for XCI.  
Allelic peaks at 275bp and 290bp are present in both the undigested (A) and digested DNA 
samples (B), indicating the X chromosome’s normal, active status. 
NB: The stutter peaks present in this figure and the following two figures are likely to have 
arisen because of polymerase errors. Evaluation and subsequent calculations were based on 

























Figure 28 A and B represent the chromatograms portraying the skewed XCI pattern in SchS 
female patient 9. (A) – The undigested DNA sample showing two peaks: 253bp and 271bp. 
(B) – The digested sample showing only one peak at 251bp. This is indicative of skewing, as 
the absence of the allelic peak at 271bp suggests use of only one of the HUMARA alleles and 

























Figure 29 A and B are chromatograms portraying the XCI pattern in aNLRP3-AID female 
patient 3. (A) – The undigested DNA sample shows two major peaks: 247bp and 286bp. (B) 
– The digested sample only appears to have one major peak at 247bp. The absence of the 
allelic peak in B, corresponding to the peak generated in A at 286bp indicates a non-random 
pattern of activation as one X-chromosome appears to be preferentially used in this sample.  
XCI only occurred in one SchS patient and one aNLRP3-AID patient, suggestive that this event 
is not common to all female patients and therefore cannot be regarded as a marker of disease 
within this cohort.  
SchS-9 had a skewed XCI. Despite age of disease onset being 60 years, not classed as 
elderly. May correspond to the low level myeloma already. Had a good response to IL-1 
inhibition. Within the aNLRP3-AID cohort, previous findings were further confirmed given that 
allelic skewing was found in the patient with 3 pathogenic mutations; two of which were in 
TET-2. 















1	 male	 62.0	 complete	 No	overt	LPL	 	 Yes	 	 -	
2	 female	 43.5	 good	 No	overt	LPL	 	 Yes	 	 random	
3	 male	 51.5	 good	 No	overt	LPL	 	 Yes	 	 -	
4	 male	 67.0	 complete	 No	overt	LPL	 	 Yes	 	 -	
5	 female	 54.5	 good	 No	overt	LPL	 	 No	 	 random	
6	 female	 72.5	 complete	 No	overt	LPL	 	 No	 	 random	
7	 female	 55.5	 complete	 No	overt	LPL	 	 No	 	 random	
8	 female	 53.0	 complete	 No	overt	LPL	 	 No	 	 random	
9	 female	 60.0	 good	 Low-grade	myeloma	 	 No	 	 non-random	-	skewed	(80%)	
10	 female	 72.5	 good	 No	overt	LPL	 	 No	 Q703K*	 -	
11	 male	 62.0	 good	 No	overt	LPL	 	 Yes	 	 -	
12	 male	 36.8	 Partial	 No	overt	LPL	 	 No	 	 -	
13	 female	 37.9	 complete	 No	overt	LPL	 	 No	 	 random	
14	 male	 43.9	 complete	 15%	BM	plasma	cell	 	 No	 	 -	
15	 female	 44.8	 complete	 No	overt	LPL	 	 No	 	 random	
16	 female	 49.6	 complete	 not	done	 	 No	 	 random	
17	 male	 49.9	 complete	 No	overt	LPL	 	 No	 	 -	
18	 male	 52.8	 complete	 No	overt	LPL	 	 No	 	 -	
19	 male	 57.1	 complete	 LPL	 	 Yes	 V198M*	 -	
20	 male	 58.1	 complete	 LPL	 STAG-2		c.559C>T	p.Gln187*	Predicted:	pathogenic	VAF:	0.081	 No	 	 -	
21	 male	 59.6	 Died	before	
treatment	
No	overt	LPL	 	 No	 	 -	
22	 male	 61.7	 complete	 No	overt	LPL	 	 No	 	 -	
23	 female	 60.7	 complete	 low	grade	marginal	zone	
lymphoma	
	 No	 	 random	
24	 female	 68.4	 complete	 No	overt	LPL	 	 No	 	 random	
25	 male	 78.9	 complete	 No	overt	LPL	 	 Yes	 	 -	
26	 female	 39.7	 complete	 No	overt	LPL	 	 No	 	 random	
27	 male	 40.7	 complete	 No	overt	LPL	 	 No	 	 -	
28	 male	 61.2	 complete	 No	overt	LPL	 	 No	 	 -	
29	 male	 43.6	 complete	 MGUS	 	 Yes	 	 -	
30	 female	 59.0	 complete	 Marginal	Zone	Lymphoma	 	 Yes	 	 random	
aNLRP3	-	1	 male	 48	 complete	 N/A	 	 No	 E567K	 -	
aNLRP3	-	2	 male	 79	 complete	 N/A	 	 No	 G569V	 -	







aNLRP3	-	4	 male	 63	 complete	 N/A	 	 No	 Y563C	 -	
aNLRP3–	5	 female	 62	 complete	 N/A	 	 No	 Y563C	 random	
aNLRP3	–	6	 female	 47	 complete	 N/A	 	 N/D	 Y536C	 random	
Table 9: Summary of Results 
Table 9 is the summary of results found in this chapter showing the clinical and laboratory findings of 30 SchS patients and 6 aNLRP3-AID patients      
LPL = lymphoproliferative lymphoma    IF: immunofluorescence        




3.4 Discussion  
The purpose of the work undertaken in this chapter was to investigate the presence of CH and 
initiating mutations within candidate genes of 30 SchS patients. Screening of the somatic 
L265P mutation within MYD88 (T > C (3:38182641) in exon 5) using ASO-PCR methodology 
was followed by assessment of the mutational status of 28 genes associated with MDS. 
Accompanying these genetic results, the functional HUMARA assay was employed to 
evaluate XCI within female subjects. 
 
To summarise, the main findings in this chapter were: 
v. The somatic MYD88 L265P mutation was present within the gDNA of 9 patients 
with SchS, but not within the fibroblasts of two SchS patients 
vi. One SchS patient harboured a pathogenic STAG-2 mutation  
vii. One aNLRP3-AID patient demonstrated three pathogenic mutations, one in 
DNMT3-A and two in TET-2  













MYD88 ASO-PCR was carried out for the gDNA from 30 SchS patients, with material from a 
further two patients also subject to this technique using DNA from their cultured fibroblasts. 
Genomic DNA was also the starting material for assessment of the panel of genes associated 
with myeloid malignancies (HMDS). Lastly, gDNA from 12 female SchS patients was used to 
















3.4.1 MYD88 L265P 
The L265P variant was detected in the PB derived DNA in nine out of 30 SchS patients by 
ASO-PCR methodology as described in 3.2.2. In comparison to Sanger sequencing, ASO-
PCR represents a highly sensitive technique, with the ability to detect the mutant allele down 
to 0.1-0.5% (256, 262). The original paper indicating that MYD88 L265P was a recurring 
somatic mutation in WM patients by Treon et al used Sanger sequencing to determine that 
mutation was present in 90% of WM patients and in 10% of IgM-MGUS patients (182). A year 
later, Varettoni et al developed an ASO-PCR assay to detect the mutant allele, demonstrating 
that 100% of their WM cohort harboured the mutation in question, alongside 47% of IgM-
MGUS patients also showing the mutation (183). Not only did the latter study further confirm 
that this mutation is a hallmark of WM irrespective of their symptomatic features, but 
highlighted the efficacy of using such an assay for a large cohort. Therefore, utilisation of this 
method was a reliable approach to screen for this mutation within the gDNA of 30 SchS 






MYD88 is comprised of 5 exons, with the T > C variation occurring in exon 5 at chromosome 
position 3:38182641. Both the forward primer and mutant primer anneal at the beginning of 
exon 5. The reverse primer located in the intronic region after exon 5. The mutant primer binds 
to the DNA and amplifies a product at 220bp if the T>C variant is present. Otherwise, a 400bp 
product is amplified and indicates the absence of this mutation.   
 
3.4.1.1 SchS and MYD88 L265P 
The frequency of SchS patients who develop WM (around 20%) is in line with those SchS 
patients positive for the MYD88 L265P variant (9/30) as described in this work. Although WM 
is not associated with inflammatory complications as those seen in SchS, establishing that a 
third of SchS patients bear this mutation could partially explain the clinical phenotype of 
systemic inflammation and NUD, with this novel finding in parallel with the frequency of those 
Figure 31: Schematic of the MYD88 ASO-PCR primer coverage. 
Forward	primer	
5’ GTG CCC ATC AGA AGC GCC C 3’	




SchS patients who go onto develop B cell malignancy. Certainly, in cases where SchS is 
speculated, screening of this mutation could corroborate a diagnosis. The absence of this 
mutation in cultured fibroblasts from patients 29 and 30, who have the mutation in their gDNA, 
indicates that this mutation must have occurred after the stem cell being committed to a HSC 
(Figure 30).   
The MYD88 adaptor protein plays a pivotal role in innate immune signalling and is an 
activating component of NLRP3 (263). Several studies have established the requirement for 
two signals for NLRP3 inflammasome activation (210, 237, 264). The first signal requires 
microbial ligand or TLR activation, thereby activating the NF-κB pathway resulting in the 
transcription and translation of inflammasome components. The second signal instigates 
assembly of the inflammasome, requiring DAMPs (Damage Associated Molecular Patterns) 
or PAMPs stimulation (265) (Figure 20).  Conformational dynamics demonstrated that the TIR 
binding domain of MYD88 can exhibit two conformational states, one supporting homo-
oligomerisation, with the other favouring hetero-oligomerisation (266). The leucine to proline 
substitution within MYD88 stabilises the homo-dimer interface of the MYD88-TIR domain (40), 
leading to spontaneous and increased homo-oligomerisation. The latter is imperative for 
protein activation downstream of MYD88. Those nine SchS patients harbouring the mutation 
in question are not likely to require TLR activation to prompt NF-κB transcription, given that 
the ‘priming’ signal is spontaneously delivered by the mutant MYD88 protein.  Thus in the 
context of SchS, one signal provided by the PAMP or DAMP would be sufficient to provoke 
NLRP3 inflammasome assembly. One way to test this hypothesis is to stimulate SchS derived 
PBMCs with LPS as the only signal, followed by probing mRNA transcripts of NLRP3 
inflammasome components, IL-1β and IL-18, via reverse-transcriptase PCR.  
The negative status of the other 21 SchS patients included in this study could be explained by 
two reasons. Firstly, sequencing of gDNA derived from these patients presents the possibility 
of missing potential populations of cells bearing this somatic mutation. For example, those 
WM patients who were MYD88 L265P negative in the research by Petrikkos et al had 
significantly low levels of lymphoplasmocytic cell infiltration in the bone marrow in comparison 
to mutation positive patients (198). The latter finding also raises the question as to whether 
this mutation is specific to the lymphoid or myeloid derived lineages. Nevertheless, probing 
bone-marrow derived DNA in place of gDNA would then categorically exclude these patients 
from harbouring the mutation. Secondly, it is possible that the remaining SchS patients 
harbour other variants in MYD88. Recent research has implicated a de-novo germline MYD88 
mutation as the cause of severe arthritis, intermittent fever and rash, of which the latter 
symptoms are frequent in SchS and other autoinflammatory conditions (267). Despite the 
difference in other clinical manifestations in the described patient, these findings emphasise 
the pathological effects MYD88 variants can have. Likewise, Ngo et al revealed multiple 




ABC subtyped DLBCL patients. Mirroring SchS, around 20%-30% of DLBCL patients also 
harbour the L265P somatic mutation. Hence, it is plausible to suspect the prevalence of other 
MYD88 variants irrespective of the MYD88 L265P status in SchS patients. 
 
3.4.1.2 MYD88 L265P and disease burden 
Presence of the MYD88 L265P mutation in IgM-MGUS patients has been shown to correlate 
with a higher disease burden, with an increased risk to WM progression (183). Two papers 
also demonstrated the increased disease burden of those with WM is correlated with the 
presence of L265P as compared to those 10% of WM patients without the mutation (182, 242). 
Interestingly, IgM levels were found to be ‘within range’ and statistically ‘insignificant’ in the 
paper by Treon et al. However, the paper by Patkar et al., found that those patients harbouring 
the L265P mutation with monoclonal gammopathy had a higher severity score on the 
International Prognostic Scoring System for WM. The nine patients harbouring the activating 
mutation in this study exhibit slightly higher levels of IgM in comparison to mutation negative 
SchS patients (7.5g/l verses 6g/l respectively). Nevertheless, deriving conclusions pertaining 
to presence of the mutation and increased monoclonal component levels in SchS patients is 
more difficult given the disparity between the average IgM values for the two groups. Varettoni 
et al further identified a subset of IgM-MGUS patients harbouring MYD88 L265P alongside 
IgM levels above 15g/l, were at higher risk of progression to malignancy (261). Only SchS 
patient 2 had an IgM level above the aforementioned level in IgM-MGUS (17g/l), with bone 
marrow histology exhibiting no overt LPL. This female patient did not demonstrate a skewed 
XCI, nor did she have any detected NLRP3 mutations.  
Notably, the examined patients by Treon and colleagues had other mutations in genes such 
as CXCR4, likely to be factors contributing to these disease manifestations (182). Only SchS 
patient 19 demonstrated evidence of a non-pathogenic NLRP3 variant (V198M), whereas 
SchS patient 20, who harboured the pathogenic STAG2 variant did not harbour MYD88 
L265P.  
In 2002, there was a report of two IgM multiple myeloma patients with neoplastic cells 
secreting elevated levels of IL-1β , though this was not replicated in WM patients with the 
latter’s IL-1β  levels as normal (268).  Given the good (n=3) and complete (n=6) response to 
IL-1 inhibition in this mutation positive SchS subset, whether supposed ‘neoplastic’ cells are 
releasing excessive IL-1β, or it is the consequence of an exacerbated innate inflammatory 
response would require further exploration. Cell sorting into myeloid and lymphoid lineages to 





3.4.2 MDS sequencing panel 
Genetic exploration into NLRP3 and MYD88 revealed that these genes are not disease 
causative within the patients probed in this thesis. Recent findings have implicated the NLRP3 
inflammasome as ‘a driver of the MDS phenotype’ (179) and given the several indications that 
the latter inflammasome plays a key role in SchS, sequencing against a panel of MDS related 
genes was the next plausible step in search for a common causative or susceptibilty marker. 
Significantly high levels of IL-18 and ASC specks alongside the successful remission of 
patients using IL-1 inhibition (Results Chapter 2), also substantiated the notion of NLRP3 
involvement in this disease. In the context of SchS, bearing mutations in MDS associated 
genes would influence the shift to a proinflammatory milieu, with the potential to development 
of additional SAID-associated somatic mutations. However, gDNA sequencing of of 30 SchS 
and six aNLRP3-AID  patients against a 28 gene panel intended for the detection of somatic 
variants within MDS suspected patients did not detect a common genetic basis. 
 
3.4.2.1 MDS variants 
HSCs develop somatic mutations throughout their existence, a large proportion of which are 
non-pathogenic passengers without functional consequences (247). Age-related 
haematopoietic clones are a frequent occurrence in individuals after 55 years of age (269), 
with the median age of patients diagnosed with SchS in the cohort presented in this chapter 
at 56.3 years. The median ages of patients diagnosed with AML and myelodysplasia, 67 and 
76 respectively (270, 271). Only SchS patient 20 presented with a pathogenic mutation in 
STAG2, thus, concluding that this is an incidental finding unrelated to the general pathology 
of SchS is probable. Interestingly, a 2014 study showed that MDS patients with STAG2 
mutations were correlated with poor survival (272), however the variant reported in this work 
(c.559C>T p.Gln187*) has not been reported in literature. There are eight subunits making up 
the protein cohesin, defined as a ‘ring-like structure that binds chromosomes together’ (273). 
STAG2 is the most mutated cohesion subunit in cancer (274), with this discovered nonsense 
mutation is likely result in a loss of sister chromatid cohesion (273). In isolation, this variant 
may signify a ‘CHIP’ (clonal haematopoiesis of indeterminate potential) mutation.  Originally 
described in 2015 by Steensma et al, CHIP represents the indolent phase of an individual 
demonstrating somatic mutation in their blood or bone marrow that is associated with 
haematological malignancy, but do not fulfil diagnostic criteria for a haematological 
malignancy (247).  
Of the aNLRP3-AID cases however, three pathogenic variants were identified in patient three. 
HSCs shown to have mutations in DNMT3-A obtain self-renewing capacities and are thus are 




in aNLRP3-AID patient 3 (c.2645G>A p.Arg882His), has been widely studied in the context of 
Acute Myeloid Leukaemia (AML) with several reports indicating the pathogenic nature of this 
specific mutation (276). Functional experiments demonstrate that cell lines harbouring the 
mutant R882H cause differentiation blockades in HSCs, by downregulation of differentiation- 
associated genes through binding with Polycomb Repressive Complex 1 (276).  The TET-2 
gene encodes for a transcriptional regulator, catalysing the hydroxylation of 5-
methylcytosines. The resulting loss of DNA methylation is constant with the findings that TET-
2 mutant AML patients demonstrate a genetically distinct hypermethylation profile (248). The 
two predicted pathogenic variants found in aNLRP3-AID patient 3 were nonsense c.4585C>T 
p.Gln1529* and c.5095C>T p.Gln1699*. TET2 mutations are described in literature to render 
a global loss of protein function (177, 277), therefore implying a lack of genomic regulation 
and potential development of a milieu to acquire further mutations. The presence of three 
pathogenic mutations in aNLRP3-AID patient 3 consequently warrants close monitoring, 
though only a few cases of MDS development in autoinflammatory conditions have been 
documented  (175, 278).  
 
    
3.4.3 X inactivation 
Clonal skewing in HSCs is a frequent finding over 55 years of age and though there are a few 
reports of late onset X-linked disorders in females (279), this phenomenon is rarely correlated 
with disease. During the course of embryonic development, random XCI occurs in females 
and stays a permanent feature of the cell’s lifespan. Underlying a majority of haematological 
malignancies, somatic mutations have long been implicated as one of the major steering 
forces behind CH, though another probable cause of the CH is the presence of polymorphic 
genes on the X chromosome yielding selective attrition or fitness upon a HSC (171).  
In this presented work, use of the HUMARA assay in female patients with autoinflammatory 
disease was substantiated by the findings that skewing is associated with MDS. First 
determined in 2012, Busque et al originally determined that CH is selectively enriched in 
women with TET-2 mutations, with one in seven subjects with CH and a TET-2 mutation 
developing haematological malignancy (248). These findings were corroborated with data 
demonstrated that XCI was more pronounced in samples with somatic mutations, typical of 
CH (171).  
Certainly in agreement with literature, for aNLRP3-AID, the degree of HUMARA skewing was 
prominent in the sample with somatic mutations, though this was not emulated in SchS. The 
one patient (SchS-9) who demonstrated an abnormal XCI ratio did not have any variants 




However, since bone marrow histology indicated low-grade myeloma within this patient, there 
is the increased probability that the skewed ratio observed is associated with the clonal 
restriction found within myeloma (280). Though, the latter statement could be contended given 
that SchS patients 23 and 30 demonstrated low grade MZL and MZL respectively, with normal 
XCI percentages. There is the likelihood that the gene panel employed did not target the 
change underlying the clonal process in SchS-9. Harbouring the pathogenic STAG-2 variant, 
the male SchS patient 20 couldn’t be investigated for XCI due to limitations of the HUMARA 
technique. 
A preliminary trial showed that the HUMARA assay when performed on gDNA from both 
mononuclear cells and whole blood from the same individuals showed no difference in XCI 
ratios obtained. Not only does this corroborate the fact that inactivation patterns are 
determined during gestation, but strengthens the fact that gDNA used in this section of work 
is representative and the likelihood of alternate ratios from other cell types is low (171).   
 
3.4.4 Chapter conclusions  
Demonstrating that around a third of SchS patients have the activating MYD88 mutation, is 
the most unifying genetic factor of SchS found to date, also in parallel with those SchS cases 
who develop WM. Though not present in all SchS samples, this novel finding provides clues 
to the pathogenesis of this heterogeneous disease. Exclusion of this somatic mutation from 
fibroblasts of two SchS patients further implies this pathogenic variant is confined to cells of 
the haematopoietic lineage. 
 
Querying the mutational status of 28 genes associated with MDS was substantiated by several 
studies implicating the NLRP3 inflammasome as the mediator of CH and pyroptosis in MDS 
(179). Thus, harbouring initiating mutations in genes related to MDS could predispose SchS 
patients to maintain a generally pro-inflammatory environment, facilitating the development of 
additional SAID somatic mutations. Given that this hypothesis was proven incorrect, the few 
variants found are likely to be age-related. Values of the HUMARA assay provides little 
diagnostic benefit in SchS, though its use as a tool of predicting or corroborating CH findings 
within females suspected of haematological malignancy is of great significance. The results of 






Chapter 4 IgM Isolation and Protein Microarray  
4.1 Introduction 
With research in chapters two and three showing no common genetic basis to SchS, the work 
presented henceforth queries properties of the enigmatic paraprotein. The aim of the work 
presented in this chapter is to therefore investigate the hypothesis that elevated titres of 
monoclonal IgM contribute to the inflammatory phenotype seen within SchS patients through 
exhibiting preferential binding properties. Whether the gammopathy is an epiphenomenon or 
central to disease manifestations is explored.  
The aim of this chapter was to explore the notion that SchS-IgM binds to a specific protein or 
set of related proteins, by utilising unbiased, proteome-wide methodology. Through 
employment of the HuProt™ V3.2 protein microarray and using isolated IgM as the probing 
sample, it was therefore possible to investigate the potential interactions of this antibody 
fraction with over 20,000 clones encoding human recombinant proteins. These represented 
more than 15,700 genes, encompassing around 75% of the annotated human protein coding 
genome. Nearly 90% of the expressed proteins are full-length, therefore representing a 
comprehensive emulation of the human proteome. 
Antigen specific antibodies are generated and secreted by long-lived plasma cells in response 
to antigenic challenge and is a central role of the adaptive immune system (282). IgM 
antibodies differ to the other classes of Igs in that their production (by B1 cells predominantly) 
can be in the absence of apparent antigen encounter (283). Whilst featuring a broad specificity 
and a low affinity to foreign epitopes, IgM has a noted binding propensity to self-structures – 
such as the ‘phylogenetically’ conserved epitopes of nucleic acids, phospholipids, and 
carbohydrates (284). 
4.1.1 Protein isolation and purification 
With the aim to retain large concentrations of the target protein, separation involves two main 
steps: (1) protein isolation and (2) protein purification. 
4.1.1.1 Antibody isolation 
Isolating IgM from bodily fluids whilst retaining its biological activity is challenging, mostly 
attributed to its large size (970 kDa) as compared to other Igs (150kDa-190kDa), sensitivity to 
alterations in pH and salt conditions, susceptibility to denaturation and its tendency to bind 
DNA (285). In the past, purifying IgM was based on ammonium sulphate precipitation of the 
protein - followed by either gel filtration, ion-exchange chromatography or zone 




impurities. Isolation of high purity antibodies has been established through the availability of 
columns (referred to as the stationary phase), harbouring antibody binding proteins as 
immobilised ligands, for example, the bacterial wall derived protein A ligand which binds to the 
Fc region (287). The latter example and other commonly used reagents like Protein G do not 
work particularly well with IgM, as its pentameric conformation blocks access to the Fc region 
required for binding the ligand. However, the HiTrap™ IgM Purification HP (GE Healthcare, 
UK) is the sole commercially available IgM column manufactured for use with automated 
chromatography systems. For this column, the ligand is 2-mercaptopyridine attached to a 
sepharose resin and functions based on the concept of thiophilic adsorption (TA).  
4.1.1.2 Antibody purification 
Fast protein liquid chromatography (FPLC) is a type of High Performance Liquid 
Chromatography (HPLC) pushing through samples containing the protein of interest (mobile 
phase), through the stationary phase (described in 1.1.3.1) under high pressure. Such column 
chromatography can be performed with automated systems such as the GE Healthcare ÄKTA 
machines.  
4.1.1.3 SchS IgM isolation 
Application of these protein purification techniques to facilitate SchS IgM isolation from serum 
is a suitable approach given the commercial availability of the HiTrap™ IgM columns and 
access to the ÄKTA Pure machine at the University of Leeds. Though the total IgM component 
will be present in serum of SchS patients and thus subject to isolation and purification, 
acquisition of the potential ‘pathological’ SchS IgM is challenging given that the group of B-
cells responsible for overproduction of a potentially pathogenic component is yet to be fully 
described.  
4.1.1.4 Protein microarray 
Protein microarrays were initially developed in the late 1990’s to 2000’s, based largely upon 
the work carried out by Roger Etkins in 1989 and the adaptation of DNA microarrays (288, 
289). This technology is essentially the fixation of thousands of proteins onto a single surface, 
where peptide interactions can be investigated for numerous purposes. Key uses of this 
versatile and sensitive platform include assessment and validation of antibody specificity, 
evaluation of protein binding reagents employed in research and clinical applications, and the 
screening of molecular interactions using a protein of interest.   
The HuProt™ v3.2 Human Proteome Microarray is the most extensive protein array available 
commercially, with this platform querying over 20,000 human recombinant proteins. This 




genome. These recombinant proteins are firstly expressed in the yeast, S.cerevisiae, and 
further subject to purification, conjugation to GST for adherence to glutathione on the array 
slide surface, followed by duplicate imprinting onto a glass slide.   
 
4.1.1.5 IgM and SchS  
The idea that IgM clonal diseases harbour the MYD88 L265P mutation was further developed 
through research by Varettoni et al in 2013, noting IgM-MGUS patients demonstrating 
‘significantly higher levels of IgM’ carried the MYD88 variant (183).  The mutation in question 
is found in 50% to 80% of IgM-MGUS patients, 6% of patients with lymphomas such as 
Marginal Zone Lymphoma (MZL) and in 5% of chronic B-cell LPD (183, 290). As demonstrated 
in Results Chapter 3, approximately a third of SchS patients harbour the MYD88 L265P 
mutation.  This novel finding was based on the hypothesis that since 20% of SchS patients go 
on to develop the IgM related WM, where over 90% of patients carry the aforementioned 
mutation, that this would be mirrored in SchS patients. However, in CAD, established 
monoclonal IgM binds to red blood cells activating the complement cascade, within the 
peripheral circulation due to cooler temperatures (189) - but patients don’t harbour the MYD88 
L265P mutation. Sequencing of the IgH regions determined that the IgHV4-34 gene segment 
encodes for the monoclonal cold agglutinin IgM molecule, indicative of particular aa 
sequences having an important role in antigen recognition (189). In CLL, the aa composition 
of the monoclonal component’s binding region is shared amongst a third of patients, indicating 
antigenic specificity (291).  Together with the hypothesis that the B-cell receptor in CLL is self-
reactive, leading to clonal expansion of a B-cell progeny (292), highlights the potentiality 
pathological consequences due to a generation of a clonal Ig. The evidence of clonality sought 
in Results Chapter 5 (e.g. presence of highly expanded CDR3 aa clones) also supports the 
concept that a certain proportion of the monoclonal component in SchS may be directed 
towards a target, or group of related targets.  
This chapter focuses on the hypothesis of a pathological Ig component, through isolating total 
IgM from the serum of three SchS patients, two WM patients and one NLRP3-AID patient, 
followed by application of these six isolated IgM samples to a protein microarray 
encompassing over 75% of the human proteome. Thus, the aims of this chapter are as follows: 
A. Isolation of IgM from three SchS patients’ serum using FPLC techniques 






4.2.1 IgM isolation 
IgM paraprotein was isolated from three SchS patients, two WM patients and one NLRP3-AID 
patient (Table 10), alongside two healthy controls. I carried this section of work out at the 
Protein Production Facility at the University of Leeds (main campus), where the relevant 
laboratory equipment is available.  First described in 1985 by Porath et al (293), ‘Thiophilic 
Adsorption’ (TA), forms the basis of Ig purification carried out in this work and is a salt 
dependent technique widely used to purify Igs. Having an affinity for sulfone groups that are 
near thioether groups (293), thiophilic proteins retain the ability to bind to an immobilised 
ligand. The protein of interest is subject to adsorption at a neutral pH, whilst its elution is 
attained by reducing the concentration of the salt components. 
Implementation of this technique to isolate IgM in this work was facilitated by the use of the 
GE Healthcare HiTrap™ columns. Manufactured from polypropylene lacking interaction with 
biomolecules, the HiTrap™ column is an affinity medium, consisting of 2-mercaptopyridine at 
a concentration of 2mg/ml, acting as the ‘ligand’ binding only IgM. This ligand is coupled to a 
sepharose resin, with the bound protein (IgM) then released by decreasing the salt 
concentration. These HiTrap™ purification columns were used in conjunction with the fast 
protein liquid chromatography system (FPLC), ÄKTA Pure™ (GE Healthcare, UK). Controlling 
the rate at which the mobile phase passes through a small diameter stationary phase forms 
the basis of FPLC, a form of medium-pressure chromatography that was first introduced in 
1982 (294). The advantages of using the ÄKTA Pure™ is primarily based on its high degree 
of automation, UV monitoring to determine protein separation and different wavelengths, with 
the system controlled by the Unicorn-6 software. Having the ability to purify micrograms to 
grams of protein, this machine operates at a maximum pressure of 5MPa.  
Alternative antibody isolation ligands such as the bacterially derived proteins A, G and L work 
well for the purpose of isolating IgG, but not in the case of IgM (295). This is mainly attributable 
to the pentameric structure of IgM Fc receptor binding site - where the latter ligands would 
bind. Furthermore, TA works well for the ‘selective depletion of immunoglobulins from complex 
biological fluids’ (296), largely due to the pH neutral elution conditions of the bound protein. 
For example, protein A based affinity chromatography requires elution with a low pH that would 
affect the structure of the antibody. In view of the later objective to apply purified IgM to a 
protein microarray, the aforementioned benefits and commercial availability of the HiTrap™ 
columns with the ÄKTA Pure™ chromatography system is the most suitable approach to 




4.2.1.1 Buffer and sample preparation  
High grade molecular water was used for making buffers and the following formulations were 
further passed through a 0.45µm filter, to ensure high purity. The following compositions were 
used for the buffers: (1) Binding buffer - 20mM sodium phosphate, 0.8M (NH4)2SO4, pH7.5; 
(2) Elution buffer - 20mM sodium phosphate, pH7.5; (3) Regeneration buffer: 20mM sodium 
phosphate, pH7.5 with 30% isopropanol. Per 1ml of serum, 0.8M of crystallised ammonium 
sulphate (required to be the same concentration as in the binding buffer) was added gradually 
to avoid IgM precipitation and passed through a 0.45µm filter immediately prior to loading into 
the HiTrap™ column.  
4.2.1.2 Experimental setup 
IgM isolation was carried out using the ÄKTATM Pure system (GE Healthcare, UK) at 4ºC, 
using the prepacked HiTrapTM IgM Purification HP as the stationary phase and column. The 
column was washed with five column volumes (1ml) of each of the buffers: binding, elution 
and regeneration, subsequently followed by equilibration with five times (1ml) of binding buffer. 
A syringe was used to pump the sample into the column connected to the ÄKTA system, using 
a flow rate of 1ml/min, taking care to avoid bubble formation. The next step involved the use 
of 15mls of binding buffer, maintained at a flow rate of 2ml/min. The elution step was carried 
out subsequently, with 12mls of elution buffer. The automated feature of peak sensing via 
monitoring the conductivity and pressure values using real-time UV traces, enabled automatic 
peak fraction collection (2mls) into a 96 well plate. Following elution, regeneration and re-
equilibration using wash buffer and binding buffer respectively, permitted reuse of the 
HiTrap™ column for subsequent IgM purification of a different serum sample. 
 
4.2.1.3 Assessment of protein purity 
Visualising the traces generated from the ÄKTA Pure™ machine facilitated identification of 
the fractions of interest. After pooling the protein fractions of relevance, protein purity was 
assessed by SDS-PAGE and further subject to fluorometric quantitation using the Qubit 
apparatus (ThermoFisher Scientific, UK). 
4.2.1.3.1 Quantitation and sample storage 
Setting aside 30ng for SDS-PAGE, purified IgM samples were aliquoted and stored in PBS at 







4.2.1.3.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
The objective of SDS-PAGE was to confirm the purification of IgM using a reducing gel. 
Polyacrylamide gels are formed by crosslinking of acrylamide and bis-acrylamide, and 
followed by electrophoresis, these gels serve to separate proteins based on their size. The 
10% separation gels were made according to the following composition and order: 4.1ml dH20, 
3.3ml acrylamide, 2.5ml Tris-HCL (1.5M, pH 8.8), 100µl SDS, 10µl TEMED, and 32µl APS 
(10%). The 4% stacking gels were made according to the following composition and order: 
6.1ml dH20, 1.3ml acrylamide, 2.5ml Tris-HCL (0.5M, pH 6.8), 100µl SDS, 10µl TEMED, and 
100µl APS (10%).  
Equal volumes of sample buffer and 30ng of the isolated fractions (10µl each) were heated to 
95°C for five minutes and then loaded into the gels. Ten microliters of the Precision Plus 
Protein marker™ (Bio-Rad, UK), was also loaded to determine the molecular weight of the 
isolated IgM and other fractions. After electrophoresis at 100V for an hour, the gel was subject 
to Coomassie Brilliant Blue staining and analysed using ImageLab software (Bio-Rad, UK).  
 



















4.2.2 Isolated IgM profiling on proteome microarray 
The following work was carried out with myself and the molecular biology scientists employed 
by Cambridge Protein Arrays Ltd (CPA) and carried out in the laboratory facility in Cambridge. 
Total IgM isolated from section 4.2.1 was used as the starting material for the following 
experiment. A total of six isolated IgM samples were included in this experimental procedure: 
three SchS patients, two WM patients and one NLRP3-AID patient. Of note, HC derived 
serum-IgM was not used as a control in the following work due to the professional advice 
obtained from CPA. They observed prior studies using IgM/IgG from HCs demonstrated 
increased reactivities to the protein array and suggested that HC derived IgM would likely bind 
a multitude of antigens given the reduced specificity and high binding capacity of IgM. 
Alternative controls were included and are described in the subsequent sections.  
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4.2.2.2 Sample probing 
Four-well dishes were used for blocking the HuProt™ arrays by using 5ml of blocking buffer 
(2% BSA/PBS-Tween 0.05%) to each compartment, and kept at 4ºC overnight. Isolated IgM 
was incubated on the HuProt™ human protein microarray (CDI Laboratories, USA), at a 
15µg/ml concentration, in a final volume of 4ml in blocking buffer for 2 hours with gentle 
rocking. A negative control array was processed in parallel with the addition of blocking buffer, 
instead of isolated IgM.  
 
4.2.2.3 Washing and antibody addition 
The arrays were washed 3x with PBS-T (PBS, 0.05% Tween), followed by two 5 minute 
washes with PBS-T. The washing solution was removed by suction. Following washing, the 
fluorophore conjugated reagents were diluted. Anti-human Alexa Fluor IgM-488 (ug/ml) and 
anti-GST-Dylight-650 (0.5ug/ml) in blocking buffer. 4ml of the diluted antibodies were added 
to each incubation compartment of the 4-well plate. These were incubated for 2 hours at room 
temperature with gentle rocking. The arrays were further washed three times with PBS-T, 
followed by another 2 washes with PBS-T. One last wash with molecular grade water was 




The array slides were scanned immediately on a Tecan LS400 microarray scanner (Tecan 
Trading, Switzerland) at 535nm to detect the interaction of the samples, and again at 633nm 
to detect GST staining of all proteins, with a resolution of 10µm. Fluorescence data was 






















Each barcoded glass slide comprises of the expressed products from 20,000 clones encoding 
human recombinant proteins. These GST-His6 tagged proteins represent nearly 15,700 
genes, covering 75% of the human protein coding genome. The slide is arranged into 24 
subarrays, with each spot representing an expressed protein, imprinted in duplicate. The 
proteins are covalently bound to the glass slide, strengthening assay stability. The slide has a 
nitro-cellulose film coating for protein binding, including a reflective backing to increase the 
sensitivity of detection. The proteins are covalently bound to the glass slide, strengthening 
assay stability. A trio of experiments carried out by Hu et al at Johns Hopkins University 
determined that the ‘vast majority of proteins are in their native conformation’ (297).  Retention 
of protein conformation is crucial for maintaining the physiological activity of the protein and in 
the context of this work, the status of IgM binding to a native protein is imperative to mimic in-
vivo activity within the patient. For the purposes of grid alignment, fluorescent control spots 
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4.2.2.5 Data analysis  
Data analysis of the array aimed to identify specific proteins interacting with the purified IgM 
samples, and was segmented into the following steps: (A) image analysis; (B) numerical 
analysis; (C) data ranking and filtering based on the outputs from (A) and (B).  For each step, 
outliers were excluded from further analysis.  
 
4.2.2.5.1 Image analysis 
Alignment of the human proteins spotted with the array positioning (.gal) file was carried out 
using GenePix software (Molecular Devices, USA). Following alignment of each of the 24 
subarrays using fluorescently-conjugated control spots (labelled in Figure 34), the spots were 
repositioned and resized by the semi-automated software to garner best fit. The alignments 
were subject to visual confirmation and observable artefacts were manually flagged. 
Determination of the fluorescent intensity for each spot on the array was calculated by 
GenePix and further saved to a (.gpr) file.  
 
4.2.2.5.2 Data analysis calculations  
The following workflow to determine numerical values ascertaining to sample-protein binding 
is split into 2 steps: 
1. Calculation of duplicate spot averages and subtraction of negative control array data 
For each array slide (n=6 patients, n=1 negative control), the average fluorescence signal 
intensity and corresponding standard deviations were calculated from both the duplicate 
spots for each protein. The average fluorescence signal intensity obtained from the 
corresponding proteins on the negative control array were subtracted from the patient 
arrays, generating the corrected protein specific fluorescence signals. These values were 
further log2 transformed.  
2. Calculation of Z-scores for the evaluation of sample signals 
For each protein present on the array, the Z-score was computed to define signal 
significance within the signal distribution according to the following formulae: 
Z= log2 (sample-control) – average log2/SD log2 






1. Data filtering and ranking  
Positive ‘hits’ correspond to those proteins with statistically significant signals due to sample 
interaction. These ‘hits’ were established by filtering the entire data set according to the 
following parameters: 
1. Relative Standard Deviation (rSD) 
The rSD of the sample signal for duplicate spots must be below a set threshold of 0.35. 
Application of this parameter ensured that bright artefacts on the spot area did not 
influence a high, erroneous reading. 
 
2. Signal to Noise ratio (S/N) 
The S/N refers to the fluorescence signal in relation to the background signal. The 
value must have been above the threshold of 2.5 to ensure that only those spots clearly 
distinct from their background were examined.  
 
3. Sample to Control ratio (S/C) 
The S/C explored the relative changed seen for the same spots on the sample array 
as compared to the negative control array. This parameter ensured the removal of 
protein signals which showed only a slight increase in signal relative to the control. 
This minor increase is considered as variation of the direct secondary reagent binding, 
rather than sample contribution.  
 
Utilising the criteria above, data for the proteins were ranked by Z-score (corresponding to 
grading according to sample signal intensity). The top hits identified according to the outlined 
methods above were visually checked by inspection of the microarray images using ImageJ. 
Furthermore, spots manually flagged as artefacts during the initial step of grid alignment, were 












This chapter presents IgM isolation from two healthy controls, three SchS patients, two WM 
patients and one NLRP3-AID patient. Subsequently, the purified IgM from the previous step 
from the patients were then applied to a protein microarray consisting of over 75% of the 
human proteome to probe for preferential protein binding. 
4.3.1 Isolated IgM levels 
















HC	–	1	 M	 30*	 N/D	 N/D	 N/A	 0.74	
HC	–	2	 M	 26*	 N/D	 N/D	 N/A	 0.26	
SchS	–	2	 F	 43	 Yes	 IgMk	 17	 0.55	
SchS	–	23	 F	 60	 No	 IgMk	 9	 0.73	
SchS	–	31	 F	 51	 Yes**	 IgMk	 14	 0.33	
NLRP3-AID	–	
7	
M	 Unavailable	 N/D	 N/A	 N/A	 0.28	
WM	–	1	 M	 69*	 Yes**	 IgMk	 Unavailable	 0.33	
WM	–	2	 F	 81*	 Yes**	 IgMk	 Unavailable	 0.61	
Table 10: Resulting IgM concentrations from the isolation procedure (g/L). 
The normal range for IgM in healthy individuals ranges between 0.4 - 2.5g/L.  
*Age upon obtaining serum 





















The trace above displays the eight stages of IgM isolation from 1ml of serum. (1) Binding wash ;(2) Elution and regeneration of the column; (3) 
Column equilibration; (4) Sample application; (5) Column wash; (6) Sample elution; (7) Regeneration; (8) Equilibration.  
The blue lines show the UV absorbance values measured in (mili-Absorbance Units) with the orange lines corresponding to the salt levels. 
The figure above was generated from Unicorn start software™.
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Figure 35 (A and B) is illustrative of the fractions collected via the AKTA machine. IgM isolation 
and purification from eight serum samples was a successful undertaking as demonstrated 
through this figure. Initially, serum containing IgM was precipitated with ammonium sulphate 
to deplete the majority of highly soluble contaminants in serum such as albumin and 
transferrin. The resulting partially purified precipitate was then subject to IgM HiTrap™ protein 
affinity column loading, previously washed and equilibrated with the buffers as described in 
section 4.2.1. HiTrap™ column attachment to the ÄKTA Pure™ system and initialisation of 
the Unicorn start software™ was followed by implementation of the purification strategy as 
outlined by Figures 35. The UV (blue line) and conductivity (orange) traces enabled automated 
collection of desalted fractions into a 96 well plate (Figure 35). The aforementioned workflow 
was an effective strategy for obtaining IgM yields using FPLC based separation as 
demonstrated by Figure 35, with the HiTrap™ column having a 5g/L IgM binding capacity. In 
this work, the purified antibody levels ranged between 0.28g/L to 0.74g/L. 
The chromatogram and SDS-PAGE blots represent the stepwise purification procedure 
performed. Steps 1, 2 and 3 from the chromatogram correspond to the binding, elution & 
regeneration, and equilibration steps, aimed to prepare the HiTrap™ column for sample 
application. The equilibrating buffer was compatible with both IgM and the resin in the column 
(i.e. not denaturing IgM). Step 4 signifies application of the serum containing IgM sample, 
indicated by the high UV peak. This is reflected in Figure 35 where the high protein 
concentration is visually apparent through the density of the detected bands together showing 
a variety of different sized proteins. Following sample application, washing of the column was 
subsequently followed by IgM protein elution. The smaller peak on the trace indicates the 
generation of the purified IgM (Step 6), and correspondingly, these antibodies are portrayed 
Figures 35A and 35B in their denatured forms (‘elution’). Whilst more prominent in Figure 35B, 
demonstration of the IgM heavy chain at around 70kDa and the light chain at around 23kDa 
indicates isolation of IgM was achieved using this strategy. The antibody containing fractions 
were pooled according to the stages of isolation and stored at -80°C until use with the 
HuProt™ array. Subsequent column regeneration and equilibration steps were successfully 
carried out to enable reuse of the IgM HiTrap™ columns. These stages are also indicated in 
the SDS-PAGE blots. Notably, the described procedures were first tested upon HC serum 









4.3.2 Protein microarray 
Using the material generated in 4.2.1, the following section of work investigates the hypothesis 
that SchS-IgM preferentially binds a protein or set of self-proteins belonging to a particular 
family. Three SchS, one NLRP3-AID and two WM samples were tested against the array 
(Table 10). Based upon previous experiments carried out by CPA, all six samples were diluted 
to a final concentration of 15 µg/ml when applied to the array. A seventh control sample was 
included as a negative control. PBS was added in lieu of a sample, but the array was incubated 
with both secondary antibodies. Likewise, a positive control (anti-GST staining) was performed 
in parallel for each of the sample arrays and negative control array. This served for overall 
array QC and assay performance, also providing data on the relative amount of all proteins 
on the slide. The samples tested gave good signal-to-background ratios and were determined 
suitable for investigation on the array, with no background issues observed on the HuProt™ 
3.2 surface for either the samples or control slides. Relative to the negative control, data 
analysis for the examined samples identified numerous hits. The top 20 strongest interactors 
for each sample are presented in this chapter.   
 
For each of the tables in the following sections, the top 20 interactors are ordered by their 
individual z-scores (calculations detailed in section 4.2.2.5.2). A hit pertaining to a z-score 
below 2.5 is unlikely to be an interaction. An additional value of interest is the Interaction Score 
(i-score), which is a measure of the signal strength obtained from the sample binding to a 
particular protein relative to the amount of immobilised protein, as judged by the staining 
intensity for the GST tag. Even for clearly detectable sample signals, the i-score can be 
relatively low in the case of strong anti-GST staining. Among proteins with a similar high z-
score, an increased i-score can be an additional indication of strong specific binding. The 
‘sample – control’ column indicates the difference of fluorescence between sample staining at 
535nm and antihuman IgM staining alone; whereas the ‘sample/control’ pertains to the 
fluorescence ratio between sample staining at 535nm and anti-human IgM staining alone, 
indicative of the relative change upon sample incubation. Values of 1 demonstrate a low 
relative change. Protein ID, functionality and location are also included – together providing a 
comprehensive overview of the obtained results. Functional descriptions of the proteins were 






















With a specific focus on subarray 22, Figure 37A denotes the anti-GST staining 
showing protein locations within the subarray; Figure 37B portrays anti-IgM staining 
showing strong reactivity with DPP10 which is absent in 37C - the negative control 
array incubated with secondary antibodies only.  
(A) Anti GST (B) Sample SchS-2 (C) Control array 
DPP10 






The target, gene name, protein function & primary locations, sample fluorescence intensities, alongside the z-scores and i-scores are presented 
within the table.  *Protein without a GST tag **Known autoantigen  
cAMP: Cyclic adenosine monophosphate; CNS: Central nervous system; ER: Endoplasmic reticulum; GA: Golgi apparatus; PM: Plasma 
membrane; TF: Transcription factor; PTM: Post-translational modification
Target	 Gene	name	 Functionality	 Location	(s)	 Sample-control	
Sample/
control	 z-score	 i-score	
FBXO2	 F-box	protein	2	 Substrate	of	an	E3	ubiquitin	ligase	complex	 ER	 9141	 11.1	 4.67	 2.4	
DPP10	 Dipeptidyl-peptidase	like	10	 Potassium	channel	regulator	 PM,	GA	 4852	 37.2	 4.21	 5.0	
ATF1	 Activating	transcription	factor-1	 TF-	regulating	cell	growth	and	survival	genes	 Nucleus	 4192	 27.2	 4.10	 3.4	
CREM	 cAMP	responsive	element	modulator	 TF	binding	to	cAMP	responsive	element	 Nucleus	 3902	 37.1	 4.05	 2.7	
TLK1	 Tousled-like	kinase	1	 Serine-threonine	kinase	involved	in	chromatin	regulation	assembly	 Nucleus	 3532	 13.5	 3.98	 2.4	
EDC4	 Enhancer	of	mRNA	decapping-4	 mRNA	decapping	 Nucleus,	cytosol	 3311	 14.1	 3.93	 1.6	
NR6A1	 Nuclear	receptor	subfamily	6	group	A,	member	1	 Hormone	receptor	–	involved	in	neurogenesis	and	germ	cell	development	 Nucleus	 3305	 35.4	 3.93	 3.5	
SSH3	 Slingshot	protein	phosphatase-3	 Protein	phosphatase	–	regulator	of	actin	filament	dynamics	 Nucleus,	cytoskeleton	 3203	 7.5	 3.91	 0.9	
ZNF384	 Zinc	finger	protein-384	 TF	–	binds	and	regulates	promoters	of	extracellular	matrix	genes	 Nucleus	 2982	 22.9	 3.85	 2.4	
LHX5	 LIM	homeobox-5	 Regulator	of	neuronal	differentiation	and	migration	during	development	of	the	CNS	 Nucleus	 2962	 20.0	 3.85	 6.2	
MLX	 MLX,	MAX	dimerisation	protein	 TF	-	Involved	in	transcriptional	regulation	–	cellular	proliferation	and	differentiation	 Nucleus	 2904	 8.0	 3.83	 0.7	
THRA	 Thyroid	hormone	receptor-alpha	 Hormone	receptor	for	the	thyroid	hormone	 Nucleus,	cytosol	 2833	 27.7	 3.82	 3.6	
MAX	 MYC-associated	factor	X	 Transcriptional	regulator	forming	a	complex	with	MYC,	an	oncogenic	associated	TF	 Nucleus,	cytosol	 2675	 34.4	 3.78	 2.7	
NR2E1	 Nuclear	receptor	sub-family	2,	group	E,	member	1	 Receptor	involved	in	retinal	development	 Nucleus	 2566	 12.6	 3.75	 7.4	
ATF7	 Activating	transcription	factor-7	 TF	–	binds	the	cAMP	responsive	element	 Nucleus	 2588	 7.8	 3.75	 0.7	




and	chromosomal	instability	–	within	the	host	 Nucleus,	cytosol	 2421	 18.0	 3.7	 n/a	
MITF**	 Melanogenesis	associated	transcription	factor	 TF-	regulates	genes	involved	in	cell	differentiation,	proliferation	and	survival	 Nucleus	 2274	 23.3	 3.66	 1.7	
H2AFY	 H2A	histone	family	member	Y	 One	of	the	proteins	responsible	for	compacting	the	nucleosome	structure	of	chromosomes	 Nucleus	 2256	 9.1	 3.65	 1.7	
PARP11	 Poly(ADP-ribose)	polymerase	family-11	 Involved	in	protein	PTM	by	addition	of	ADP-ribose	moieties	 Nucleus,	cytosol	 2221	 4.5	 3.64	 1.8	





Eighteen out of 20 proteins are reported to be nuclear, and also can be located within the 
cytosol (5); cytoskeleton (1), PM (1) & GA (1), and another within the ER. This sample shares 
nine targets with WM-2: FBXO2, CREM, EDC4, NR6A1, ZNF384, LHX5, THRA, NR2E1 and 
ATF7. Another five proteins hits are shared amongst this sample, SchS-23 and WM-2: DPP10, 
ATF1, TLK1, SSH3, MLX; with H2AFY unique to this sample and SchS-23. 
Function 
Even though FBXO2 was the top interactor in this sample, this protein is noted to retain strong 
binding capacities on the array, and therefore is regarded with caution. Nevertheless, this 
ubiquitinating protein was the second top hit for WM-2 with a very similar z and i-score. The 
potassium channel regulator DPP10 (indicated in Figure 37) was the second top hit – was also 
found significant in SchS-23 and WM-2. Interestingly, TLK1 was the top interactor in WM-2 
and also was ranked 16 in sample SchS-23.  This protein belongs to a family of nuclear 
serine/threonine kinases is predicted to play a role in chromatin assembly and remodelling. 
Another chromatin associated hit was H2AFY. Although ranked towards the bottom of the 
shown data, this transcriptional repressor was the top antigen in SchS-23 and signifies the 
only top hit seen in the SchS samples. Out of the other nuclear located proteins, seven were 
transcription factors: ATF1, CREM, ZNF384, MLX, ATF7, BHLHE22 and MITF. Of note, MITF 
is a known autoantigen associated with the autoimmune condition, Vitiligo. Proteins MAX, 
BHLHE22, Hep B Protein X, MITF and PARP11 were unique to this sample. Particularly, 
interaction with the Hep B protein may represent a mounted response to recent infection or 
vaccination. NR6A1, NR2E1 and THRA were three receptors found in this dataset, located in 
the nucleus with ligand binding resulting in cellular growth and development. The latter three 
proteins also interacted with WM-2. Other top interactors included an mRNA degradation 
protein, EDC4; the neuronal cell regulator LHX5, and the protein phosphatase, SSH3.  
Fluorescence, z-score + i-score 
This sample had weaker fluorescence intensities than SchS-31, but similar to those values 
found in SchS-23 and WM-1 and stronger than WM-2 and NLRP3-AID-7. The i-scores ranged 
























With a specific focus on subarray 11 for illustrative purposes, Figure 38A represents anti-
GST staining showing protein locations within the subarray. Figure 38B portrays anti-IgM 
staining showing strong reactivity with COL4A, H2AFY & CCNB2- which are absent in 38C - 
the negative control array incubated with secondary antibodies only. 
  








Target	 Gene	name	 Functionality	 Location	 Sample-control	
Sample/c
ontrol	 z-score	 i-score	
H2AFY	 H2A	histone	family	Y	 One	of	the	proteins	responsible	for	compacting	the	nucleosome	structure	of	chromosomes	 Nucleus	 10208	 37.7	 4.62	 9.8	
GCLC	 Glutamate-cysteine	ligase	catalytic	subunit	 Rate-limiting	enzyme	of	glutathione	synthesis	 Nucleus,	cytosol,	mitochondrion	 9883	 7.0	 4.59	 1.5	
FAM84A	 Family	with	sequence	similarity	84,	member	A	 Involved	in	cell	migration	and	wound	healing	 Nucleus,	cytosol,	perixosome	 9524	 4.6	 4.57	 1.5	
CCNB2	 Cyclin	B2	 Cell	cycle	control	at	G2/mitosis	transition	 Nucleus,	cytosol,	cytoskeleton	 7832	 28.2	 4.42	 6.4	
GALK2	 Galactokinase	2	 Galactose	phosphorylation	activity	 Nucleus,	cytosol,	GA	 7392	 12.3	 4.37	 1.7	
MAF1	 MAF1	homolog,	negative	regulator	of	RNA	polymerase-III	 Transcriptional	repressor	of	RNA	polymerase-III	 Nucleus,	cytosol	 5526	 5.8	 4.15	 0.9	
SMOX	 Spermidine	Oxidase	 Spermidine	forming	activity	 Nucleus,	cytosol	 4830	 12	 4.05	 1.4	
PLEKH-O2	 Pleckstrin	homology	domain	containing	O2	 Potential	regulator	of	macrophage	survival	 Cytosol	 4039	 17.9	 3.92	 2.2	
TFG	 TRK-fused	gene	 Involved	in	ER	functioning	and	its	associated	microtubules	 Cytosol,	ER	 3676	 3.9	 3.84	 0.7	
ZMYM3	 Zinc	finger	MYM	type	containing-3	 Component	of	histone	deacetylase-containing	complexes	 Nucleus	 3216	 6.1	 3.74	 0.6	
COG3	 Component	of	oligomeric	golgi	complex-3	
Forms	part	of	the	conserved	oligomeric	golgi	complex-3	
involved	in	normal	GA	functioning	 GA,	PM	 3014	 6.0	 3.69	 0.8	
ATF1	 Activating	transcription	factor	1	 TF-	regulating	cell	growth	and	survival	genes	 Nucleus	 2840	 18.8	 3.65	 2.3	
GMPPA	 GDP-mannose	pyrophosphorylase	A	 Enzyme	involved	in	the	formation	of	GDP-mannose	 Nucleus	 2792	 4.8	 3.64	 0.8	
COL4A5	 Collagen	type	IV	alpha	5	chain	 Forms	part	of	type	IV	collagen,	a	structural	component	of	basement	membranes	 ER	 2820	 17.4	 3.64	 4.9	
MLX	 MLX,	MAX	dimerisation	protein	 TF	-	Involved	in	transcriptional	regulation	–	cellular	proliferation	and	differentiation	 Nucleus	 2770	 7.7	 3.63	 0.7	
TLK1	 Tousled-like	kinase	1	 Serine-threonine	kinase	involved	in	chromatin	regulation	assembly	 Nucleus	 2760	 8.0	 3.63	 2.0	
DPP10	 Dipeptidyl	peptidase	like	10	 Potassium	channel	regulator	 PM,	GA	 2655	 20.8	 3.59	 3.0	
BCAR1	 Breast	cancer	anti-oestrogen	resistance	protein	1	
Involved	in	tyrosine	kinase	based	signalling,	role	in	cell	adhesion	
and	migration	 Cytosol,	cytoskeleton	 2526	 5.7	 3.56	 0.7	
SSH3	 Slingshot	protein	phosphatase	3	 Protein	phosphatase	–	regulator	of	actin	filament	dynamics	 Nucleus,	cytoskeleton	 2507	 6.1	 3.55	 0.6	
GORAS-P2	 Golgi	reassembly	stacking	protein	2	 Involved	in	assembly	and	membrane	stacking	of	the	GA	 GA	 2320	 4.9	 3.49	 0.4	
Table 12: Top 20 hits from the protein microarray for SchS patient 23. 
The target, gene name, protein function & primary locations, sample fluorescence intensities, alongside the z-scores and i-scores are 





Thirteen out of the top 20 interactors can be found within the nucleus. Interestingly, four 
proteins can also be found in the GA, indicating roles pertaining to protein modifications and 
secretion. Other locations for these hits were cytosolic (9), cytoskeleton (3), PM (2), and/or 
ER (2).  This sample shares five top hits with both SchS-2 and WM-2 and solely H2AFY was 
shared with SchS-2.  
Function 
SchS-23 showed strongest reactivity with H2AFY, also interacting with SchS-2 IgM found as 
the 19th hit, though interestingly this protein was not within the top 20 of the other samples. 
This reaction was closely followed by the glutathione synthesis rate limiting enzyme, GCLC. 
The cell migration and wound healing associated protein, FAM84A, was the third hit within this 
sample. Though this has been noted by CPA to reoccur numerous times with other arrays, 
FAM84A was not witnessed with the other five samples and is therefore unique to SchS-23.   
Located in the cytosol, PLEKH-O2 is a potential regulator of macrophage survival and is an 
interesting hit given that SchS is an autoinflammatory disease with macrophages/monocytes 
known to be cells mediating inflammation. Other hits include the transcriptional regulators, 
MAF1, ZMYM3, and TLK1. The latter protein was also seen as the top hit in WM-2, but was 
the fifth hit in SchS-2. A further two TF’s identified were ATF-1 and MLX; hits also seen in 
SchS-2 and WM-2. DPP10 and SSH3 were also seen in samples SchS-2 and WM-2 with roles 
in potassium channel function and actin regulation respectively. Proteins located in the ER 
included COL4A5, forming parts of the basement membrane of a cell and TFG, with roles in 
functioning of the ER and its associated microtubules. CCBN2 and BCAR1 were other proteins 
also functioning within the cytoskeleton. COG3 AND GORAS-P2 are involved in the regulation 
and functioning of the GA, whereas GALK2 is simply found here known to be a 
phosphorylating enzyme of galactose. Other nuclear located proteins included the enzymes 
spermidine oxidase, SMOX and GMPPA – involved in the generation of GDP mannose. 
 
Fluorescence activity z-score + i-score 
In comparison to the other five samples, the fluorescence intensities were similar to those 
found in SchS-2 and WM-1, higher than WM-2 and NLRP3-AID-7 but much lower than those 





















With a specific focus on subarray 7, Figure 39A represents the anti-GST staining showing 
protein locations within the subarray. Figure 39B shows the anti-IgM staining illustrating 
strong reactivity with SRSF7 and SART3 – which is absent in 39C - the negative control 
array incubated with secondary antibodies only.
(A) Anti GST (B) Sample SchS -31 (C) Control array 
SRSF7 
SART3 






The target, gene name, protein function & primary locations, sample fluorescence intensities, alongside the z-scores and i-scores are presented 
within the table.  
EGFR: Epidermal growth factor receptor; ER: Endoplasmic reticulum; GA: Golgi apparatus; MAPK: mitogen-activated protein kinases; PM: 
Plasma membrane; TF: Transcription factor
Target	 Gene	name	 Functionality	 Cellular	location(s)	 Sample-control	
Sample/c
ontrol	 z-score	 i-score	
SRSF7	 Serine	and	arginine	rich	splicing	factor-7	 RNA	binding	and	splicing	 Nucleus,	cytosol	 64758	 91.2	 5.99	 29.4	
UBL7	 Ubiquitin-like	7	 Regulation	of	bone	marrow	stem	cells	function	and/or	differentiation	 Nucleus,	cytosol	 64303	 55.5	 5.99	 9.8	
CNKSR1	 Connector	enhancer	of	kinase	suppressor	of	Ras	1	 Adaptor	protein	and/or	regulator	of	Ras	signalling	pathways	 Nucleus,	cytosol,	PM	 38806	 69.2	 5.62	 8.4	
OGFR	 Opioid	growth	factor	receptor	 Growth	regulator	 Nucleus,	cytosol	 35541	 121.1	 5.55	 7.4	
PNPO	 Pyridoxamine	5’-phosphate	oxidase	 Oxidoreductase	activity	 Nucleus,	cytosol,	mitochondrion	 30337	 22.6	 5.44	 5.7	
OXR1	 Oxidation	resistance-1	 Oxidoreductase	activity	 Nucleus,	cytosol,	mitochondrion	 18609	 31.3	 5.07	 3.0	
DAXX	 Death	domain	associated	protein	 Apoptosis	modulator/transcriptional	repressor	 Nucleus,	cytosol	 15758	 37.1	 4.95	 4.1	
PDZD3	 PDZ	domain	containing-3	 Protein	C	terminus	binding/	guanylate	cyclase	inhibitor	activity	 Nucleus,	PM	 15062	 12.3	 4.92	 3.4	
RHBDF1	 Rhomboid	5,	homolog-1	 Regulates	secretion	of	eGFR	associated	ligands	 ER,	GA	 13474	 73.4	 4.84	 10	
CYB5R3	 Cytochrome	B5	reductase-3	 Fatty	acid	regulator,	cholesterol	biosynthesis,	methemoglobin	reduction	 Mitochondrion,	cytosol,	ER	 10288	 6.8	 4.64	 1.6	
SMARCC1	 SWI/SNF	related,	matrix	associated,	actin	dependent	regulator	of	chromatin	subfamily	c,	member	1	
Transcription	activation/repression	of	select	
genes	by	chromatin	remodelling	 Nucleus	 9358	 10.8	 4.56	 1.4	
TRIM16	 Tripartite	motif	containing-16	
Tumour	suppressor,	nucleic	acid	binding,	NACHT	
domain	binding	 Nucleus,	cytosol,	PM	 8825	 5.8	 4.52	 1.4	
TRAPPC12	 Trafficking	protein	particle	complex-12	 Component	of	TRAPP	complex	–	ER	to	GA	protein	trafficking	 Nucleus,	cytosol	 5154	 70.6	 4.12	 4.4	
CNNM1	 Cyclin	and	CBS	domain	divalent	metal	cation	transport	mediator-1	 Copper/metal	binding	activity	 PM	 4906	 5.1	 4.09	 0.8	
FAM53C	 Family	with	sequence	similarity	53,	member	C	 Bind	to	transcriptional	regulators	modulating	cellular	proliferation	 Nucleus,	cytosol	 4580	 4.9	 4.04	 1.0	
ZFP36L2	 ZFP36	ring	finger	protein	like-2	 TF	–	regulates	the	response	to	growth	factors	 Nucleus	 4163	 17	 3.96	 3.2	
SNX4	 Sorting	nexin-4	 Involved	in	several	stages	of	intracellular	trafficking,	EGFR	binding	 PM,	cytoskeleton,	endosome	 3959	 6.9	 3.93	 0.7	
FAM131B	 Family	with	sequence	similarity	131	member	B	 Involved	in	oncogenic	MAPK	signalling,	HIV	life	cycle	
Nucleus,	





splicing	 Nucleus	 3764	 3.8	 3.89	 0.6	
CREB3L1	 cAMP	responsive	element	binding	protein	3	like-1	 TF	–	involved	in	the	unfolded	protein	response	 Nucleus,	ER	 3121	 20.3	 3.75	 2.0	





All hits shown in this table were unique to this sample. Eleven out of 20 top interactors are 
both nuclear and cytosolic, with two of these also found within the mitochondrion. Other 
proteins reside within the PM, cytoskeleton, ER, endosome and/or GA.   
Function 
The strongest hit was SRSF7, an RNA binding and splicing molecule forming part of the 
spliceosome with a nuclear location. Another splicing associated protein identified was 
SART3, though ranked towards the end of the top 20 hits. Coming second, UBL7 also has 
nuclear location and has been noted to be involved with bone-marrow stem cell differentiation. 
The third top hit was the adaptor CNKSR1, known to be involved with Ras signalling pathways. 
Coming fourth, OGFR encodes a growth factor receptor, and interestingly, two EGFR 
signalling related proteins were also identified: RHBDF1 and SNX4, playing roles in EGFR 
ligand signalling and EGFR binding respectively. Mainly situated in the mitochondria, PNPO 
and OXR1 both exhibit oxidoreductase activity, with the enzyme CYB5R3 being regulator of 
fatty acids and cholesterol biosynthesis. Where DAXX is noted to be a transcriptional 
repressor only, SMARCC1 is both a transcriptional activator and repressor acting through 
chromatin remodelling. FAM53C has been documented to bind to transcriptional regulators, 
modulating cellular proliferation. PDZD3 binds proteins at their C-terminal, with additional 
guanylate cyclase inhibitor activity. TRIM16, binding to the evolutionary conserved NACHT 
domains is a notable hit, given the role of NLRP3 in SchS. TRAPPC12 is an integral 
component of the TRAPP complex, the latter responsible for trafficking proteins from the ER 
to the GA. CNNM1 was an interesting finding, known to have copper binding activity. FP36L2 
and CREB3L1 were two TF’s amongst the top hits, with the former regulating the response to 
growth factors and the latter transcribing genes associated with the unfolded protein response. 
FAM131B is known to play a role in oncogenic MAPK signalling.  
Fluorescence, z-score + i-score 
This sample had the highest sample intensities in comparison to the other five samples and 
therefore strongest interactions. The i-scores ranged between 0.6 and 29.4, with the highest 
score pertaining to the top hit (SRSF7) within this sample. Not only is this elevated value 
obtained reflective of the strong protein interaction, but this can also be attributed to the slightly 






















With a specific focus on subarray 8, Figure 44A illustrates anti-GST staining showing 
protein locations within the subarray.  Figure 44B is the anti-IgM staining showing 
strong reactivity towards TAF9 – which is absent in 44C - the negative control array 
incubated with secondary antibodies only.   
(A) Anti GST (B) Sample RS (C) Control array 
TAF9 









TAF9	 TATA-box	binding	protein	associated	factor	9	 Transcriptional	activation	and	repression	 Nucleus	 11128	 8.4	 4.04	 4.1	
FAM175B	 Family	with	sequence	similarity	175,	member	B	 Protein	metabolism,	deubiquinating	activity	 Nucleus,	cytosol	 10558	 10.8	 4.01	 2.5	





6958	 6	 3.69	 1.8	
MRPL1	 Mitochondrial	ribosomal	protein	L1	 Structural	component	of	mitochondrial	ribosomes	 Mitochondrion	 6828	 8.3	 3.68	 2.3	
EXOC3	 Exocyst	complex	component	3	 Component	of	the	exocyst	complex	–	docks	exocytic	vesicles	on	the	PM	 Cytosol,	GA,	PM	 5972	 5.8	 3.58	 2.0	
GAPDHS	 Glyceraldehyde-3-phosphate	dehydrogenase,	spermatogenic	
Involved	in	carbohydrate	metabolism	during	
spermatogenesis	 Cytosol	 4546	 5.1	 3.38	 1.3	
TMPRSS12	 Transmembrane	protease,	serine	12	 Serine	type	endopeptidase	activity	 PM	 4346	 10.8	 3.35	 4.8	
RAD51	 RAD51	recombinase	 Assists	in	the	repair	of	double-stranded	DNA	breaks	 Nucleus,	mitochondrion	 4230	 7.2	 3.32	 4.9	
TOLLIP	 Toll-interacting	protein	 IL-1R	trafficking,	ubiquitin	binding,	interacts	with	TLR	signaling	cascade	components	 Cytosol,	lysosome,	PM	 3880	 8.2	 3.26	 2.8	
MTPAP	 Mitochondrial	poly(A)	polymerase	 Synthesises	the	3’	poly(A)	tail	of	mitochondrial	transcripts,	involved	in	mRNA	degradation	 Mitochondrion,	cytosol	 3832	 8.5	 3.25	 5.3	
TPMT	 Thiopurine	S-methyltransferase	 Catalyses	S-methylation	of	thiopurine	drugs	 Cytosol		 3223	 6.1	 3.12	 1.1	
NXF2	 Nuclear	RNA	export	factor	2	 Export	of	mRNA	and	association	with	the	nuclear	envelope	 Nucleus,	cytosol	 2920	 10	 3.05	 6.3	
RGS18	 Regulator	of	G	protein	signalling	18	 Attenuates	signaling	of	G	proteins	 Cytosol,	PM	 2760	 6.1	 3.01	 1.3	
MIC13	 Micos	complex	subunit	13	 Component	of	MICOS	complex	–	within	the	inner	mitochondrial	membrane		 Nucleus,	mitochondrion	 2772	 5.3	 3.01	 1.6	
C17orf64	 Chromosome	17	open	reading	frame	64	 Uncharacterised	 /	 2740	 7.6	 3.00	 1.9	
VGLL4	 Vestigial	like	family	member	4	 Co-activator	of	transcription-enhancer	factor	 Nucleus		 2712	 4.1	 2.99	 0.9	
NDOR1	 NADPH	dependent	diflavin	oxidoreductase	1	 NADPH	reductase	–	oxidoreductase	activity	 Nucleus,	cytosol,	cytoskeleton	 2675	 3.0	 2.98	 0.4	
AGTR1	 Angiotensin	II	receptor	type	1	 Receptor	for	the	vasopressor	hormone,	angiotensin	II	 PM	 2580	 16.7	 2.95	 7.4	
USP2	 Ubiquitin	specific	peptidase	2	 Enzyme	required	for	TNF-	induced	NF-κB	signalling	 Nucleus,	cytosol	 2515	 120.8	 2.94	 143.7	
Table 14: Top 20 hits from the protein microarray for sample WM-1. 
The target, gene name, protein function & primary locations, sample fluorescence intensities, alongside the z-scores and i-scores are 





All interactions within the table are unique to this sample with nine out of the top 20 interactors 
reported to be located within the nucleus, and six also mitochondrial associated. The 
remaining proteins reside within the cytosol, cytoskeleton, ER, GA and/or PM, with two 
reported to also be found within the lysosome and peroxisome.  
Function 
Notably, the two WM patients did not share any of the top proteins found on the array. TAF9 
presented as the chief hit in this dataset, a transcriptional activator and repressor, reported to 
bind and potentially activate NF- κB and interestingly, the IL-1R and TLR interactor, TOLLIP 
was amongst the top proteins. The latter protein plays an important adaptive role in AI disease 
signalling cascades associated with MYD88. Both FAM175B (2nd top hit) and USP2 
demonstrate deubiquitinating activity with the third interactor being TTLL2, an enzyme with 
ligase activity related to tubulin. Other enzymes include DHRS4 and NDOR1, exhibiting 
oxidoreductase activity. Associated with mitochondria, MRPL1 is a structural component of 
mitochondrial ribosomes, whereas MIC13 forms part of the MICOS complex located within the 
inner mitochondrial membrane. MTPAP primarily functions to generate the 3’end poly (A) tail 
of mitochondrial transcripts, but can also be involved with mRNA degradation. The four PM 
located proteins were (1) EXOC3 – involved in exocyst vesicle docking; (2) TMPRSS12 – with 
serine type endopeptidase activity; (3) RGS18 – halting G-protein signalling and (4) AGTR1 – 
the angiotensin II receptor. Unusually, TPMT is an enzyme responsible for the breaking down 
of thiopurine-containing drugs. An example of the latter drug is methotrexate, a 
chemotherapeutic which can be prescribed for WM.  
Although TFs are present in the other five samples, none were found within the top 20 of WM-
1, although TAF9 and VGLL4 are known to play roles in transcriptional activation. Other hits 
included the DNA repair enzyme – RAD51; GAPDHS, involved in spermatogenesis 
metabolism, and NXF2 involved in mRNA export. C17orf64 was within the top 20 but is a 
protein yet to be characterised. 
Fluorescence, i-score and z-score 
This sample demonstrated fluorescence activity comparable to SchS-2 and SchS-23. Though 
higher than the other WM sample and NLRP3-AID-7, this sample showed a reduced intensity 
in comparison to SchS-31.  The i-scores varied between 0.4 to an elevated 143.7. Though the 
latter value can be regarded as another indicator of strong protein-protein binding, this skewed 
value is likely due to the extremely weak GST staining intensity in comparison to the average 



















With a specific focus on subarray 24, Figure 45A is representative of anti-GST staining 
showing protein locations within the subarray. Figure 45B indicates anti-IgM staining 
showing strong reactivity towards TLK1 (2 different clones) – which is absent in 45C -  
the negative control array incubated with secondary antibodies only.   
(A) Anti GST (B) Sample SR (C) Control array 
TLK1 TLK1 






The target, gene name, protein function & primary locations, sample fluorescence intensities, alongside the z-scores and i-scores are presented 
within the table. cAMP: Cyclic adenosine monophosphate; ER: Endoplasmic reticulum; GA: Golgi apparatus; PM: Plasma membrane; TF: 
Transcription factor  
Target	 Gene	name	 Functionality	 Location(s)	 Sample	–	control	
Sample/c
ontrol	 z-score	 i-score	
TLK1	 Tousled	like	kinase-1	 Serine-threonine	kinase	involved	in	chromatin	regulation	assembly	 Nucleus	 3652	 14	 4.59	 2.8	
FBXO2	 F-box	protein	2	 Substrate	of	an	E3	ubiquitin	ligase	complex	 ER	 3339	 4.7	 4.53	 0.9	
ATF1	 Activating	transcription	factor-1	 TF-	regulating	cell	growth	and	survival	genes	 Nucleus	 2376	 15.8	 4.26	 1.7	
DPP10	 Dipeptidyl	peptidase	like	10	 Potassium	channel	regulator	 PM,	GA	 2194	 17.4	 4.20	 2.2	
PNMA1	 PNMA	family	member-1	 Neuronal	specific	protein	 Nucleus	 1730	 4.4	 4.01	 0.7	
























Nucleus	 1244	 9.0	 3.75	 2.2	
NR2E1	 Nuclear	receptor	subfamily	2,	group	E,	member	1	 Receptor	involved	in	retinal	development	 Nucleus	 1158	 6.2	 3.70	 4.4	
Onecut1	 One	cut	homeobox-1	 Transcriptional	activator,	particularly	of	liver-associated	genes	 Nucleus		 1158	 26.2	 3.70	 3.6	
ATF7	 Activating	transcription	factor-7	 TF	–	binds	the	cAMP	responsive	element	 Nucleus	 1127	 3.9	 3.67	 0.3	
BARX1	 BARX	homeobox	-1	 TF	–	craniofacial	development	and	stomach	organogenesis	 Nucleus	 1078	 2.1	 3.64	 0.3	




Nucleus	 1004	 11	 3.58	 1.6	
CREB1	 cAMP	responsive	element	binding	protein-1	 Binds	the	cAMP	response	element,	stimulating	transcription	 Nucleus	 979	 15.4	 3.57	 1.5	
SOX8	 SRY-box	8	 TF	–	embryonic	development	and	cell	fate	determination	 Nucleus	 952	 7.9	 3.54	 0.6	





Eighteen out of the 20 hits are nuclear, with two of these proteins also found within the 
cytosol. The other two interactors were located within the ER (FBXO2), alongside DPP10 
located both in the GA and PM. This sample shares nine hits with SchS-2 and a further five 
hits with both SchS-2 and WM-2.  
Function 
The basic functions of the five overlapping proteins seen in this dataset with SchS-2 and SchS-
23 have been outlined in the abovementioned sections (ATF1, MLX, TLK1, DPP10 and 
SSH3). These proteins were found within the top 10 hits of this sample. WM-2 IgM uniquely 
bound proteins associated with organ development. Two of these were the transcription 
factors BARX1 and SOX8; the transcriptional activators onecut1 and CREB1; alongside the 




Fluorescence, i-score and z-score 
This sample exhibited reduced fluorescence intensities when compared to SchS-2, 23, 31 
and WM-1, but comparable to those values sought in NLRP3-AID-7. Nevertheless, the i-
scores were in the range of 0.4 to 4.4 with the z-scores above 3.54, confirming the accuracy 
































With a specific focus on subarray 15, Figure 46A represents anti-GST staining 
showing protein locations within the subarray. Figure 46B indicates anti-IgM staining 
showing strong reactivity with TMEM185B, DCPS5 & KRAS – which is absent in 46C 
- the negative control array incubated with secondary antibodies only.  













DCPS	 Decapping	enzyme,	scavenger	 mRNA	decapping	enzyme	 Nucleus,	cytosol,	mitochondrion	 3062	 5.8	 4.16	 0.8	
DDIAS	 DNA-damage	induced	apoptosis	suppressor	 Anti-apoptotic	protein	involved	in	DNA	repair/cell	cycle	networks	 Nucleus	 2767	 3.8	 4.06	 0.5	
GTF3C3	 General	transcription	factor	IIIC	subunit-3	 TF	-	Recruitment	of	RNA	polymerase	III	 Nucleus	 2706	 4.2	 4.04	 0.4	
NINJ1	 Ninjurin-1	 Cell	adhesion	protein	with	axonal	growth	roles	 PM	 2343	 3.2	 3.89	 1.4	
KRAS	 KRAS	proto-oncogene,	GTPase	 GTPase	activity,	regulation	of	cell	proliferation,	silencing	of	tumour	suppressing	genes	 Cytosol,	PM	 1996	 7.7	 3.73	 1.2	
TMEM185B	 Transmembrane	protein	185B	 Unknown	 PM	 1946	 6.2	 3.70	 1.3	
RHOD	 Ras	homolog	family	member	D	 Involved	in	endosome	dynamics	and	actin	cytoskeleton	reorganisation	 Cytosol,	endosome,	PM	 1907	 13.1	 3.68	 1.1	
TMEM243	 Transmembrane	protein-243	 Unknown	 Perixosome,	PM	 1698	 4.5	 3.56	 0.6	
AQP5	 Aquaporin	5	 Water	channel	 PM	 1580	 4.9	 3.49	 1.1	
RND2	 Rho	family	GTPase-2	 Actin	cytoskeleton	organisation,	specifically	in	neuronal	and	hepatic	networks	 Cytosol,	cytokskeleton	 1449	 4.2	 3.40	 0.7	
PMAIP1	 PMA	induced	protein-1	 Promotes	activation	of	caspases	and	apoptosis	 Nucleus,	cytosol,	mitochondrion	 1408	 3.8	 3.37	 0.5	
POTEB	 POTE	Ankyrin	domain	family	member	B	 Intracellular	signalling	and	protein-protein	interaction	 Cytosol,	PM*	 1406	 5.7	 3.37	 1.7	
RHOG	 Ras	homolog	family	member	G	 Actin	cytoskeleton	arrangement,	cell	migration	 Cytosol,	ER,	PM	 1261	 3.2	 3.26	 0.3	
PRRG2	 Proline	rich	and	GLA	domain-2	 Transmembrane	protein,	involved	in	calcium	binding	 PM	 1249	 3.9	 3.25	 1.0	
RND1	 Rho	family	GTPase-1	 Actin	cytoskeleton	arrangement	 Cytosol,	cytoskeleton,	PM	 1173	 3.2	 3.19	 0.6	
EDIL3	 EGF-like	repeats	and	discoidin	domains-3	 Integrin	ligand	–	mediates	endothelial	cell	adhesion	 PM	 1172	 3.6	 3.18	 0.9	
SFT2D2	 SFT2	domain	containing-2	 Involved	with	the	fusion	of	endocytic	transport	vesicles	to	the	GA	 Endosome,	GA	 1162	 3.3	 3.18	 0.7	
ING3	 Inhibitor	of	growth	family	member-3	 Tumour	suppressor	–	inhibits	cell	growth	and	induces	apoptosis	 Nucleus,	cytosol	 1083	 5.5	 3.11	 0.5	
ACP6	 Acid	phosphatase	6,	lysophosphatidic	 Hydrolyses	lysophosphatidic	acid	 Mitochondrion	 1078	 2.8	 3.1	 0.4	
ORAI3	 ORAI	calcium	release	activated	calcium	modulator-3	 Calcium	channel	regulator	 Cytosol,	PM	 1062	 3	 3.08	 0.5	
Table 16: Top 20 hits from the protein microarray for sample NLRP3-AID 7. 
The target, gene name, protein function & primary locations, sample fluorescence intensities, alongside the z-scores and i-scores are presented 
within the table. *likely to be based on function – not confirmed. 





All hits were exclusive to this sample. Five out of 20 protein hits were reported to be nuclear, 
with the majority located within the cytosol or components within the cytoplasm. Interestingly, 
three proteins are located within the mitochondrion, but a majority reside within the cytosol/and 
or PM. These results are in contrast to B2, whereby 90% of the top 20 interactors were 
primarily located in the nucleus.  
 
Function 
The top hit in this sample was DCPS, an enzyme necessary for the complete degradation of 
mRNA, closely followed by DDIAS - an anti-apoptotic protein involved in DNA repair and cell 
cycle networks. The latter interaction is contrasted by ING3 and PMAIP1 findings, both having 
roles in the induction of apoptosis. GTF3C3 was the only TF associated protein within this set 
of interactors. This is in contrast to the other five samples, where at least over 80% were TF’s. 
The fourth top protein was NINJ1, understood to be a cell adhesion molecule. Interestingly, 
EDIL3, another significant hit, has a similar role and is known as an integrin ligand. There are 
several recurrent hits on families of GTPases or GTP binding proteins: KRAS, RHOD, RND2, 
RHOG, RND1, (in order of significant interactions), suggesting linkage to signal transduction 
and cell signalling. Intriguingly, ORAI3 and PRRG2 are play roles in regulating calcium binding 
and transport. Among the other principle interactions were AQP5 – a water channel, POTEB 
– playing a role within intracellular signalling, SFT2D2 – involved in vesicle transport to the 
GA and ACP6, an enzyme known to hydrolyse lysophosphatidic acid. Two of the identified 
transmembrane proteins, TMEM185B and TMEM243, have unknown protein function.  
 
Fluorescence, z-score + i-score 
The serum IgM obtained from this sample demonstrated the lowest fluorescent intensities in 
evaluation with the other five samples tested. This is an unsurprising observation given that 
NLRP3-AID is not an IgM-associated disorder and therefore the low affinity of IgM can also 
be reflected in these antigen binding reduced fluorescent values. Nonetheless, the i-score 
values were between 0.3 to 1.7, the z-score values obtained for each interaction all above 
3.08 and with the three top interactors all having z-scores above 4.0, indicating the high 







4.3.3 Shared protein targets 
The top 20 hits found within samples SchS-31, NLRP3-AID-7 and WM-1 are exclusive to 
each patient; whereas SchS-2, SchS-23 and WM-2 share common targets. Figure 47 
provides an overview of shared protein targets with considerations of the hits for each 











Three out of the six samples tested for IgM binding had shared hits and these results are 
further depicted as a Venn diagram above.  
Nine antigenic targets were exclusively shared between WM-2 and SchS-2, one between 
SchS-2 and SchS-23, but none were unique to both WM-2 and SchS-23. ATF-1 (transcription 
factor), MLX (transcription), TLK-1 (chromatin assembly), DPP10 (peptidase) and SSH3 
(protein phosphatase) are the five proteins which bound serum IgM from SchS-2, SchS-23 
and WM-2. Whilst the overarching function of the aforementioned proteins could be broadly 
linked to cellular growth and pro-survival, their disparate functions and intracellular locations 
essentially indicate they don’t belong to a specific pathway or collectively serve a combined 
purpose. Considerably, the observation of shared antigenic targets underscores the potential 












The work described in this chapter isolated the IgM from individuals with SchS, NLRP3-AID, 
WM and HCs, in order to explore the idea that the IgM paraprotein produced by SchS patients 
differs to IgM generated by other control groups in view of its preferential binding capacity to 
a select group of proteins.  
To summarise, the main outcomes and findings in this chapter were: 
i. Serum IgM was effectively isolated from two HCs, three SchS patients, two WM 
patients and one NLRP3-AID patient 
ii. SchS IgM appears to bind to mainly intracellular targets 
iii. Shared hits were seen between two SchS patients and one WM patient 
 
4.4.1 IgM isolation from serum 
In order to investigate the activity of the monoclonal component characteristic of SchS, 
purification of such antibodies from serum was therefore necessary. Employment of the FPLC 
based AKTA Pure system in union with IgM HiTrap™ column enabled antibody isolation. 
Despite high levels of the monoclonal component in the serum of SchS and WM patients, this 
was not reflected in the quantity of isolated protein in comparison to the other samples where 
paraproteinaemia is uncharacteristic. This observation could highlight ligand saturation within 
the column but also the fact that partial loss of material occurred during the washing steps. 
Nevertheless, the resulting antibody fractions obtained required approximately a 40 fold 
dilution for protein microarray application (Section 4.2.2).  
The clonal population of B cells responsible for SchS paraproteinaemia is yet to be 
characterised, thus simply isolating the monoclonal component poses a challenge. It is 
therefore imperative to consider the fractions garnered through the described isolation 
methodology comprise of both the monoclonal component and generally produced IgM. 
Regardless, even a limited part of the clonal IgM repertoire directed at a specific antigen 









4.4.1.1 Protein microarray 
All patient samples were suitable for HuProt™ analysis with no background observed and 
showed a moderate strength of microarray spot interaction as indicated by the z-scores and i-
scores, with the exception of SchS-31 demonstrating strong binding. As show in Figure 38, 
the proteins immobilised on the array were tagged with GST, thus anti-GST staining on each 
of the microarrays served as a positive control. The negative control was a seventh slide, 












The proteins comprised of kinases, cell death, membrane, nuclear, metabolism, transduction 
of signals, secretory and transcription factor categories.  
 
WM patients together with the SchS patients found over 90% of their top 20 hits as nuclear, 
whereas NLRP3-AID-IgM was directed towards both nuclear and PM associated proteins. A 
significant proportion of these intracellular targets included transcription factors and 
transcriptional activators; regulators of chromatin and RNA related proteins. In contrast, 
extracellular antigens were largely absent with all samples. Given the inability of IgM to 
penetrate the cell, presence of these targets extracellularly is therefore assumed and therefore 
implies cellular release of contents into the milieu. Alternatively, the interactions noted could 
refer to the humoral immune response in generating a low affinity IgM with broad range 
specificity (298). Nevertheless, the shared targets seen within SchS-2, SchS-23 and WM-2 





















probed, it is unlikely that these findings are merely coincidental. Whether SchS and WM share 
resemblance within their antibody repertoires is experimentally addressed in the following 
results chapter.  
 
4.4.1.2 Autoimmune-related hits 
The presence of a few proteins in this data that are also targeted by autoantibodies in several 
autoimmune conditions could indicate that the paraprotein generated in SchS and WM bears 
a predisposition to recognising self-proteins as antigenic targets. Given that autoinflammatory 
syndromes rarely present with paraproteinaemia, attempting to functionally characterise the 
overabundant IgM based on shared mechanisms is rather challenging. Nevertheless, there is 
a broader range of literature comprehensively describing autoantigens found in autoimmunity-
related conditions. Therefore, the following section highlights microarray hits of particular 
interest found in this work that are known autoantigens in autoimmune disorders. Comparison 
of autoantibody targets generated in SLE for example, to those found in autoinflammatory and 
haematological diseases may underscore the shared characteristics of the clonal components 
produced and indicate the aspects triggering antibody production towards such proteins. 
Notably, the hits described were solely within SchS and were found unique to each sample 
(aside from H2AFY found in two samples). 
The strongest interaction seen in the entire dataset was that observed between SchS-31 and 
SRSF7, an RNA binding and splicing molecule. This protein forms part of the nuclear 
‘spliceosome’ with literature reporting this as an autoantigen in MS (191, 299). Around 30% of  
SLE patients demonstrate activity against several other spliceosome components (known as 
Sm antigens) (300, 301), with other research linking these interactions to kidney damage 
(302).   HIV and antigenic components of EBV (EBNA-1 and EBNA-2) have shown strong 
capability of inducing autoantibody production against Sm antigens (303, 304), though this 
unlikely to be the scenario for patient SchS-31 given the absence of the latter viruses. Another 
RNA splicing molecule SART3, was another top hit in SchS-31. Interestingly, IgG auto-abs 
against other members of the SART family have been distinguished in atopic dermatitis (305), 
a condition linked to autoimmunity. Given the dermal manifestations of SchS (NUD),  
Located within the nuclear envelope, the opioid growth factor receptor (OGFR) was the fourth 
hit in SchS-31. Clinically, blockade of the pathway through low doses of Naltrexone results in 
increased encephalin levels of patients associated with an improvement in clinical symptoms 
such as fatigue and decreased motor activity. These observations are seen in several 
autoimmune diseases such as Crohn’s (306), fibromyalgia (307), and Multiple Sclerosis (MS) 




Both H2AFY and COL4A5 are known auto-antigens in SLE (310, 311). Whilst the histone 
H2AFY was the top interactor with SchS-23, COL4A5 reacted more weakly within this sample. 
SchS-2 also demonstrated interaction with H2AFY though to a lower intensity relative to SchS-
23 and signifies the only shared hit amongst SchS. Anti-histone antibodies are directed to the 
transcriptionally inactive chromatin and are predominantly found in 95% of patients with drug 
induced SLE (312). The aforementioned antibodies can also be found in other autoimmune 
rheumatic diseases such as Scleroderma and RA and also discovered upon chronic EBV 
infection (313). The other notable hit was COL4A5, seen with SchS-23 only. This subunit forms 
the collagen IV protein (COL4), important for the cellular structure of basement membranes . 
Whilst denatured COL4 is a noted auto-antigen in RA, Scleroderma, and SLE (314, 315), this 
protein is the sole target protein implicated in the autoimmune Goodpasture’s syndrome 
(GPS), manifesting in kidney and pulmonary damage (311). Whilst the latter occurrence is not 
documented in SchS, there have been various kidney complications such as 
glomerulonephritis and diffuse tubulointerstitial nephritis in five SchS patients (50, 54). The 
development of histone autoantibodies is linked to drug induced SLE and also polyoma virus 
infection (316), but the aetiology of COL4 autoantibodies remains obscure – likewise to the 
monoclonal component seen in SchS and WM.  
Evidently, these observed autoimmune related hits are unique to the SchS samples but are 
also found in both common and rare autoimmune conditions. Based on these descriptions, 
previous exposure to viral proteins or environmental components bearing unknown motifs may 
predispose to a heightened immune response is a credible supposition to suggest. 
Subsequent misidentification of numerous self-peptides as foreign by the already precarious 
immune repertoire may render the generation of a monoclonal component with a wide-ranging 
antigen binding capacity. 
4.4.1.3 Link to clonal entities and autoinflammatory manifestations 
Papers have reported WM-IgM exhibiting anti heparin activity (317), and against mixed 
cryoglobulins with high titre rheumatoid factor (318). Other research has established a 
proportion of WM-IgM directed at polysaccharides, lipids and DNA (319), thus akin to SchS 
and from the results in this work, the WM monoclonal component does not preferentially bind 
a common antigen. Another study also looking into the immunological properties of the 
paraproteinaemia produced in both MGUS and MM also found no universal hits. Screening of 
115 patient sera with cDNA libraries originating from human tissues, found one IgA 
monoclonal component bound to sperm specific cyclin 2, with another three patients IgG 
binding to either TPP2, IGFBP2 or porcine kinesin. Arguably and likewise to this study, 




were exposed, thus the interactions noted may not represent the correct antigenic target. 
Nevertheless, the absence of a common antigen largely indicates that the monoclonal 
components derived from MGUS, MM, WM and SchS lack functional antigen binding 
properties (188, 319).  Hence in view of the results presented in this chapter, the function of 
the IgM paraprotein remains unclear with regards to SchS pathobiology. This is in opposition 
to autoimmune diseases such as RA where generation of antibodies of IgM, IgG and IgA 
isotypes against citrullinated proteins contribute to bone destruction and are considered 
biomarkers of disease (320).  
IgM was isolated from sera at one time point, with the biologically significant SchS monoclonal 
component isolated alongside other IgM present in the serum. The latter aspect is an 
imperative detail to consider with regards to target specificity as 15% of serum antibodies are 
IgM type, and the proportion of clonally derived IgM is unknown. Though intriguingly, the top 
20 hits for each sample principally pertained to proteins located intracellularly and considering 
the relatively size of IgM (>900kDa), its infiltration into cells is highly unlikely. As SchS is an 
auto-inflammatory condition, intracellular protein contact with the monoclonal component 
could be achieved through pyroptosis. Although complete disease remission with IL-1 
blockade is achieved in a majority of SchS patients, a persistent level of baseline inflammation 
still exists (i.e. significantly higher levels of ASC specks – Results Chapter 2). Thus, continual 
inflammasome activation substantiates the latter proposition and could further suggest that 
SchS IgM may not be biologically relevant in the disease mechanism – but instead, a by-
product of pyroptosis.  
 
Speculation as to whether the monoclonal component produced is a consequence of 
inflammation manifestations or formed as part of the disease presentation remains unknown. 
Even though SchS patients demonstrate chronic stimulation as evidenced through pro 
inflammatory manifestations, the broad range of interacting antigens renders the hypothesised 
‘pathogenic’ role of SchS-IgM unlikely. Rather, an already biased IgH repertoire exposed to a 
broad spectrum of cell debris as a consequence of pyroptosis characterises a more fitting 
theory in view of the paraproteinaemia. Granted the remarkable response of anti-IL-1 therapy 
in SchS patients sustaining reduced autoinflammation, a degree of autonomous inflammation 
is likely to still exist (321), supporting IgM overproduction through presentation of non-specific 
antigens. Further speculation that an already hyper-inflammatory environment exposed to 
exogenous antigens (i.e. bacteria) not necessarily pathogenic, may also result in persistence 
of the monoclonal response. Although IgM levels and SchS disease activity do not immediately 





4.4.2 Chapter conclusions 
The identification of IgM targets was achievable by taking advantage of FPLC techniques 
facilitating the isolation of IgM from serum samples and subsequent application onto a protein 
microarray. The predominance of nuclear located targets of SchS-IgM and WM as opposed 
to NLRP3-AID IgM is noteworthy. Access of the Ig to these intracellular proteins through 
autoinflammatory-mediated cell death (pyroptosis) is one plausible explanation considering 
the pivotal role of NLRP3, ASC specks and IL-1 in the pathogenesis behind SchS (Results 
Chapter 2). Furthermore, the levels of IgM witnessed in SchS patients remain the same as 
upon diagnosis or elevate over the course of disease, despite IL-1 inhibition. Though the 
blockade of IL-1 successfully abrogates the inflammatory symptoms phenotypically, the 
results of this thesis could lead to the hypothesis that baseline levels of inflammation caused 
by inflammasome activation in innate immunity related cells such as neutrophils, leading to 
pyroptosis stimulates the continual production of IgM from B cells. The absence of 
inflammatory symptoms in WM renders applicability of aforesaid supposition to WM 
questionable.  
In view of these results and the fact that clonal evolution to haematological malignancy is an 
outcome in 20% of SchS patients, it is therefore reasonable to propose that the paraprotein 
seen in both conditions share inherent features that may arise from Ig recombination. The 
investigations presented in the following results chapter explores this theory through 
sequencing of the IgH region to probe for genomic evidence of a clonal B-cell population – as 














Chapter 5 IgH sequencing  
5.1 Introduction  
The aim of the work presented in this chapter is to genetically investigate the hypothesis that 
a clonal population of B cells secreting elevated titres of monoclonal IgM contribute to the 
inflammatory phenotype seen within SchS. Identification of a shared B cell clone between 
SchS patients could suggest that the manifesting paraproteinaemia may bear the same 
antigenic property. Through next-generation sequencing of the IgH region, this chapter more 
specifically assesses the CDR3 region and VH usage dynamics of 10 SchS patients. 
As a consequence of the V(D)J rearrangement events B cells, a vast degree of diversity is 
generated within the hypervariable CDR3 region. In the context of Igs, CDR3 loops are critical 
for antigenic binding, with various research papers discussing and employing the length and 
composition of said region to assess B cell clonality. For example, Kriangkum et al analysed 
the CDR3 region of 198 CLL cases to identify 26 patients who demonstrated evidence more 
than the usual one CDR3 clone detected in CLL, and followed these clones over the course 
of three to nine years to determine the degree of B cell expansion (322). Another study utilised 
the number of unique CDR3 sequences to gauge clonal characteristics of liver disease (323). 
Accordingly, this work investigates the length distribution and composition of both entire CDR3 
repertoire and expanded CDR3 clones per sample.  
The production of an identical Ig rearrangement is very rare at a 10-9 probability, underscoring 
the diminished likelihood of this event occurring at random, further emphasises this is not by 
chance (324).  The exposure of individuals to a common antigen results in the formation of 
stereotyped CDR3 aa sequences (i.e. identical shared sequences), highlighting the increased 
degree of similarity generated by different immune repertoires (325). Evidence that malignant 
cells found in LPDs do not survive autonomously or ex-vivo further propagates the notion that 
clonal expansions are largely dependent on endogenous or exogenous antigenic stimulation 
(324). Clinically, the therapeutic efficacy of B cell receptor associated kinase antagonists such 
as spleen tyrosine kinase and Bruton’s tyrosine kinase, underscores the latter postulation 
through hindrance of B cell signalling (324).  
Whilst the phenomenon of detecting stereotyped receptors is imperative to those evaluating 
vaccination responses (i.e. influenza – (326)), in the context of chronic B cell LPDs, numerous 
studies show homologous heavy chain CDR3 aa sequences accounting for nearly 30% of CLL 
cohorts. Strongly inferring the role of antigen selection in the shaping of the expressed B cell 




The study of VDJ gene usage has been of tremendous interest, given the possibility that 
immune repertoires from certain lymphoproliferative conditions exhibit properties suggestive 
of presence of a clonal B cell population (329). Such characteristics include preference 
towards the usage of certain V, D and J gene families, usage of a particular one of these gene 
segments and/or specific V-J combinations perhaps utilised to higher degrees. In conditions 
where the pathogenic role of the monoclonal Ig is questionable, comparison of V gene usage 
may be helpful for documenting common antibody reactivity, as highlighted by Fermand et al 
(330).  
5.1.1 Properties of the IgH region 
The adaptive immune system yields a significant breadth of diversity by the generation of 
antigen-specific T-cell receptors and immunoglobulins (Igs). The diversity of an antibody is 
generated by recombination events between one of each of the following: 44 VH gene 
segments; 27 DH gene segments and 6 JH gene segments – ultimately coding for the CDR3 
region of the Ig heavy chain region (IgH) responsible for antigen binding (Fab) (Figures 42 and 
43). Removal or addition of non-templated and palindromic nucleotides within junctional 
regions in the recombination process, followed by further changes resulting from somatic 
hypermutation later in antibody development, increases the diversity within the antigen binding 
areas (331).  For light chain production (IgL), the combinatorial process is identical except for 
the absence of light chain D gene segments. IgL is either of kappa or lambda subtype 
constructed from one V gene (out of 30-36 V genes) and one J gene (out of 4-5 J genes),. 
Thus, the greater diversity of the IgH region allows for more detailed analyses (V, D and J 
genes) as opposed to IgL (V and J genes only).  Due to the aforementioned process of somatic 
recombination and hypermutation, an estimated 1013 unique antibodies can be generated by 






Antibody diversity is attributed to the different combinations of gene segments of both the heavy and 
light chain variable regions. Numbers of V, D and J gene segments are shown for each antigen receptor 
locus. Due to genetic polymorphism the numbers vary from individual to individual (333).  
 
Segment Heavy chain Light chain    Κ                             λ 
Variable (V) 38-46 31-36 29-33 
Diversity (D) 27 0 0 
Joining (J) 6 5 4-5 
















The IgH locus is located on chromosome 14, and rearrangement of genes at this position 
initially starts with D-J recombination alongside the constant region, followed by V-DJ 
recombination. The IgL variable chain can either be of κ or λ subtype, with these loci positioned 
on chromosomes 2 and 22 respectively. Somatic recombination results in the formation of V-
J rearranged DNA. Figure 45 adapted and recreated using references (332) and (333). 
 
The diverse B-cell populations of healthy individuals permits the identification of broad ranges 
of foreign antigens, through the binding of B-cell receptors or secreted antibodies to antigenic 
epitopes. Following recognition, a strong, adaptive immune response is mounted, allowing the 
degradation and removal of the antigen.  Within a B-cell, following successful VDJ (heavy 
chain) or VJ (light chain) recombination, the rearrangement machinery ceases to work and 
thus stops the potential production of a second functional heavy or light chain being generated 
from the alternate alleles. The latter phenomenon is known as allelic exclusion (334), and thus 
one B cell expresses one unique BCR (335).  
Each B cell V(D)J rearrangement is unique, with an extremely low probability that the same 
sequence will be common to two unrelated cells (336). Hence, when identical sequences are 


































Figure 45: Overview of VDJ recombination. 




5.1.1.1 Complementarity-Determining and Framework regions 
Complementarity determining regions (CDRs) form part of the antibody recognising and 
binding antigens in a cooperative manner (337). CDR1 and CDR2 are encoded by germline V 
segments for both heavy and light chains, but can be altered by somatic mutation. 
Contrastingly, CDR3 regions are created during V(D)J recombination and can also be subject 
to further somatic hypermutation (337, 338). The structural location of CDRs was initially 
resolved through the work of Chothia and Lesk (339, 340), with their findings further 
demonstrating that CDRs maintain limited sets of conformations due to particular aa residues 
at certain positions within the CDRs and their flanking framework regions (FRs). The four FRs 
are primarily known as the scaffolding beta-sheet peptides holding the CDRs in position, 
though demonstration that amino acid (aa) residues for antigenic contact can be located within 
the conserved FRs highlights the role this region plays for antibody affinity (341). Between the 
V-D and D-J gene segments (largely encoding CDR3), diversity is further achieved by the 








CDR1 and CDR2 are encoded by germline V gene segments, whereas CDR3 is encoded by 
the latter part of the V gene, the entire D gene and the former part of the J gene via somatic 
recombination. There are four framework regions (FR-1, FR-2, FR-3 and FR-4), mainly acting 
as a scaffold for the CDRs within an antibody. Diversity of the antigen receptor loci is further 
increased by the addition of non-templated nucleotides (N) between the junctional regions of 
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Figure 46: Generation of the antigen binding section an antibody from 
























 (A) Antibodies comprise of two identical heavy chains and two identical light chains. The 
heavy and light chains are linked together by disulphide bond. There are two variable domains 
in the F(ab) region, VH and VL), responsible for antigen binding. The constant domains (CH1 
– heavy chain) and (CL – light chain) are also within the Fab region. CH2 and CH3 make up 
the Fc region which act as meditators for the antibody activity.  
(B) Each variable domain consists of 3 CDR regions (CDR1, CDR2, CDR3), thus each 
antibody consists of 12 hypervariable loops. The variable domains are folded in a way uniting 
the CDR hypervariable loops to form an antigen-binding site. Four conserved framework 
regions (FRs) flank these CDR regions. The heavy domains and light domains are linked 


















Among the CDRs, the heavy chain CDR3 is recognised as the region bearing most variability, 
due to the fusion of V, (D) and J gene segments. Bagnara et al defined the heavy chain CDR3 
to be the ‘nucleotide region comprised between the invariant cysteine residue at the end of all 
VH genes and the invariant tryptophan from all JH segments (298).  Given the absence of the 
diversity set of genes in the light chain loci, heavy chain CDR3 is regarded as the most diverse. 
Though the other 5 CDRs demonstrate a supportive role by increasing the affinity of antigen 
binding (337). Where CDR3 hypervariable loops characterise the ‘highly antigen specific 
recognition core’, it has been hypothesised that the other CDRs bind ‘opportunistically’ (345).  
The structural and central location of the CDR3 within the antigen binding region of the 
antibody not only enables contact with the antigen, but also permits the interface between 
CDR1, CDR2 and FRs from both the heavy and light chains (346).  
In spite of the extensive variability within CDR3, analysing its aa sequences provides clues to 
the extent of constraint on this structure due to the aforementioned process of recombination 
(347).  Typically, CDR3 length follows a Gaussian distribution, with skewed profiles indicative 
of lymphocyte selection and conceivably, clonal expansion (348). Commonly, aa’s forming a 
large proportion of the CDR3 region tend to be neutral or leaning towards hydrophilicity (347).  
Alterations in the length and composition of CDR3 consequently changes the charge, 
hydrophobicity and shape of the site where the antigen binds - thus affecting potential 
antibody-antigen interaction and binding (349). 
Features of CDR3 were initially determined from electrophoresis, Sanger sequencing and 
spectratyping until the emergence of NGS in the mid 2000’s. Since then, vast amounts of data 
has been published in regards to CDR3 characteristics within a variety of B-cell malignancies 
such as Chronic Lymphocytic Leukaemia (CLL) (350) and Burkitt’s lymphoma (351), and also 
conditions where the pathology of antibody under or overproduction is largely unknown such 











5.1.1.3 V(D)J recombination/usage 
V(D)J recombination (Figure 45) has been studied in-depth owing to the concept that skewed 
immune repertoires are attributed the increased usage of particular V(D)J gene families, or 
even certain V, D or J gene segments (353).  Preferential uses of specific gene segments may 
result in a restricted immune repertoire, as potential specificities to antigens are reduced 
thereby constricting diversity (354). Two main factors have hindered the extensive efforts to 
define the human repertoire over the past couple of decades since the initial sequencing of 
the Ig genes in the 1980’s (355) . (A) The vast diversity of the antibody repertoire itself; and 
(B) the fact that the repertoire of each individual is ever changing and dynamic - in response 
to both intrinsic factors (e.g. ageing) and extrinsic factors (e.g. infection) (353).  
Antigen exposure largely shapes the immune repertoire of an individual, though repeated 
interaction can result in preferential recombinations and employment of V(D)J families/gene 
segments due to B cell selection. Generally, exposure to a wide-range of antigenic challenges 
usually forms an extensive repertoire in preparation for future contact with previously 
encountered antigens in a more efficient and rapid response than the prior interaction (356). 
Though V(D)J recombination and its associated processes such as somatic hypermutation 
and class switching yields large amounts of antibody specificities, certain factors indicate that 
this process is not entirely random. For example, in early years of life, V-region gene segments 
and other diversifier use is limited (357) - reflecting the underdeveloped immune system. The 
study by Hong et al found that neonates particularly used the IgHV3 sub-family in contrast to 
healthy adults preferentially using IgHV4 (353). Even within different types of B cells, usage 
differences have been demonstrated. In three healthy controls, Wu et al showed an increased 
usage of IgHV3 sub-family and decreased usage of IgHV1 sub-family in IgM memory cells, 
with these findings not mirrored in switched memory cells (356). With regards to clonal 
diseases such as WM and IgM-MGUS, research has shown that the IgHV3-23 segment are 
preferentially used at 24% (out of all V gene segments), whereas the same segment was used 
at 12% in healthy controls (358). Thus, analysis of V(D)J recombination and gene segment 
usage can be used deduce common patterns seen within a given condition, providing clues to 









5.1.1.4 IgM  
Generated during the primary immune response, IgM constitutes a major antibody class 
persisting in serum for 5 to 8 days (359). Monomeric IgM is initially attached to the surface of 
B cells and upon antigenic stimulation, the process of V(D)J recombination (outlined in Section 
5.1.1.3) is initiated to generate the pentameric form of IgM. Highly effective against viruses, 
the latter type of IgM is a 900kDa multimeric antibody (Figure 48), generally having a low 
affinity and broad specificity perpetuating binding of this antibody to both self and foreign 
antigens (360). One IgM antibody consists of 60 CDRs given its pentameric structure (5 x 2 
binding units), thus the high avidity of this Ig compensates for its low affinity. However, steric 











IgM is made up of μ heavy chains and κ or λ light chains. The five monomers are held together 
by disulphide bonds and the joining (J) chain. The J chain is necessary for monomer 
polymerisation. Figure 48 recreated using information from reference (361).  
 Forming 10% of total Ig in humans and mostly found in extravascular spaces, the IgM 
pentamer is a potent activator of complement. It is known to activate the classical pathway by 
a singularly bound IgM, in contrast to where over a thousand IgG antibodies are warranted to 
yield the equivalent (362). B cell receptors also recognise the inactive form of C3 – i.e. iC3b, 
C3d or C3dg, and thus the IgM-antigenic complex alongside the activated component of 
complement (C3), markedly augments the B-cell response (359). Interestingly, recent 
research demonstrates that IgM defective of complement activating properties can still yield a 
humoral response through the Fc binding region. The IgM-antigenic complex also promotes 
the survival and activation of B cells through crosslinking of the B-cell receptor and Fc 
receptors on B cells.  













Healthy individuals have IgM levels within the range of 0.2-2.8mg/ml, whereas the SchS 
patients included in this work demonstrate levels above 3mg/ml (range: between 3 and 
8mg/ml), except for patient 15 at 1mg/ml. It has been noted that within SchS, these IgM levels 
either remain stable or demonstrate an incline of 0.5 to 1mg/ml per year (26). Several lipid 
antigens such as phosphorylcholine and malondialdehyde are known autoantigens 
recognised by subsets of naturally occurring IgM (363). More specifically, IgM generated by 
the autoimmune condition SLE, has a tendency to target nuclear antigens (364), with the 
aforementioned disease largely associated with inflammation leading to permanent tissue 
damage (365). The possibility that the monoclonal component of SchS bears a specific 
physiological role is borne from the fact that over 90% of SchS patients demonstrate 
monoclonal IgMκ - seen in 7 out of 10 SchS patients included in this work (Table 20). A 
previous study indicated that IgM skin deposits were responsible for the pathophysiology of 






















5.1.2 Assessment of the immune repertoire 
Recent technical advances have enabled the detailed assessment of T and B-cell repertoires. 
In depth sequencing of the immune repertoire serves several purposes including disease 
monitoring (i.e. minimal residual disease (MRD), therapeutic antibody development, and 
vaccine design (366)).  
5.1.2.1 NGS 
The past two decades have seen the heightened development of PCR based analysis of Ig 
as the gold standard for molecular clonality testing, primarily built upon the work of the 
Euroclonality/BIOMED-2 consortium published in 2003 (367). These standardised multiplex 
PCR assays for all Ig/TCR receptor targets, with overrepresentation of particular V-J/D-J 
sequences detected by gel or capillary electrophoresis. With millions of reads, NGS permits 
the depth of sequencing to be significantly greater than the amount of B cells within a sample, 
‘’allowing comprehensive snapshots of repertoire diversity’’(344). These high-throughput 
platforms have taken the examination of immune repertoires beyond the question of clonality, 
but rather provide a comprehensive insight into the dynamics of the immune repertoire (e.g. 
CDR3 diversity & analysis and VDJ allele identification)(331). Sequencing gDNA allows the 
approximation of the number of B cells expressing a particular antibody (i.e. clonality), as the 
number of sequencing reads will be relative to the quantity of gDNA template input (368). 
Employing this concept, the objective of this section of work was to utilise NGS for 
comprehensive analysis of the IgH repertoire in SchS, specifically surveying IGHV gene family 
usage and CDR3 diversity.   
 
5.1.2.2 Data analysis 
Over the past 2 decades, bioinformatics tools have been developed for in-depth study of VDJ 
rearrangements and CDR3 aa sequences. Analysing up to 500,000 Ig or T cell receptor 
sequences, IMGT™ (ImMunoGeneTics)/HiVQuest identifies the closest V, D and J germline 
genes pertaining to an arrangement, analyses the presence of somatic mutations and changes 
in amino acids with a detailed examination of the junction additions and deletions (369). The 
resulting outputs are based on the following models: (A) classification based on nomenclature 







5.1.2.3 The Role of B cells in SchS 
Although the prevalence of TCR clones are greater within ‘non-neoplastic diseases’(374), 
abnormal B-cell rearrangements are also found in autoimmune diseases such as Systemic 
Lupus Erythematous (SLE) and Rheumatoid Arthritis (RA) (375), Cold Agglutinin Disease 
(CAD) (376) and are a conventional finding with ageing (377). SLE, RA and CAD present with 
autoantibodies mainly targeted at nuclear components, rheumatoid factors and the 
carbohydrate antigens on red blood cell surfaces respectively, with the former two diseases 
manifesting inflammatory consequences. Additionally, an IgM paraproteinaemia of unknown 
significance is a key diagnostic criterion (above levels of 60g/l) for the B-cell LPD, 
Waldenström's Macroglobulinaemia (290). The latter condition develops in 20% of SchS 
patients, whereas in SchS, the monoclonal gammopathy is of unknown implication.  
Since IgM overproduction is a hallmark of SchS and taking the disease models of SLE, RA 
and CAD into consideration, it is plausible to consider that these high levels may contribute to 
the pathophysiology of the condition by binding of SchS IgM to an unknown molecule/antigen. 
Surveying the general metrics of repertoire skewing (as described in sections 5.1.1.2 and 
5.1.1.3) is one approach to investigate if the auto-inflammation seen within this disease is 
perpetuated by the monoclonal component. Investigating the latter within 10 SchS patients 
will not only provide evidence pertaining to the usage of VDJ gene families and segments, but 
could also indicate if the SchS B-cell populations share similar antigen binding regions through 
CDR3 aa sequence evaluation. Moreover, a clonal population may be in a germline 
configuration indicating a response to a natural antigen, or alternatively, could be heavily 
mutated with SHM, suggesting a specific antigen response  As the generation of one heavy 
chain CDR3 aa sequence can be the product of alternative events, including different IgH 
gene segment recombination and the random insertion of non-templated and palindromic 
nucleotides at the junctional regions (378), these sequences are rarely shared inter-
individually in health. However these shared sequences (also known as public repertoires or 
stereotyped sequences), can be seen in disease conditions (368). Out of many such 
examples, stereotyped CDR3 sequences were found in those individuals suffering from 
Dengue Fever (379). Highly suggestive of derivation from a parent B-cell, overrepresented 
CDR3 sequences can be considered as clones when they make up a certain percentage of 
the overall repertoire (e.g. 2.5% (331)). Indicative of B-cell repertoire skewing, large CDR3 
clones can further be evident of bias towards the clonal expansion of a progeny derivative 
from a parent B-cell (clonality). Theoretically, a restricted IgH repertoire leading to the 
expansion of a sub-set of clonal cells could also be those IgM generating cells – hence the 
establishment of high IgM titres as seen in SchS. Thus, examination of the IgH region will 




5.1.2.4 IgM related disorders 
The idea that IgM clonal diseases harbour the MYD88 L265P mutation was further developed 
through research by Varettoni et al in 2013, who noted that those IgM-MGUS patients who 
had ‘significantly higher levels of IgM’ carried the MYD88 variant (183).  The mutation in 
question is found in 50% to 80% of IgM-MGUS patients, 6% of patients with lymphomas such 
as Marginal Zone Lymphoma (MZL) and in 5% of chronic B-cell LPD (183, 290). As 
demonstrated in Results Chapter 2, approximately a third of SchS patients harbour the MYD88 
L265P mutation.  This novel finding was based on the hypothesis that since 20% of SchS 
patients go on to develop the IgM related WM, where over 90% of patients carry the 
aforementioned mutation, that this would be mirrored in SchS patients. However, in CAD, 
established monoclonal IgM binds to red blood cells activating the complement cascade, 
within peripheral blood circulation due to cooler temperatures (189) - but patients don’t harbour 
the MYD88 L265P mutation. Sequencing of the VH regions determined that the IgHV4-34 
gene segment encodes for the monoclonal cold agglutinin IgM molecule, indicative of 
particular aa sequences having an important role in antigen recognition (189). Given the 
pathophysiology of the latter, though the MYD88 mutation is not universally present in SchS 
patients, it is plausible that the IgM paraprotein may have a pathological effect in SchS. 
Together with the results of the previous chapter, the following research investigates the 
aforementioned concept through sequencing of SchS IgH regions in order to search for shared 
patterns (n=10). Therefore, the aims of this chapter are as follows: 
 
A. Amplify the IgH region of 10 SchS patients for deep sequencing  
B. Bioinformatics pipeline construction using the Galaxy, AR Galaxy and IMGT® open access 















5.2.1 IgH NGS 
This part of the project was conducted to evaluate if SchS demonstrates evidence of B cell 
clonality by analysis of the B cell repertoire followed by assessment of CDR3 region 
characteristics, within 10 SchS patients. The following work describes the NGS methodology 
used to review the landscape of the B cell repertoire in SchS. Formal power calculations to 
determine sample size were not carried out due to the rarity of SchS and the limited availability 
of starting sample material.  
5.2.1.1 PCR and agarose-gel electrophoresis 
The Leader sequence and JH consensus primers (367, 380) listed within section 7.2.1, 
appendix were used to amplify the IgH region of B cells via PCR, using a minimum of 200ng 
of gDNA from PB (DNA extraction method described in 2.2.5). Figure 49 below demonstrates 
the amplification strategy employed within this section of work.  
	
Figure 49: Amplification of the IgH region 
 
Figure 49 is a schematic diagram of the gDNA IgH amplification from the peptide leader region 




consensus primers are indicated with their appropriate orientations. The forward primers 
initiate amplification from the first, untranslated exon and are regarded as superior to the 
commonly used BIOMED-2 primers (367). The latter primers bind to the Framework-1 (FR-1) 
region of the VH segment, which is commonly subject to somatic hypermutation and thus loss 
of binding can occur (381). The sequence ends of the 500bp product (indicated in blue) are 
recognised by the Nextera indexing primers used in the second round of PCR.  
 
5.2.1.1.1 Primary PCR 
The initial PCR amplified the IgH region as illustrated in Figure 49, using 200ng of gDNA as a 
starting template and 10µl of Phusion Flash High-Fidelity Master Mix (Thermo-Fisher 
Scientific, UK), per sample. The primers, with adapter sequences recognised by the Nextera 
indexing primers (section 7.2.1, Appendix), were diluted down 10µm working stocks to a final 
1µm concentration. 0.29µl of an equimolar stock of the 7 leader primers was added to the final 
PCR reaction. 0.40µl from a 10µM stock of JH primer was added, with the total reaction made 
up to 20µl with DNase-free water. Thermocycling conditions were as follows for 35 cycles: 
denaturation at 98°C for 10 seconds; annealing at 65°C for 5 seconds and elongation at 72°C 
for 30 seconds. Following PCR amplification, 0.8µl of Midori Green Direct, (Nippon Genetics, 
Duren, Germany), was added to each PCR reaction to enable visualisation on the agarose 
gel. The gel was visualised using the blue light GelDoc system and Quantity-One analysis 
software (BioRad, USA). Alongside a 100bp ladder (NEB, UK), all the PCR products were run 
on a 2% agarose gel for 30 minutes at 90V. Bands corresponding to a region around 500bp 
were cut out and the DNA purified using the Zymoclean Gel DNA recovery kit (Zymo 
Research, USA). Further details of the latter technique are outlined in Results Chapter 2, 
Section 2.2. 
 
5.2.1.1.2 Second round PCR 
The aim of the second round PCR was to incorporate the multiplex indices and Illumina 
sequence tags onto the 5’ end and 3’ ends of the PCR products, in order for sample pooling 
and NGS.  PCR with the following primers	below	adds the P5 and P7 termini that bind to the 
flowcell on the Illumina sequencer:  
(1) 5’ AATGATACGGCGACCACCGAGATCTACAC[i5]TCGTCGGCAGCGTC 3’  
(2) 5’ CAAGCAGAAGACGGCATACGAGAT[i7]GTCTCGTGGGCTCGG 3’ 
This step also adds the dual 8bp tags denoted by ‘i5’ and ‘i7’. The PCR mix consisted of 8µl 




indexing primer as stated. The limited cycle PCR conditions were as follows: Initial 
denaturation at 95°C for 10 minutes, followed by denaturation at 95°C for 30 seconds, 
annealing at 60°C for 30 seconds and extension at 72°C at 45 seconds for 10 cycles. A final 
extension step was carried out at 72°C for 10 minutes. Agarose-gel electrophoresis, gel 
visualisation and purification were carried out as outlined in section 2.2.6.  
 
5.2.1.2 Quality control  
The concentrations of the final individual libraries were determined by pico-green fluorescence 
using the Quant-iT™ dsDNA Assay Kit (Invitrogen, USA) with the size of the final amplicons 
(~700bp) and purity determined using the Agilent 2200 TapeStation system (Agilent 
Technologies, UK). The aforementioned methodologies are discussed in depth within Results 
Chapter 2 (Section 2.2.6.5). Equal quantities of uniquely tagged PCR products were mixed, 
generating a multiplexed pool of uniquely indexed samples.  
5.2.1.3 Sequencing run 
Sequencing was carried out by the NGS facility within the Leeds Institute of Medical Research 
at St James’s Hospital. NGS was performed on an Illumina MiSeq sequencing instrument 
(Illumina, UK), with a 600 cycle (2 x 300bp) paired-end run, according to the manufacturer’s 
instructions. MiSeq reporter software demultiplexed the samples with FastQ (.fastq) files as 
the final output. 
5.2.1.4 Data analysis and Bioinformatics 
The sequencing reads generated by MiSeq were demultiplexed based on their unique adaptor, 
resulting in fastq files generated for the 10 samples. The resulting data were subject to 
downstream processing, analysis and visualisation as outlined in Figure 50. The following 
NGS platforms are open access web-based programs and used sequentially in this work: 
www.usegalaxy.org; www.imgt.org; and www.bioinf-galaxian.erasmusmc.nl/argalaxy. Figure 
54 portrays how these bioinformatics tools are utilised, starting from the Illumina MiSeq 
generated fastq file (Galaxy), to the generation of CSV files for use with Microsoft Excel (IMGT 
HiVQuest), and finally to the downloadable graphs and plots generated by AR Galaxy 




























Figure 50 provides an overview of the four stages required to process the IgH data obtained 
from the MiSeq sequencing platform.  The first stage retrieves fastq files from the sequencing 
platform. The second stage requires the transfer of these fastq files to the Galaxy open access 
database for the following actions: (I) file trimming, (II) QC, (III) filtering and (IV) fastq to fasta 
file conversion and (V) fasta file modifications. The third stage necessitates the upload of the 
fasta file from stage two onto the IMGT database – resulting in the alignment and translation 
of the input sequences. The output from this stage are 12 CSV files per sample. The 
compressed TXZ file from (3) is the starting file for implementation of the Immune Repertoire 
pipeline on the Antigen Receptor (AR) Galaxy platform. The aim of this last step is to generate 






























All 10 SchS fastq files were subject to strict filtering criteria in order to exclude sequences that 
did not pass the stringent quality control filters, and thus were irrelevant for further downstream 
exploration. Firstly, the employment of the ‘FastQC’ tool provided basic statistics such as GC 
content, adaptor content and sequence lengths. The single output files contained the filtered 
reads only. Subsequently, the ‘Trimmomatic Crop’ tool was utilised to define the number of 
bases to keep at the start of the read, determined by the quality of the sequences. The ‘Filter 
by Quality’ tool narrowed the sequences down by application of a Phred Quality Score of 20 
and a base call accuracy of 99%, ensuring the removal of sequences due to sequencing 
artefacts. The ‘FASTQ to FASTA’ step converted the resulting Galaxy ‘FASTQ’ file to a 
‘FASTA’ file suitable for use with the IGMT platform after using fastawidth (removes artificial 
nucleotide line breaks).  
 
5.2.1.4.2 IMGT HighV-Quest 
The output FASTA files from the previous step consisting of IgH sequences from 10 SchS 
patients were uploaded onto the IMGT HighV-Quest platform - for assignment of the germline 
V, D and J segments and CDR3 region identification (382). User-defined parameters included 
selection of the locus (IgH) and the species (Homosapiens). Processing took up to 72 hours 
and the 12 output CSV files were archived into one TXZ file, per sample. These resulting TXZ 
files were extracted using the Windows default archive tool (7-zip) and subsequently opened 
with Microsoft Excel for visualisation of the assigned data. 
 
5.2.1.4.3 AR Galaxy 
Antigen Receptor (AR) Galaxy extracts information from the IMGT Archive created with HighV-
Quest (383). The TXZ files were uploaded onto the AR galaxy platform for processing through 
the ‘Immune Repertoire Pipeline’. Multiple filtering stages were employed to eliminate 
sequencing reads where the rearrangement was non-functional, or a rearrangement was not 
found. The first stage of the pipeline only considered the best matched V, D and J gene, as 
assigned by IMGT/HighV-Quest. Secondly, reads pertaining to ‘no-results’ from IMGT/HighV-
Quest were removed. Thirdly, the ‘clonal type definition’ filter was applied to remove duplicate 
rearrangements. The output of this pipeline initially showed the total number of sequences 
and the productive/unproductive sequences (Table 18). Other files from this analysis included 







In this chapter I sequenced the heavy chain region (IgH) of 10 SchS patients. Clonal expansion 
of lymphocytes is a defining element of the immune response (384), but work involving SchS 
patients has not experimentally explored the notion that SchS may be a clonally-derived B cell 
disorder. Given that IgM paraproteinaemia is fundamental to a SchS diagnosis, exploring the 
landscape of the IgH repertoire by examining CDR3 characteristics and VDJ gene usage 
provides detail on this concept.  
 
5.3.1 PCR and agarose gel-electrophoresis  
The aim of the primary PCR was to amplify the IgH segment using the Leader sequence and 
JH primers under the conditions listed in Table 26, appendix. Use of Leader sequence primers 
enabled amplification of the entire rearranged IgHV-IgHD-IgHJ genetic sequence. BIOMED-2 
primers are more prone to fail to amplify the whole IG gene, harbouring the possibility of failure 










Lane 1 corresponds to the 10KB ladder used. Lane 2 contained primers only, Lane 3-6 
contained SchS gDNA samples. Bands corresponding to around 500bp (range 450bp – 
500bp) were cut out and subject to gel digestion and purification as described in section 2.2, 

















The aim of the second PCR was to add the NEXTERA indices and Illumina sequencing tags 









Lane 1 corresponds to the 1kb ladder used, lanes 2, 4-8 show the successfully indexed DNA, 
with lane 3 being a negative control (primers and water only). Bands corresponding to around 
700bp were cut out and subject to another round of gel digestion and subsequent QC (as 
described in 2.2.8) prior to mixing to generate the sequencing library for the MiSeq run. The 
NEXTERA dual indexing principle utilises 2 indices of 8 base pairs in length. This strategy is 
employed by addition of a unique index 1 (i7) and a unique index 2 (i5) to each end of a sample 




Figure 52: Representative PCR image denoting the second 












5.3.2 Quality control of the libraries 
Prior to pooling the samples for MiSeq loading, two QC steps were carried out in order to 
quantitate and assess the purity of the indexed libraries: (1) TapeStation analysis to determine 





Figure 53: Representative bioanalyser trace. 
 
Figure 53 is a representative bioanalyser trace demonstrating the average size and distribution 
of the indexed library constructed from the steps described for sample 12. The trace was 
acquired using the Agilent DH1000 DNA screen tape assay in conjunction with Agilent 2200 
Tapestation system (Agilent Technologies, UK). Figure 53 shows the size fragment 
distribution of the indexed library for sample 12. The X axis refers to the size in base pairs of 
the DNA library, with the Sample Intensity (normalised fluorescence units) on the Y axis. The 
lower marker (left peak) and the upper marker (rightmost peak) correspond to the size markers 
of 25bp and 1500bp respectively. The average size of the library was 700bp, thus this broad 
peak is expected to cover the range of VDJ rearrangements. Given the average size of the 
amplified VDJ rearrangement in the 1st round of PCR was 500bp, combined with adaptor 
ligation in the 2nd round of PCR, the average size of the assembled library would fall within the 
broad peak as seen in the figure, thus covering the array of DNA rearrangements. The 
absence of other peaks (i.e. primer dimer at 50bp) within the sample, indicates there are no 




5.3.2.2 Quant-IT™ PicoGreen assay 
The purpose of carrying out Quant-iT™ assay was to accurately assess the amount of the 
DNA library per sample, in order to ultimately pool together the samples for sequencing in 












The X-axis demonstrates the concentration of DNA in ng/ml (0-100ng/ml) with relative 
fluorescence units on the Y-axis (arbitrary). The samples were excited at 480nm with the 
fluorescence emission intensity measured at 520nm. Per DNA library, equimolar amounts of 
each sample were pooled to generate a combined library with equal amounts of DNA for 

































































Figure 56 demonstrates the box plots for the sequencing quality score as generated by Galaxy 
for sample 12. The yellow boxes represent the 25th to 75th percentiles, with the upper and 
lower whiskers demonstrating the 10th and 90th percentiles respectively.  
The Y-axis refers to the Phred quality scores, with the X-axis showing the results in relation to 
the position in the read (1-300bp). A Phred quality score of 20 implies the probability of an 
incorrect base call is 1 in 100, with a 99% base call accuracy. An increased Phred score of 30 
implies that the probability of an incorrect base call is 1 in 1000, and a 99.99% base call 
accuracy. Although there is an apparent dip in quality (Phred scores from below 20), and these 
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Figure 55: Schematic showing the sequencing coverage of 
the VDJ region carried out. 




5.3.4 Repertoire diversity 
Initially, 5,185,201 raw sequences were obtained, with application of stringent filtering (as 
described in 5.3.4) cutting this initial value down to 2,860,786 sequences. These sequences 




Sample ID, the number of total sequences, productive sequences and unproductive 
sequences are stated in Table 18. Total sequences refers to the sum of productive sequences 
and unproductive sequences. Productive sequences refers to the rearranged Igs with the 
coding region having an open-reading frame, no stop codon and no defect in the initiating 
codons, splicing sites, and comprises an in-frame Junction. Unproductive sequences can be 
characterised by an out-of-frame junction, and/or the presence of stop codons, frameshift 
mutations within splicing sites or regulatory elements. These unproductive rearrangements 
originate from B-cell DNA that underwent a productive rearrangement on their second allele, 
therefore, these sequences have not been chosen and allow the study of VDJ recombination 
without selection influence (383). Only productive, and thus functional sequences were carried 
downstream for further analysis.  
 
The high percentage of productive sequences (ranging from 74% to 92%) in comparison to 
healthy controls and other diseases may indicate that a proportion of IgH DNA is rearranged 
for a second time – an infrequent occurrence though found in autoimmune disease (385) and 









SchS – 12 156142 133271 85 22871 15 
SchS – 14 172577 145525 84 27052 16 
SchS – 15 153256 131436 86 21820 14 
SchS – 16 169726 146656 86 23070 14 
SchS – 18 419474 328040 78 91434 22 
SchS – 20 270400 212452 79 57948 21 
SchS – 21 250427 216294 86 34133 14 
SchS – 22 619601 568651 92 50950 8 
SchS – 24 564216 415622 74 148594 26 
SchS – 25 84967 71806 85 13161 15 




controls had an average productive percentage of 70% (n=10), whereas 18 patients with 
common variable immune deficiency (CVID) showed an average 64% productive percentage 
(386). Given the aforementioned suggestion that a pool of proliferating clonal B cells 
generating Igs could be the cause of high productive sequence percentages seen in this data, 
the proposal that SchS patients demonstrate oligoclonality in a polyclonal background is a 
proposal further investigated in subsequent analyses.  
 
5.3.5 CDR3 characteristics  
The CDR3 region is formed as a result of VDJ recombination and is the interface by which 
most antibodies and antigenic epitopes interact. Given that antibody specificity is largely 
determined by the heavy chain site of recombination which is CDR3, analysing the 
characteristics of this region within 10 SchS patients may indicate whether the B-cell repertoire 
is of a clonal nature. Although there is high sequence variability within this region, through 
studying the length, composition, and frequency of CDR3 clones, it is possible to gauge the 
degree of repertoire skewing (387). Self-antigens bearing structural motifs that are recognised 
by a particular CDR3 sequences could explain the occurrence of CDR3 clones within a sample 
(344).  
5.3.5.1 CDR3 clone definition 
In this work, a clone refers to a unique CDR3 aa sequence generated by the Ig heavy chain 
locus, irrespective of V or J gene usage. The presence of a clone in this work is defined as an 
aa sequence making up 2% or over of the total productive reads per sample, based on 
previous experimental design. Where the research on RA by Tak et al referred to a CDR3 
clone comprising of over 5% of the total CDR3 sequences (388), work on the plasma cell 
repertoire (389) and autoimmune liver disease (323) pertained to CDR3 sequences as clones 
over 1% or over 0.1% respectively.  
 
5.3.5.2 Frequency of CDR3 clones  
As stated by Tan et al in 2016 (323), the precise number of B cells expressing each CDR3 
cannot be precisely clarified – denoting one of the few limitations of implementing this NGS 
technique of B-cell repertoire sequencing. However it is possible to estimate the number of 
cells, and in turn, lymphocyte frequency, based on the quantity of gDNA isolated from whole 
blood. Whilst the B-cell count was unknown for the 10 SchS patients in this work, estimation 




abundance of certain CDR3 sequences in samples can be an indicator of a clonal population 
of B cells and hence the following calculations provide approximate number of sequencing 
reads, alongside a B cell count. The 2 estimates detailed below are based on the postulation 
that the gDNA starting sample has a 10% B cell population, or a 1% B cell population. Given 
these assumptions, these results are not absolute, but rather provide a general insight into the 
measure of clonality within 10 SchS patients.  Presuming no gDNA amplification and library 
preparation bias, the number of sequencing reads pertaining to a certain CDR3 aa sequence 
should be ‘directly proportional to the number of clonal lymphocytes bearing a certain receptor’ 
(333). Taking into account the addition of non-templated nucleotides and exonuclease activity 
at junctional regions, the likelihood of two clonally un-related cells producing the same CDR3 
aa sequence has been estimated at 1%, (325). Thus, CDR3 sequence analysis can be an 
additional indicator of recombination and usage patterns of V, D and J genes.  
The aforementioned lack of clinical data available in this study hinders the accuracy of the 
analyses undertaken in this work. One method to address the hypothesised concept that SchS 
is a clonal disease is to explore the richness and diversity of CDR3 aa sequences within a 
sample. Analysing the proportional abundance of the top CDR3 aa sequences per sample (i.e. 
top 50 sequences versus top 10 sequences), assesses if the top clones remain represented 






Figure 57: The calculated number of input cells and reads per B cell. 
 
The theoretical number of B cells was estimated using the amount of gDNA with the 
assumption that 10%, or 1%, of the gDNA content comprised of B cells. This outlined 
estimation was applied to all 10 SchS patients (all calculations are listed in Section 7.4, 
appendix).   
*The minor reduction in B cells was computed by the addition of all reads at a 1% assumption, 





































For each sample, the initial PCR reaction for IgH amplification had an initial 200ng input, 
equating to 200,000pg. 6pg of DNA is estimated to be in each human nucleated cell (390), 
therefore, dividing 200,000pg by 6pg provides an approximate number of all cells input into 
the PCR. The following step assumes either a 1% B-cell content or 10% B-cell content, by 
multiplying the approximate cell count by either 0.01 or 0.10 respectively, resulting in the 
number of B cells. Dividing the total number of productive reads by the approximate B-cell 
count equates to the number of reads per cell. Finally, taking the clone count and dividing that 
by the number of reads per cell provides a clone frequency per number of B cells. Figure 57 





Sample ID’s, number of B cells and reads per B cells – based on a 10%, or 1% B cell 
assumption. This summary table was constructed using the figures as calculated in Figure 57.  
On a 10% assumption, the number of B-cells for the 10 SchS samples vary from 3149 to 3380, 
with range of reads per B cell from 25 to 167. On a 1% assumption, the number of B-cells vary 
from 321 to 336 with the number of reads ranging from 211 to 1672. The purpose of calculating 
2 different parameters was to demonstrate that despite the fluctuations in estimating the B-
cells, this does not affect the proportions of the top CDR3 aa sequences (as demonstrated by 
Figure 57). 
Sample ID No. of B cells     (10% assumption) 
Reads per B cell 
(10% assumption) 
No. of B cells       
(1% assumption) 
Reads per B cell   
(1% assumption) 
SchS – 12 3322 39 328 390 
SchS – 14 3281 43 328 428 
SchS – 15 3215 39 321 387 
SchS – 16 3270 43 327 431 
SchS – 18 3279 96 328 964 
SchS – 20 3361 63 336 625 
SchS – 21 3380 64 338 636 
SchS – 22 3225 167 325 1672 
SchS – 24 3282 122 328 1222 
SchS – 25 3149 25 315 211 




5.3.5.3 Patient details  
 
 
Clinical data and previous findings pertaining to the SchS patients included in this chapter are outlined above. Patient number, sex, age at 
symptom onset, CRP levels, paraprotein type and level, response to IL-1 inhibition, bone marrow histology and findings from the previous two 
results chapters are included in this table. 





























12 male 36.8 IgMk 3 Partial No overt 
LPL 
   - 
14 male 43.9 IgGλ N/A complete 15% 
plasma cell 
   - 
15 female 44.8 IgMk 1 complete No overt 
LPL 
   random 
16 female 49.6 IgMk 4 complete not done    random 
18 male 52.8 IgMλ (IF) N/A complete No overt 
LPL 
   - 




  - 




   - 
22 male 61.7 IgMk 5 complete No overt 
LPL 
   - 
24 female 68.4 IgMk 8 complete No overt 
LPL 
   random 
25 male 78.9 IgMk 7 complete No overt 
LPL 
 L265P  - 































Figure 58 shows the ranking of decreasing frequency for sample SchS – 21. Panel A 
represents all CDR3 sequences, with panel B showing  the ranking of the top 50 CDR3 
sequences. 

















































































































5.3.5.4 Summary of results 
Sample	ID	 CDR3	clone	sequence	 %	of	total	
repertoire	




12	 CAREVVGGYYGMDVW	 8	 VH3	74	 DH3	16	 JH6	 100	 15	 0.17	
CARDHGGYFDYW	 6	 VH3	53	 DH4	23	 JH4	 99	 12	 -0.99	
CTRPNYYYYMDVW	 6	 VH3	73	 	 JH6	 100	 13	 -0.86	
CARDGGGYNYFDYW	 5	 VH3	11	 DH2	15	 JH4	 100	 14	 -0.99	
CARAVAGTTDYW	 5	 VH3	43	 DH6	19		 JH4	 99	 12	 0.00	
CATQLEHDAFDIW	 5	 VH3	66	 DH1	1	 JH3	 100	 13	 -0.12	
CAREATGGYSYGPGGYW	 4	 VH3	11	 DH5	18	 JH4	 100	 17	 -0.69	
CARGSEGCFDYW	 4	 VH3	64	 DH7	27	 JH4	 99	 12	 -0.48	
CARDRVQHQPFGNYYYYYGMDVW	 4	 VH6	1	 DH6	19		 JH6	 100	 23	 -0.96	
CARDQSSGWYYFDYW	 4	 VH3	20	 DH6	19	 JH4	 100	 15	 -1.04	
CAKVLRRDGGALAYW	 4	 VH3	30	 DH2	21	 JH4	 100	 15	 0.02	
CASPDSSGYYYW	 3	 VH3	74	 DH3	22	 JH4	 100	 12	 -0.70	
CARDRQQLTYW	 3	 VH3	11	 DH6	13	 JH4	 100	 11	 -1.30	
CARDSSGFYYYYYGMDVW	 3	 VH3	74	 DH6	19	 JH6	 100	 18	 -0.45	
CARVEMSVAAEDYW	 3	 VH3	73	 DH2	15	 JH4	 96	 14	 0.02	
CARDFDRWAPSEYFQHW	 2	 VH3	11	 DH3	9	 JH4	 98	 17	 -1.12	
CASPRAFDYW	 2	 VH3	48	 DH1	26	 JH4	 99	 10	 -0.37	
	         
14	 CARLDRPGIAVAGQDQW	 7	 VH3	11	 DH6	19	 JH4	 95	 17	 -0.35	
CARDFYGDYDYW	 6	 VH3	11	 DH3	31	 JH4	 98	 12	 -1.09	
CAKSRRDPQLDYW	 6	 VH3	30	 DH5	24	 JH4	 100	 13	 -1.53	
CARDSTTVTYYYYYGMDVW	 4	 VH3	11	 DH4	11	 JH6	 100	 19	 -0.40	
CARGGGSYLHYYYYYGMDVW	 4	 VH3	33	 DH1	26	 JH6	 95	 20	 -0.41	
CAGTTVTTSYW	 4	 VH3	30	 DH4	17	 JH4	 95	 11	 -0.21	
CARRYFDLW	 4	 VH3	74	 	 JH2	 100	 9	 -0.42	
CAKGRGYGSGSSLDYW	 4	 VH3	30	 DH3	10	 JH4	 100	 16	 -0.71	
CARGGAAASDPFDYW	 4	 VH3	11	 DH6	13	 JH4	 99	 15	 -0.29	





CARDRCSGGSCLFYYYGMDVW	 3	 VH3	30	 DH2	15	 JH6	 96	 21	 -0.07	
CARDWGTSSWRWFDSW	 3	 VH3	11	 DH6	13	 JH5	 100	 16	 -1.00	
CASIQDCSGGRCRDYW	 3	 VH3	48	 DH2	15	 JH4	 100	 16	 -0.64	
CARERATTVVTPAFDYW	 3	 VH3	30	 DH4	23	 JH4	 100	 17	 -0.16	
CAKDVLDITVAGTVDYW	 3	 VH3	23	 DH6	19	 JH4	 92	 17	 0.50	
CARDSIYSSGWGMFDYW	 3	 VH3	11	 DH6	19	 JH4	 100	 17	 -0.33	
CARDTPYYDFWSGYGGFYGMDVW	 3	 VH3	53		 DH3	3	 JH6	 100	 23	 -0.47	
CARECGYSYGCFDYW	 3	 VH3	30	 DH5	18	 JH4	 100	 15	 -0.39	
CARDRGALNDFDIW	 2	 VH3	74	 DH5	18	 JH4	 93	 14	 -0.51	
CARVRGGCIRGGCHSDYW	 2	 VH3	30	 DH3	10	 JH4	 81	 18	 -0.38	
CARATLGSDAFDIW	 2	 VH3	74	 DH3	16	 JH3	 100	 14	 0.34	
CAKDQTYYDFGLVDYW	 2	 VH3	48	 DH3	3		 JH4	 96	 16	 -0.54	
	         
15	 CARETAGTGAFDYW	 3	 VH6	1	 DH6	13	 JH4	 99	 14	 -0.37	
CARARLAYCGGDCHYYFDYW	 3	 VH3	11	 DH2	21	 JH4	 98	 20	 -0.33	
CARGFGAYLLDYW	 3	 VH6	1	 DH3	10	 JH4	 99	 13	 0.32	
CARAADYYMDVW	 2	 VH3	30	 DH4	17	 JH6	 99	 12	 -0.08	
CAKAGETYGLGWYYYDSW	 2	 VH3	30	 DH5	18	 JH4	 84	 18	 -0.59	
	         
16	 CARASALLARALDYW	 9	 VH3	74	 DH1	14	 JH4	 97	 15	 0.49	
CAKPGYNSGWYPGYYYAMDVW	 5	 VH3	11	 DH6	19	 JH6	 98	 21	 -0.58	
CARENWNDPLEDYW	 5	 VH3	11	 DH1	1	 JH4	 96	 14	 -1.58	
CAKGHAFEIW	 4	 VH6	1	 DH5	12	 JH3	 98	 10	 0.15	
CARAGDIVVVPAARDYYYYGMDVW	 4	 VH3	30	 DH2	2	 JH6	 100	 24	 0.20	
CANQLEGHNYGLDVW	 4	 VH3	11	 DH5	24	 JH6	 92	 15	 -0.51	
CARVEGYSSSWTIYYYYYGMDVW	 4	 VH3	74	 DH6	13	 JH6	 98	 23	 -0.26	
CARDFGGIAAAGRFGMDVW	 4	 VH3	30	 DH6	13	 JH6	 100	 19	 0.39	
CASFRAVMGSPNW	 4	 VH3	74	 DH5	18	 JH5	 100	 13	 0.19	
CARESSSSWPYYFDYW	 4	 VH3	11	 DH6	13	 JH4	 100	 16	 -0.93	
CARDGLLSGYYYYYGMDVW	 3	 VH3	30	 DH3	9	 JH6	 100	 19	 -0.15	
CARDAKTTVTTYPHFDYW	 3	 VH3	30	 DH4	11	 JH4	 100	 18	 -0.74	
CGFSTRVWGIAARRLYYGMDVW	 3	 VH3	11	 DH6	6	 JH6	 100	 22	 0.15	
CAKDRAAAAGYYYYGMDVW	 3	 VH3	30	 DH6	13	 JH6	 100	 19	 -0.25	




CARERADFWSGYYAAGYYYGMDVW	 2	 VH3	30	 DH3	3	 JH6	 100	 24	 -0.47	
CARESPSAYYSGTYYYGMDVW	 2	 VH3	11	 DH1	26	 JH6	 100	 21	 -0.58	
CARDRYSSSWYGGDDYW	 2	 VH3	11	 DH6	13	 JH4	 98	 17	 -1.42	
CARDLLSSVGRFDPW	 2	 VH3	11	 DH3	10	 JH5	 99	 15	 -0.10	
CTRDPRLSIPSFDDW	 2	 VH3	48	 DH2	21	 JH4	 93	 15	 -0.82	
CVKDSSSWSHYYYYYGMDVW	 2	 VH3	64	 DH6	13	 JH6	 100	 20	 0.66	
	         
18	 CARVLVRGALDYW	 4	 VH6	1	 DH3	10	 JH4	 100	 13	 0.54	
CGRDGRDGGYGMDVW	 3	 VH6	1	 DH1	26	 JH6	 98	 15	 -1.00	
	         
20	 CATGKWNYEENYW	 23	 VH3	74	 DH1	7	 JH4	 97	 13	 -1.47	
CARDNGRYAVDYC	 19	 VH3	11	 DH6	19	 JH4	 92	 13	 -0.75	
CARGRGGWSGALDDW	 9	 VH3	11	 DH6	19	 JH4	 96	 15	 -0.69	
CARDKWELQTSLLPDYW	 9	 VH3	30	 DH1	26	 JH4	 100	 17	 -0.76	
CARHINWGWDSW	 8	 VH3	11	 DH1	26	 JH5	 93	 12	 -0.82	
CARAIGAYEGLDIR	 6	 VH3	11	 DH2	8	 JH3	 85	 14	 0.19	
CAKDIAPATTKTTYGMDVW	 6	 VH3	43	 DH6	25	 JH6	 97	 19	 -0.17	
CARGSGGNSDSPLDYW	 5	 VH3	11	 DH2	15	 JH4	 88	 16	 -0.89	
CARGRYGGGNAYSGTDSW	 3	 VH4	30	 DH2	21	 JH4	 92	 18	 -0.98	
	         
21	 CARATVTLDYYYYGMDVW	 2	 VH6	1	 DH1	1	 JH6	 100	 18	 0.04	
CARDRVSLAIFDYW	 2	 VH6	1	 DH2	2	 JH4	 97	 14	 0.17	
CARVTFGEFDPW	 2	 VH6	2	 DH3	10	 JH5	 100	 12	 -0.08	
	         
22	 CARGYSSSGGTNWFDPW	 14	 VH6	1	 DH6	13	 JH5	 100	 17	 -0.79	
CASDVSMSESW	 4	 VH3	74	 DH1	26	 JH4	 95	 11	 -0.06	
CAKAGETYGLGWYYYDSW	 4	 VH3	30		 DH5-18	 JH4	 84	 18	 -0.59	
CARRVGLPGGGMDVW	 4	 VH6	1	 DH3	16	 JH6	 99	 15	 0.12	
CTSLHSVSSVYW	 3	 VH3	74	 DH3	9	 JH4	 99	 12	 0.45	
CARDRDGYSHYFDYW	 3	 VH3	30		 DH5	24	 JH4	 100	 15	 -1.44	
CVRDGWELPRNYYYYMDVW	 3	 VH3	64	 DH1	26	 JH6	 97	 19	 -0.81	
CASPPYGDYDYW	 2	 VH3	30		 DH4	17	 JH4	 98	 12	 -0.99	




CARALGWMSSSWQMGYW	 2	 VH3	30		 DH6	13	 JH4	 100	 17	 -0.09	
CVKNSGPGWRFDPW	 2	 VH3	30		 DH5	12	 JH5	 93	 14	 -0.89	
CARDRASAGEYW	 2	 VH3	74	 DH6	13	 JH4	 95	 12	 -0.96	
	         
24	 CAREGCGGDCYDFDYW	 29	 VH3	11	 DH2	21	 JH4	 99	 16	 -0.69	
CARDHSGSSYGWAFW	 15	 VH3	11	 DH1	26	 JH4	 93	 15	 -0.57	
CVRGEYSGYDGKGNLDYW	 11	 VH3	74	 DH5	12	 JH4	 92	 18	 -1.06	
CARRGSIWGVSSSGPRHFFDYW	 10	 VH3	64	 DH6	6	 JH4	 90	 22	 -0.48	
CAREIVAAGTLSSDYW	 7	 VH3	23	 DH6	13	 JH4	 96	 16	 0.25	
CAKDTLPYGDFFDYW	 7	 VH3	30		 DH4	17	 JH4	 96	 15	 -0.46	
CARDRPNSGYDMDYW	 7	 VH3	30		 DH5	12	 JH4	 95	 15	 -1.54	
CAPTHSSGWAYFDYW	 4	 VH2	5	 DH6	19	 JH4	 99	 15	 -0.43	
CARHGGWIPHSFYGMDIW	 3	 VH4	39	 DH4	23	 JH6	 83	 18	 -0.17	
	         
25	 CARAPVRANWFDPW	 19	 VH6	1	 DH1	1	 JH4	 100	 14	 -0.44	
CSREHSEGSAPIWGLDYW	 9	 VH6	1	 DH5	18	 JH4	 86	 18	 -0.75	
CARDSWFGERVLVFDIW	 8	 VH6	1	 DH3	10	 JH3	 77	 17	 0.24	
CAREGRKRGYFDYW	 4	 VH3	23	 DH5	24	 JH4	 100	 14	 -1.54	
CARHFSGTLPDYFDYW	 3	 VH5	51	 DH1	26	 JH4	 99	 16	 -0.50	
CARDSSGSSWRWFDPW	 3	 VH4	31	 DH6	13	 JH5	 100	 16	 -1.05	
CARQLGYGMDVW	 3	 VH5	10	 DH5	24	 JH6	 99	 12	 -0.03	
CVREVGATWDLGHW	 2	 VH3	13	 DH1	26	 JH6	 95	 14	 -0.10	
CARSSGSGSYYKYGMDVW	 2	 VH4	30	 DH3	10	 JH6	 82	 18	 -0.59	
CARRSYGDYSDYW	 2	 VH6	1	 DH2	2	 JH4	 96	 13	 -1.42	
CARNKQHHYLIFDYW	 2	 VH4	30	 DH2	2	 JH4	 100	 15	 -0.89	
CARLFSSAWYEDFDYW	 2	 VH4	39	 DH2	2	 JH4	 86	 16	 -0.34	
CALSGSYLDYFDYW	 2	 VH5	51	 DH1	26	 JH4	 99	 14	 -0.06	
Table 21: CDR3 clones derived from the IgH sequencing data. 
Sample ID, CDR3 clone sequence, percentage of the total CDR3 aa repertoire these clones make up, V, D and J gene usage, V-region 





The maximally expanded clone amongst all samples was seen within SchS-24, making up 
nearly a third of its total CDR3 repertoire. This was closely followed by the topmost clone in 
SchS-20 at 23%, SchS-25 at 19% and SchS-22 at 14. Samples 12, 14 and 16 harboured their 
most abundant clone between 7% and 9%, lower than the aforementioned samples but higher 
than those of samples 15, 18 and 22. The latter samples demonstrated the lowest degree of 
clonal expansion and frequency amongst the SchS patients assessed.   
Seventy-eight percent of CDR3 sequences making up 2% or over of the total CDR3 aa 
repertoire largely utilised the VH3 family, with JH4 and JH6 being the common J families 
amongst these sequences. DH1 to DH6 were the most utilised D families. Based on published 
CLL analyses, deviance of less than 2% from germline indicates that these sequences are 
unlikely to be mutated (391), with the latter being true for the top clone in eight out of ten SchS 
samples. For top clone in samples 14 and 20, the percentage variance from germline was 5% 
and 3% respectively, indicating possible hypermutation.  
The clone length varied from 9 aa (sample 14) to 24 aa (sample 16), with the median value 
being 15 aa, comparable to healthy individuals (298, 367). The median values all CDR3 aa 
sequences seen in these SchS patients were in the range of 13 to 15 aa (Figure 61). The 
grand average of hydropathicity index (GRAVY) value represents the hydrophobicity of a given 
peptide. This formula calculates the sum of the hydropathy values of each aa in a sequence 
divided by the sequence length (based on the values provided by Kyte and Doolittle) (392). 
Positive GRAVY scores indicate the hydrophobic nature of the peptide whereas negative 
scores denote hydrophilicity. Though the values obtained for the clones in this SchS data set 
were in the range of -1.54 and +0.66, 81% demonstrated a negative score indicating that the 




















Figure 59 portrays the frequency distribution of all CDR3 aa sequences identified per SchS patient (n=10). One bar is representative of one 
sample. Each colour is representative of a unique CDR3 found within that sample, with bar thickness pertaining to the frequency of that CDR3 
aa sequence.  

















Composition of CDR3 aa sequences per individual as a total of whole




The cumulative prevalence of CDR3 aa sequences that appear at a level of 2% of over (regarded as a clone) within each SchS sample (blue), 
versus those sequences that appear at percentages less than 2% (orange), are shown in Figure 60.









































Proportion of CDR3 clones




Table 20 indicates the clinical and laboratory findings of the SchS patients included in this 
body of work. All SchS patients demonstrated evidence of a monoclonal component and NUD 
(latter detail not indicated in Table 20). The age of symptom onset ranged between 36.8 and 
78.9 years, with the eldest patient harbouring the MYD88 L265P as detected by ASO-PCR. 
None of the patients demonstrated evidence of NLRP3 mutations, nor did the female SchS 
patients show XCI as determined by the HUMARA assay. Patient 20 was the only patient out 
of the SchS cohort (n=30, Results Chapter 2), who had a mutation in the MDS-related 28 gene 
panel (stop-gain mutation in STAG2).  
From the data shown in Figures 59 and 60 (based on a 10% gDNA B cell content), each SchS 
sample is indicative of CDR3 aa sequence expansion, though to varying degrees. Likewise, it 
is possible to categorise these samples into four groups based on these figures. Group one 
comprises of SchS patients 12, 14 and 16; group two comprises of 15, 18 and 21; group three 
consists of 20 and 24, with the last group containing 22 and 25. Imperatively, no public 
sequences were found in this dataset and therefore the aa sequences referred to are unique 
to each participant.  
The most frequent CDR3 clone for each sample in group one exist within the range of 220 to 
291 times, with the second most common appearing between 182 to 212 times. For samples 
12, 14 and 16, those aa sequences regarded as a ‘clone’ (Section 5.3.5) cumulatively makeup 
70%, 80% and 73% of the total CDR3 aa sequences respectively. Thus, deducing that 20%-
30% of these sequences are not ‘clones’ indicates the existence of considerably sized CDR3  
aa sequences amongst a polyclonal background. Interestingly, the detected monoclonal 
components of samples 12 and 16 are IgMκ, but that of sample 14 is IgGλ. The latter is 
documented to have a 15% plasma cell bone marrow infiltration, not seen in the other two 
samples in this group. However, in view of clonality, long term follow up would assess whether 
this disparity has an effect on clone size and frequency. 
Amongst group two, the proportion of CDR3 aa sequences pertaining to a clone are less than 
14% in each sample, with the most expanded sequence falling within the range of 76 to 127 
times. Hence, in comparison to groups one, three and four, the clonal population is markedly 
lower. Unusually, SchS patient 15 had levels of IgMκ falling within the ‘normal’ range at 1g/l, 
which could be explanatory of the decreased clonality seen. Interestingly, the other two 
samples in this grouping had the monoclonal IgM of the lambda subtype. Literature indicates 
that 90% of SchS cases have been associated with a kappa light chain (26), therefore, the 
possible degree to which persistence of IgMλ has a bearing over clonal expansion, remains 




Patients 20 and 24 establish CDR3 clones amounting to 88% and 93% of their total repertoires 
respectively. The relatively higher frequency of the unique CDR3 sequences making up their 
B cell repertoire suggests the existence of a subset of clonally expanded B-cells. The LPL and 
MDS-associated mutation documented in patient 20 is likely to influence clonal expansion and 
predisposition to a proinflammatory environment respectively. Inference that this increased 
degree of clonality is not entirely causative by the LPL or the STAG2 mutation, is on the basis 
that SchS 24 didn’t demonstrate these findings, yet showed a larger proportion of CDR3 
clones.  
SchS patients 22 and 25 can be placed into group four with their clones corresponding to 45% 
and 65% of their total sequences respectively. The top clone for each sample appeared 
between 452 and 638 times. Interestingly, patient 25 harbours the L265P mutation and the 
latter pathogenic variant is a predisposition to an altered proinflammatory microenvironment 
and increased NF-κB signalling (393), possibly leading to the expansion of a subset of B cells 
producing the monoclonal component. However, the absence of this mutation in the other 
SchS patients also demonstrating clonal expansion indicates that this mutation is not entirely 
causative of such clonal events. 
Although patient 12 had a partial response to treatment established a degree of clonality, those 
patients who were deemed ‘most clonal’ (i.e. groups three and four) established a successful 
response. Though the treatment outcome may be influential upon B-cell expansion, a clear 
association between IL-1 blockade and a clonal reaction can be ruled out. 
The arrangement of these samples into four distinct groups based on the abundance of CDR3 
clones per individual, perhaps indicates that SchS is a condition progressing into a more clonal 
disease over time, with a subset of patients likely to develop WM as a consequence of such 
expansion. Evidently, age plays a role in SchS, as those patients demonstrating the most 
clonal proliferation, were amongst the eldest in this cohort.   
Regardless of a 10% or 1% B-cell DNA content, the CDR3 aa sequences remain represented 
at the same levels. For example, the first ranked sequence in both assumptions makes up 
19% of the total CDR3 repertoire. In view of the top 10 CDR3 sequences, although the 
percentages remain the same, removal of the tail end leaves those aa sequences that pertain 
to a clone (making up over 2% of the CDR3 repertoire). Although this panel described refers 







5.3.5.6 CDR3 length 
As the length of the CDR3 region of the Ig gene bears great influence over antigen specificity, 
the following section examines the length of this region from the resulting sequencing data. 
Analysis of CDR3 length variation may reveal certain trends in view of the hypothesis that 
SchS is a B-cell clonal disease, sharing IgH characteristics amongst 10 SchS patients.  
	
Figure 61: Box and whisker plots comparing CDR3 lengths across 10 SchS patients. 
  
Figure 61 compares the CDR3 length data obtained from the 10 SchS patients included in this 
work. The whiskers denote the ranges, with the interquartile and median values indicated by 
the boxes. The median CDR3 lengths across all 10 SchS patients were either 13, 14 or 15 aa, 
with range between 3 and 31 aa. A large amount of data demonstrates that the majority 
‘healthy’ CDR3 lengths are amongst 8 to 18 aa with median values of 15.5 to 16 aa (298, 353), 




































































































































































































































































Bar graphs demonstrating the distribution of the CDR3 length in amino acids between all 
sequences from 10 SchS patients. Each peak corresponds to a CDR3 length, comprising of 
multiple sequences. 
 
The graphs in Figure 62 demonstrate the CDR3 lengths used within a sample, plotted as a 
percentage of total CDR3 aa sequences. Visualisation of length distribution is also possible 
with this figure and all 10 SchS samples generally follow a Gaussian distribution. SchS 12 had 
a median length of 13 and 95% of the CDR3 sequences varied between 8 to 21 aa’s. The 
most commonly seen length was 13 aa, making up 15% of the total sequences. SchS 14 
showed a median length of 14 with 99% of CDR3 sequences falling between the range of 6 
to 24 aa’s. The predominantly used length was determined to be 14 aa at a 16% frequency. 
Analogous to SchS-14, 14 aa was the commonly employed length in sample 15, but with a 
reduced fraction of these sequences at 13%. Fourteen aa was its median length and 94% of 
CDR3 sequences fell between 9 to 25 aa’s. Sample 16 had 97% of its CDR3 sequence lengths 
encompassed within 8 to 23 aa’s and the most prevalent length of 13 aa formulating 14% of 
the total sequences. The median for this sample was 15, with sample 18 showing the same. 
The latter sample encompassed 99% of its lengths between 9 and 26 aa’s, with the most 
commonly used length of 13 aa pertaining to a 12% value of total. In contrast to the previous 
sample, 11 aa was the most frequently used length in SchS 20 at a 14% value, despite having 
93% of its lengths between the same range as SchS 18. The median length for SchS 20 was 
14. Similarly, sample 21 presented a median length of 14 aa, with the most frequently used 
length at 15 aa making up 11% of the total CDR3 sequences. Nearly 100% of CDR3 lengths 
found within SchS 21 were included within the range of 5 to 27 aa’s. Identical to sample 21, 
sample 22 demonstrated 15 aa as the most prevalent length, but this pertained to a slightly 



















































covering 96% of total sequences, accompanied by a median of 15. Comprising over a fifth of 
total sequences, 13 aa was the most common CDR3 length in sample 24. The median was 
14 aa and 97% of sequences within this sample sat in the range between 9 and 26 aa. Lastly, 
sample 25 had a range of 7 to 24 aa, which encompassed 90% of the total CDR3 lengths 
found. Closely, 12 aa and 14 aa were the most prevalent lengths within this sample, making 
up 14.7% and 14% of the total frequency respectively. This sample had 14 aa median. 
Notably, samples 12, 20 and 22 demonstrated a 2%, 4% and 1% length at 31 aa’s respectively, 
the largest length seen within this dataset with a percentage usage of 1% or over. Likewise, 
the shortest length of 5aa was seen within SchS 21, exhibiting a 1% frequency of total CDR3 
samples.  
In addition, the skewness and kurtosis of the data were calculated to assess whether the 
CDR3 lengths conformed to a normal distribution. Where skewness measured the CDR3 
length distribution symmetry above and below the mean, kurtosis measured the events in the 
central part of CDR3 distribution in comparison to that in the tails of the data. Kurtosis therefore 
defines the height and peakedness of the central data, relative to a standard Gaussian 
distribution (348, 394). The following inferences have been made on the basis that values 
obtained between -1 to +1 for skewness and between -2 and +2 for kurtosis indicates a 
symmetric and univariate distribution (395).  With regards to skewing, samples 12 and 20 are 
above 1 and thus highly skewed. Interestingly, sample 20 demonstrates one of the highest 
levels of clonal expansion in comparison to a majority of the other samples, whereas sample 
12 shows evidence of such expansion but to a lesser degree. Samples 18, 21, 22, 24 and 25 
have a moderately skewed distribution, although sample 21 can be considered as the sample 
exhibiting the least evidence of clonal expansion. Showing values between -0.5 and +0.5, 
samples 14, 15 and 16 can be considered as approximately symmetric, but show a degree of 
clonality. Overall, the lack of equivalence for length of distribution as denoted by the skewness 
of the data for seven out of 10 samples and the fact that all 10 samples demonstrated kurtosis 
values above 2 suggests that the CDR3 lengths do not generally follow a Gaussian 
distribution.  
The median lengths for the clones (Table 21), remained in the region of 14 aa to 16 aa for 
each sample aside from sample 16, whose median clone length was 19 aa. In view of the 
kurtosis seen for each sample, this essentially indicates that the clones are not located in the 







5.3.5.7 CDR3 aa composition 
The CDR3 is highly diverse in composition and thus, correlations can be drawn between B 















































































































































































































































































































































































































Figure 63 comprises of bar graphs visualising how frequent each amino acid is used in the 
CDR3 of all sequences from 10 SchS patients. Percentages are plotted for each amino acid 
ranging from Hydrophilic to Hydrophobic, the order based on the Kyte & Doolittle scale of 
hydrophobicity (392).  
Each graph shows the aa’s on the X-axis – arranged by the Kyle Doolittle scale of 
hydrophobicity (392) – with the percentage of total aa’s in the CDR3 region on the Y-axis. On 
the whole, each SchS sample had similar percentage compositions of aa’s in their respective 
CDR3 regions, though minor fluctuations could be seen. The most commonly used aa’s were 
tyrosine (Y), glycine (G), alanine (A), aspartic acid (D) and arginine (R) accompanied by the 
following ranges respectively: (Y) 11.4% - 15.9%; (G) 10.8% - 12.4%; (A) 9.5% - 11.8%; (D) 
9.5% to 10.9% and (R) 7.8% to 9.9%. Cysteine (C), histidine (H), lysine (K), asparagine (N), 
methionine (M), glutamine (G) and tryptophan (W) were amongst the least employed aa’s with 



















































































































































































































































































Amino acids, from Hydrophilic (left) to   
Hydrophobic (right)
SchS - 25



























Comparison of 10 SchS CDR3 aa composition 64A, with the compositions of 2 sets of data 
derived from literature. Figure 64B represents healthy controls (n=33) vs neonates (n=10). 
Figure 64B has been included as an illustrative comparison for the CDR3 composition results 
obtained. Figure 64B corresponds to the work by Hong et al (353), in which the cord blood of 
10 newborns and the peripheral blood of 33 healthy controls (average age of 44 years) was 
analysed using gDNA – analogous to the work presented in this section of work. Comparing 
Figure 64A and B, SchS patients and healthy controls both use top frequently occurring aa’s 
in CDR3, arginine, lysine, tyrosine, glycine and alanine. Further, as shown in Table 21, a 
majority of the clones seen in the SchS data are largely hydrophilic, whereas more 























































































5.3.6 VDJ usage  
The second parameter to study the entire immune repertoire of SchS patients in this work was the analysis of V-D-J gene segment 
combinations.   
5.3.6.1 Frequency of VH, DH and JH gene usage (genes) 
A widely used metric is the assessment of how frequently V gene segments are used, with the following data demonstrating the percentage of 
V gene segments utilised within the SchS cohort.   






































Figure 66: D gene usage in 10 SchS patients. 
 
































































































































































Figure 68 shows bar charts summarising VH, DH and JH gene usage in the SchS cohort. The 
percentage of sequences are on the Y axis with the sample number on the X axis. VH, DH 
and JH usages are shown as the percentage of sequences on the Y axis.  
The IgHV, IgHD and IgHJ genes are grouped into major families based upon the homology of 
their nucleotide sequences. Dependent upon the haplotype of an individual, the IgHV locus 
comprises of over 50 functional genes and are grouped into 7 major families; the IgHD locus 
spans across 27 genes and grouped into 7 families; and the IgH locus consists of 6 genes and 
grouped into 6 families (398). The data presented in this section illustrates the usage bias that 
occurs to certain V/D/J genes and families within SchS patients, and comparing this to usage 
to other disease groups and healthy controls as stated in literature.  
5.3.6.3 VH usage 
Whilst encoding CDR1 and CDR2, the V gene family only contributes a few nucleotides to the 
CDR3 region. VH3 is the most used VH family in nine out of 10 SchS patients at an average 
of 75% and in contrast, sample 25 shows preference to VH6 at 40% usage of total sequences, 
closely followed by VH4 usage at 30%. More precisely, VH3-11, VH3-30, VH3-74 and VH6-1 
are the most commonly employed VH gene segments in the data presented (Figure 65).  In 
regards to the clones (Table 21), VH3-11, VH3-30, VH3-74, VH3-64 and VH3-23 were the 






































Samples 20, 22, 24 and in particular, sample 25, showed disparity with regards to VH gene 
segment patterns within their clones. The VH2 family was absent from the top CDR3 aa 
sequences of the other nine samples, although VH2-5 was exclusively used by sample 24 at 
4%. The VH4 family was employed in the clones of SchS 20, 24 and 25, a finding not emulated 
in the other seven patients. Where the VH5 family usage in clones was exclusive to SchS 25, 
this sample also demonstrated VH6-1 usage at 36%, the highest VH6 family usage in the top 
clones of the samples, followed by sample 22 using VH6-1 at a cumulative 18%. The other 
patients utilised VH6 to a decreased percentage (i.e. top clones for SchS 18 and SchS 21 
used VH6-1 at 7% and 6% respectively).  
5.3.6.4 DH usage 
Between the V, D and J genes families, the D gene family bears the greatest influence on 
CDR3 by the contribution of all nucleotides (391). In seven out of the 10 samples (SchS 12-
18 and SchS 22) with a 25% usage each, DH3 and DH6 were the most frequently used gene 
families in the entire repertoire. Similar to VH findings, samples 20, 24 and 25 showed 
differential DH usage patterns in their repertoires. SchS 20 preferentially employed DH1 at 
40%, sample 24 using DH2 at 29% and sample 25 used both DH1 and DH3 at 26% and 25% 
respectively. In view of the clones, these DH gene families were used to largely the same 
values. 
5.3.6.5 JH usage 
Encoding part of the last section of CDR3, J genes are also important contributors to the 
generation of antibody diversity (196). Each of the 10 SchS patients followed the same JH 
usage patterns in their repertoires with JH4 being the most frequent J gene followed by JH6. 
JH4 was the most used within the range of 40% to 90% and JH6 usage was within the range 
of 6% to 39%. These gene families were also recurrently used by the clones.  
5.3.6.6 Comparison to WM and Healthy Controls 
Interestingly, isolation of IgM from a WM patient and subsequent cloning of the variable region 
of the antibody (Figures 45, 46 and 47), showed preferential usage of VH3-30 (399), a 
segment used biasedly in this data at an average of 14.5% of all SchS patients. The former 
finding was further mirrored in the study by Petrikkos et al, demonstrating that 74% of the WM 
patients included in their research demonstrated preferential usage of the VH3 family, with 
distinctive usages of VH3-30 in 8% and VH3-74 in 17% of the patients (198). The authors also 
found VH3-23 particularly used in a quarter of the patients (averagely used at 2% in the entire 
repertoire of all SchS patients – but at 4% and 7% in SchS 24 and 25 respectively); however, 




the other WM findings, a largely VH3 restricted repertoire alongside preferential JH4 usage 
were the conclusions made by Kriangkum et al through repertoire analysis of 15 WM patients 
(400). Within the data sought through this chapter, JH4 was the most preferentially selected 
member of the JH family in all SchS samples at an average of 57%.  
Bearing percentage similarities to SchS, a study sequencing the IgH region of monoclonal IgG 
antibodies derived from memory B cells from four healthy donors noted the heightened usage 
of the VH3 family at over 50% of the repertoires, followed by the VH4 family at around 25% 
(401). However, research by Hong et al (353) sequencing cDNA deduced that healthy 
individuals (n=33) used VH4 at 43% and VH3 at 25%, alongside neonates (n=10) using both 
these VH families at an average of 31%, both cohorts in stark contrast to nine out of the 10 
SchS patients sequenced in this work where 75% was the average VH3 usage. The 
differences seen between the aforementioned papers maybe to do with the variation in sample 
size, or the fact that the latter study attempted to assess the entire IgH repertoire, as opposed 
to the former study where calculations were made based on secreted IgG antibodies only.  
Though comparably, Hong et al found the DH3, DH6, JH4 and JH6 the most frequently used 




















Figure X (A-J): Representative circos plots of V-J recombination, illustrating the frequency of gene combinations. The width of the ribbons The  
The plots shown in Figure 69 indicate the frequency at which a V-J combination is used.  The colours indicate those V-J combinations pertaining 








Figure 69: Representative circos plots of V-J recombination. 
	
	
The circos plots in Figure 69 summarise the V to J combinations used in the rearranged Ig 
genes for IgH in 10 SchS gDNA samples. Rearrangement of a V gene with a J gene is shown 
by the presence of a ribbon. Each ribbon has a designated colour, each colour indicating a 
different member of the VH gene family participating in the recombination event. The greater 
the width of the ribbon, the higher the frequency of that particular VH gene combined with a 
certain JH gene. As alluded to in greater depth in Section 5.3.5.1, a ‘clone’ in this data was 
referred to as an identical CDR3 aa sequence using the same VH gene and JH segments 
forming 2% and above of the entire IgH repertoire sequenced. Therefore, additional V-J 
combinations resulting in CDR3 aa sequences not categorised as clones are also illustrated 
in the figures. These plots are a visual representation of the recombinations and easy to 
denote overrepresentation. Although the prevalence of certain V-J combinations are not 
entirely indicative of clonality (i.e. clonal populations of B cells), preferential usage of particular 
gene segments point towards a skewed IgH repertoire.  
The light blue and navy blue arcs located within the bottom half of the circos plots denote the 
JH4 and JH6 families respectively (aside from sample 25, where the navy blue arc represents 
JH5). The VH family arcs within the top half of the plots are in clockwise order of most 
employed VH segment to the least. For each sample, the red and orange ribbons demonstrate 
the most frequent recombination within each patient. Samples 12, 14 and 16 preferentially pair 
the VH3/JH4 and JH6 families whereas samples 15, 18 and 21 have a preference to joining 
VH6/VH3 to JH4 and JH6. A substantial portion of the IgH repertoire in SchS 20, 22 and 24 is 
restricted to VH3/JH4 pairings, and in contrast to the other nine samples, sample 25 exhibits 
enhanced familial pairing of VH6/VH4 to the J4 and J5 genes. The sample grouping here is 
similar to that of those suggested in Section 5.3.5.5, where expansion of CDR3 aa sequences 
are described. The more clonal samples are those with a more restricted repertoire (i.e. 
samples 20, 22, 24 and 25) in contrast to the other SchS patients demonstrating more diverse 



















HC and CLL plots were obtained from the work carried out by IJspeert et al, 2017 (383) 
 
Figure 70 aims to visually compare HC and the clonal disease CLL circos plots with SchS. A 
diverse IgH repertoire is seen in the HC, in stark contrast to the CLL sample where clear 
overrepresentation of VH4-34 to JH6 is demonstrated - indicating clonal expansion of a 
particular B cell. Amongst the 10 SchS samples, SchS-24 can be considered as the one of 
the most clonal in terms of the increased frequency of CDR3 clones (Table 21). Comparison 
of this sample to HC and CLL illustrates a few disproportionately combined V-J genes (VH3-
11 to JH4), but not to the extent of CLL and is more visually akin to the HC plot as compared 
to the CLL plot.  
Similar to SchS, overrepresentations of the VH3 and JH4/JH6 genes in WM (400) and VH3 
and JH3/JH4/JH5 families in IgM MGUS have been reported (402) - although V-J 
recombination has not been directly studied in the latter conditions. Subtle 
overrepresentations of VH4/JH4 in healthy individuals between the ages of 18 to 89 were 
observed in spleen derived gDNA samples; the same study also analysed lymph node derived 
gDNA, reporting a recombinational bias of the VH6 and JH6 families (403). Thus, in view of 
SchS where largely VH3/JH4 preferential combinations were seen, SchS bears more 
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The aim of this chapter was to utilise an NGS approach to sequence gDNA, for the purposes 
of investigating IgH gene usage alongside CDR3 characteristics, and comparing these metrics 
amongst 10 SchS patients.  
To summarise, the main findings in this chapter were: 
i. Each SchS patient demonstrated evidence of intraclonality 
ii. Identical CDR3 aa sequences were not shared amongst the 10 SchS patients 
iii. The CDR3 aa lengths were found skewed for all patients, but the composition for 
these sequences were comparative to healthy individuals 
iv. For the complete and clonal repertoires VH3, VH6 and JH4 and JH6 were the most 
abundantly utilised genes 
v. A combinatorial bias was observed through the favoured rearrangements of VH3 
and/or VH6, to the JH4 and/or JH6 gene segments in every sample, though to 
varying degrees 
5.4.1 IgH 
In this section of work, the humoral/adaptive response in the setting of an autoinflammatory 
condition was investigated, analysing three general metrics of B cell repertoire skewing: CDR3 
length distribution, CDR3 aa composition and VH gene usage. Importantly, the approach of 
discriminating between different B cell populations was not employed; rather, gDNA 
representing pooled B cells derived from PB was used as the initial PCR template. Utilisation 
of gDNA provides two main benefits, with this sample type most frequently used in a clinical 
setting. Primarily, working with gDNA is robust, in that it is unlikely to be degraded in 
comparison to mRNA. When working with suboptimal samples (i.e. low viability/frozen EDTA 
samples), as was the case for some patients in this cohort, gDNA was a versatile starting 
material. Secondly, non-productive gene rearrangements can be investigated, “providing a 
potential second target to identify a clone in B cells with two heavy chain rearrangements” 
(195), though single cell analysis would be required . Additionally, the correction of differences 
is required when starting with RNA, due to varied quantities of transcript (325).  
High yields of gDNA from B cells are imperative when trying to obtain comprehensive 
representation of the IgH repertoire, however this poses challenges when working with 
samples with limited numbers of lymphocytes (404). In heterogeneous conditions such as 
SchS, where the IgM paraprotein is likely originating from a small subset of clonally expanded 
B cells, it is important to consider that certain rearrangements may have not been detected 




analyses presented in this section are representative of the B cell repertoire in 10 SchS 
patients with the comparisons made and conclusions derived from this data not absolute, but 
rather, comparative.  
5.4.1.1 Repertoire Diversity 
Until the advent of NGS in recent years, only limited B-cell receptor rearrangements (10-100) 
could be studied due to the use of traditional cloning and sequencing, simply providing a very 
restricted overview of diversity (386). At any given point, analysing the diversity of the 
repertoire by sequencing gDNA from whole blood provides a snapshot of only 2% of the total 
B-cell repertoire (368). It is imperative to know the B-cell count for a fully accurate assessment 
of the repertoire, as generally each B-cell is capable of solely one productive rearrangement 
for an Ig. Though with clonal populations, numerous B-cells with identical rearrangements are 
likely to be present.  For example, with a starting sample comprising of 50,000 B-cells, 
discovering the same amount of different productive rearrangements is highly unlikely. 
However, taking into consideration PCR and sequencing error, more than 50,000 sequences 
will be produced in this scenario. Ideally, a precise B cell count would be obtained by either 
flow cytometry or qPCR assessing B cell markers (368). However, this was not possible in this 
work due to the type and availability of SchS samples.  
Where the B-cell count was unknown, other studies used inference models to estimate the B-
cell content and the maximum number of productive rearrangements (195, 353). In this work, 
inference of the number of B cells was based on the assumption that each cell has contains 
6pg of DNA and the total B-cell content of that gDNA was either 10% or 1%. Amongst all 10 
SchS samples, the expanded clones remained represented at the same levels, supposing 
either a 10% B-cell assumption or a 1% content of B cell DNA (Figure 57). The research by 
Rosenfeld et al assumed the following parameters to deduce B cell-content and hence 
productive rearrangements: (1) each cell has 6.7pg of DNA; (2) one B cell harbours at least 
one heavy chain rearrangement; and (3) 1.4 VDJ rearrangements will occur per cell (195). 
Applying the latter two parameters stipulates that 71% sequences would be productive, with 
this value was surpassed by SchS patients. The percentages of productive sequences were 
in the range of 74% to 92%, in line with the 75% productivity found in a patient with Follicular 
lymphoma, also bearing clonal B cell populations (405). Contrastingly in CLL, several studies 
have documented the decreased percentage of productive sequences (ranging from 21% to 
40%) (406-408), and could be explained by the occurrence of oligoclonality through the 
abnormal expansion of one clone. The relatively higher percentage of productive sequences 
seen in SchS could indicate clonal expansion, to a much lesser degree than seen in CLL but 




5.4.1.1.1 Definition and frequency of CDR3 clones 
The IMGT numbering system was used for CDR3 identification and annotation (382). In this 
work, a clone is defined as a unique CDR3 sequence appearing in more than 2% of the total 
CDR3 sequences per individual based on previous cut-off values by Tak et al (>2.5-5%) and 
Tan et al (>0.1%) (323, 388). Given the potential diversity of B-cell receptors generated by 
VDJ recombination (detailed in Section 5.1.1), the rare probability of converging upon the 
same IgH sequence renders each CDR3 aa sequence as a unique tag for a B-cell clone (409). 
Similar cut-off values have been used to define clonal populations in T cell analyses (0.1%-
1%) (410). Arguably, the percentage limits drawn in literature for clone classifications is rather 
specific to each study and therefore classifying such clones could be deemed as subjective. 
However, portrayed via Figure 57 in this work, the CDR3 aa sequence composition generated 
from entire IgH repertoire at the nucleotide level is accurately representative of the proportional 
frequency of such CDR3 sequences per SchS patient.  
 
5.4.1.1.2 CDR3 clone analyses 
As demonstrated by both Figures 59 and 60, the increased abundance of specific CDR3 
sequences demonstrates the level of cell clone expansion. The degree to which a healthy 
individual demonstrates clonality has been previously investigated. For example, Wang et al 
found that out of an average of 229,317 unique CDR3 aa sequences found for 6 HC’s, only 
an average of 0.004% total sequences corresponded to clones (411). In contrast, each SchS 
patient demonstrated evidence of expanded CDR3 clones (7% to 93%) out of total CDR3 aa 
sequences. This stark variation in clone percentage amongst the 10 SchS patients underscore 
the variances seen with regards to the diversity of the IgH repertoire and resulting CDR3 
sequences of this AI disease. Although may signify a recently mounted antigenic response, 
correlations between the reduction in diversity and other factors can be postulated. For 
example, samples 20 and 25 demonstrate pathogenic mutations in STAG2 and MYD88 
respectively, a feature not present in the other eight patients. Likewise, samples 22 and 24, 
also demonstrating a narrower CDR3 repertoire are amongst the oldest three in this SchS 
group (Tables 20 and 21).  
 
5.4.1.1.3 CDR3 length distribution  
Within a diverse repertoire of B cells, it is expected that the length of CDR3 when plotted 
against percentage of sequences corresponding to that CDR3 loop, follows a ‘discretised 




Alternately, a skewed CDR3 distribution indicates overabundance of certain clones. The latter 
may be a consequence of abnormal VDJ recombination or demonstrative of a recently 
mounted response to an antigen (348). All 10 SchS samples do not follow a bell-shaped curve 
and bear increased numbers of CDR3 length classes (range of 11-14). Reflecting the entire 
repertoire, the median lengths of SchS patients were in the range of 13 aa to 15 aa, equivalent 
to the median length described in 123 patients with WM or IgM-MGUS (13 aa) but substantially 
shorter than that of CLL – 17 aa as portrayed by 7424 subjects (291). Median values obtained 
from healthy controls show CDR3 lengths at 15.5 aa to 16 aa (298, 353). Considering the 
clonal populations, the median lengths remained between 14 aa to 16 aa, with sample 16 
bearing an overall longer length at 19 aa. The latter value is identical to CDR3 lengths 
established in clonal sequences of 68 CLL patients with VH4-39 overrepresentation (291) 
whereas VH was largely used in the clonal populations of SchS-16. Logically, longer CDR3 
lengths (i.e.> 24 aa (412)) have an increased capacity of sequence variation with the potential 
to reach ‘narrower antigenic pockets’ (413), reflecting the role of innate immunity to broadly 
neutralise foreign antigens not previously encountered (412). Whereas decreased CDR3 
lengths reflect previous antigenic exposure. For example, with SLE, shorter CDR3 length 
(averaging 14 aa) have been documented (396, 397), likely indicating the preponderance of 
the generated autoantibody reactivity to known antigens in this condition such as dsDNA (ref 
Shi short term again). In the data obtained with SchS patients, the inclination towards shorter 
median values in both clonal populations and the entire repertoire could be an consequence 
of selection bias those B cells producing longer CDR3 regions but also recurrent exposure to 
a particular epitope or group of peptides possessing canonical properties i.e. binding motifs. 
Though these speculations can be only precisely confirmed using through SchS-IgM analysis 
(i.e. exposure to a protein microarray), the trend in shorter CDR3 lengths proposes the 
likelihood of the SchS monoclonal component retaining binding partialities.   
5.4.1.1.4 CDR3 composition 
Augmented use of certain aa’s in CDR regions have been suggested as a consequence of 
clonality. For example, increased frequency of arginine was suggested as the result of clonal 
B cell expansion in a study assessing anti-Cardiolipin antibodies (414). The CDR3 aa 
compositions of each SchS sample are akin to those percentages sought in healthy individuals 
(and thus CDR3 composition is less informative in regards to assessment of the adaptive 
response in comparison to length and hydrophobicity/hydrophilicity dynamics.  
Observations that BM heavy chain CDR3 peptides are more hydrophobic in comparison to 
those found in PB (415), largely implies that selection against this feature occurs during central 




associated with autoreactivity in autoimmune conditions such as SLE (396, 397).  In view of 
SchS, generation of the GRAVY scores for the clonal CDR3 sequences overall denoted a 
hydrophilic preponderance and is in accordance with the gDNA derived from PB, and not BM. 
Interestingly, Ademokun et al investigating the B-cell repertoire characteristics post 
pneumococcal vaccination demonstrated both young and old participants had significantly 
lower (hydrophilic) GRAVY scores in those CDR3 sequences deemed as clonal, as opposed 
to that of the entire repertoire (416). Following the aforementioned paper and in view of SchS 
– where the CDR3 clones are largely hydrophilic and the CDR3 lengths are in accordance 
with those associated with experienced repertoires, could suggest that an element of the SchS 
adaptive system is geared towards an antigenic response.  
5.4.1.1.5 Stereotyped CDR3 sequences  
In contrast to CLL but analogous to SchS, IgM-MGUS and WM demonstrated no evidence of 
stereotypy in cohort of 59 and 64 patients respectively (358). Thus, the lack of stereotypy 
amongst these patients and within SchS patients indicates the pathogenesis in these disorders 
are not B cell receptor mediated. Thus, whether the distinctive paraproteinaemia seen in the 
aforesaid conditions are essentially by-products of B cell expansion or are intentionally 
produced remains to be clarified. Such definitive answers can be sought through the isolation 
of the monoclonal component for investigation of its binding properties. 
5.4.2 VH usage 
The VH3 family was employed at an average of 75% in nine out of the 10 SchS patients, akin 
to the populations considered as clonal (76%, Table 21). Comprehensive research indicates 
the favoured use of both VH3 and VH4 in healthy individuals. Through sequencing IgH regions 
specific to the IgM derived heavy chains using cDNA (353), or gDNA derived from flow 
cytometry sorted B-cell populations (i.e. plasma cells) (417), VH4 was most favourably used 
family followed by VH3. Interestingly, the latter study noted a neonatal preferential bias of 
VH3. However, another recent study by Petrova et al noted around 60% of IgH sequences 
(IgM specific) analysed from 19 healthy controls utilised VH3 (418),  the same as detected in 
WM (198, 419) and IgM MGUS (402). However, the difference sought between the latter B-
cell malignancies and HC immune repertoires is the overrepresentation of certain gene 
segments, rendering a skewed immune profile. For example, while VH3 was used between 
the ranges of 42% - 66% in clonal populations of B cells derived from CLL and MBL, 77% of 
sequences were encoded by only 12 VH genes out of the possible 46 VH genes (420). 
Petrikkos et al found all IgH sequences derived from BM derived gDNA of 34 WM patients 
utilising only 14 VH segments (198). Likewise, all the CDR3 clones found in SchS were 




from patient 25, VH3-11, VH3-30 and VH3-74 were the most used gene segments, both in the 
clonal and entire IgH repertoires. Primary Biliary Cholangitis, where the role of elevated serum 
IgM is elusive (analogous to SchS), has also shown a VH3 family preference (421).  
Notably, autoimmune diseases such as SLE and RA demonstrate VH4-34 usage bias (422). 
Use of this region has documented to be integral to the formation of autoreactive antibodies, 
shown to recognise anti-DNA antibodies (423), the Fc portion of IgG (424) as well as 
commensal bacteria such as Clostridium difficile (425).  The underrepresentation of VH4-34 
in the germinal centre and memory B-cells from healthy subjects has been regarded as a 
conscious effort to hinder plasma cells from producing such auto-antibodies (426). With the 
cohort sequenced in this chapter, usage of this naïve B cell repertoire associated gene 
segment was not observed, generally supporting the notion that SchS is an autoinflammatory 
condition lacking autoantibody activity. 
Although DH usage is more varied compared to the similar usage patterns observed in the VH 
and JH gene groups, seven out of 10 patients bear preference to using DH3 and DH6 at an 
average of 25% in their whole repertoires, also mirrored in their clonal populations. Where 
healthy individuals demonstrate favoured DH3 and DH6 usage, certain B-cell malignancies 
such as WM (n=22) and IgM-MGUS (n=5) both exhibit bias towards the DH1 and DH6 families 
(402). The latter findings were emulated in samples 20 and 25, with DH1 being the 
preferentially employed DH gene, whereas sample 24 exhibited highest preference towards 
DH2, different to the rest of the samples.  
The data obtained from the entire repertoires show all patients demonstrating preferential JH4 
gene family usage at a 57% average of all IgH sequences, essentially comparable to those 
values sought in plasma cells derived from a healthy control (50%) (417) and B-cell LPDs 
(range of 40% - 48%) (420).  
 
5.4.2.1.1 VH-JH Recombinations 
To obtain a more detailed insight into the combinatorial dynamics of SchS patients, V-J 
recombination was examined. Identification of specific gene recombinations within each 
patient underscores the observations in the previous work indicating that SchS bears 
preference to usage of certain gene segments. Nine out of 10 SchS samples demonstrated 
recombinations of VH3 to JH4, similar to the genes employed in WM and IgM MGUS. Although 
to varying degrees and not to the magnitude at which CLL presents, each SchS patient 
exhibits evidence of preferential recombination and such skewed patterns could be interpreted 




polyclonal B-cell disorder in amidst a fairly diverse environment is founded by clear 
overrepresentations of the aforementioned pairings (Section 5.3.7) in each SchS sample. 
In this work, IgH sequences were considered to belong to the same clone if they shared V and 
J gene usage alongside identical CDR3 amino acid sequence at a level of 2% or over of the 
entire individual IgH repertoire. Therefore, it is imperative to note that although the clones are 
clearly represented in the circos plots, these figures also depict those recombinations not 
categorised as a clone in the analyses carried out in Section 5.3.5. Identical V-J 
recombinations can result in different CDR3 sequences, in part attributed to the employment 
of one of 27 DH region genes, and occurring at the VDJ junctional region – enzymatic addition 
of palindromic ‘P’ and random, non-templated ‘N’ nucleotides in conjunction with exonuclease 
activity (329).   
5.4.2.1.2 MYD88 L265P and VH usage 
SchS patient 25 presented with the MYD88 L265P mutation as deduced in Results Chapter 
3, with the aforementioned pathogenic mutation diagnostic of the LPD, WM. The VH6-1 
segment was mainly overrepresented in both the entire IgH repertoire and the clonal 
population in SchS-25 (Figures 65, 68 and 69, Table 21). Heightened use of VH6-1 has been 
linked to autoantibody production directed towards IL-18 in MS (427), and increased usage in 
autoimmune diseases such as Type I Diabetes and Idiopathic Thrombocytopenic Purpura 
(428) and is rarely employed in healthy individuals (417, 418). Another study assessing the 
IgH repertoire in healthy individuals using gDNA derived from BM and lymph nodes revealed 
preferential VH6-1/JH6 recombinations, mirrored in both young (<45 years) and older (>61 
years) populations (403).  Biased usage of VH3-30, VH3-74 and VH3-23 has been widely 
documented in WM (198, 419), with the latter gene segment used within a prevalent CDR3 
clone making up 4% of the entire repertoire of sample 25. Though this was not the case for 
VH3-30 and VH3-74 in SchS-25, these genes were overrepresented other MYD88 mutation 
negative SchS patients, signifying traits of a related immune repertoire between SchS and 
WM, despite MYD88 status. Though the presence of the MYD88 L265P mutation alongside 
alternative VDJ segment usage in sample 25 emphasises the concept of biological variance 
seen amongst those positive and negative for the variant (198), similar patterns of VH usage 
amongst SchS patients negative for the mutation and WM patients positive for the mutation 
suggests VDJ gene segment biases are not entirely linked to the co-existence of the MYD88 
L265P mutation. Increasing age is linked to the formation of a more restricted B-cell repertoire 
(403) and therefore could explain the disparity seen in terms of VDJ usage between this 
patient (78 years upon diagnosis) and the other SchS patients. Alternatively, recent response 
antigenic exposure could further corroborate the existence of a more skewed IgH repertoire. 







Present within each of the 10 analysed samples, the abundance of CDR3 clones, VDJ biased 
usage and distinct VJ recombinations, indicates that SchS has the bearings of a B cell clonal 
disorder. However, the degree of such clonal expansions vary immensely between the 
patients. For example, the clonal population in SchS-24 makes up 92% of its entire CDR3 aa 
repertoire, whereas the clonal population in SchS-21 comprises of only 6% of its CDR3 aa 
repertoire. Such findings make inter-disease clustering more challenging, and given that no 
public CDR3 aa sequences were discovered amongst these 10 SchS patients may suggest 
that clonal IgM may be produced as a consequence to non-specific antigenic stimulation within 
an autoinflammatory setting. However, these interpretations are in contrast with the evidence 
of combinatorial bias and relatively restricted VH, DH and JH gene usage sought in this work. 
Overrepresentation of VDJ gene segments indicates the existence of skewed IgH repertoire 
and could indicate that a certain division of the SchS IgH repertoire is directed at a particular 
group of antigens. 
Since a majority B cells present in PB are in transit towards tissues, gDNA derived from the B 
cells here are likely to represent only a small subset of their repertoire in terms of both 
composition and phenotype. Chaudhary et al estimated that such select sequencing results in 
representation of only 2% of the entire B cell population (329). Therefore, the data gathered 
provides only a snapshot of the occurrences in SchS. Although these findings support the view 
that IgM dysregulation is likely due to an abnormal IgH setting, the research presented in this 
chapter could be further strengthened through the deep sequencing of B cell subsets in an 
effort to pinpoint the stage at which malignant transformation could be occurring. Though 












5.4.2.3 Clinical perspectives 
Given that a minority SchS patients are inclined to develop an LPD over the course of 
approximately eight years (range: four to 20 years) (21, 36), analysing degrees of clonal 
expansion presents an opportunity to identify those who are more likely to develop 
malignancy. Greater extents of clonal expansion and reduced diversity may predispose to WM 
on the basis of a narrower IgH repertoire. Identification of highly expanded CDR3 clones such 
as those documented in SchS 20, 22, 24 and 25, where the top clones are present at over 
14% of the total CDR3 repertoires, warrant close monitoring to determine if these are 
causative of clonal evolution to WM. Halting the progression to WM or other LPDs would allow 
a prompt response with regards to appropriate treatment (i.e. B cell depletion) and 
preventative measures such as plasmapheresis to reduce the risk of associated complications 
such hyperviscosity syndrome (429).  
Relating the data garnered from this chapter alongside the stated clinical findings (Table 20), 
out of the 10 patients investigated, SchS-20 is the most likely individual to develop WM. Upon 
SchS diagnosis, this patient demonstrated LPL in their bone marrow histology, a pathogenic 
STAG2 mutation (Results Chapter 3) and increased prevalence of CDR3 clones (88% of their 
CDR3 repertoire regarded as clonal, Figure 60). This postulation is further strengthened via 
data indicating that males are twice as likely to develop WM as opposed to females (429). 
Samples 22, 24 and 25 could also be hypothesised to potentially progress to a LPD, on the 
basis of increased age (61, 68 and 78 years upon diagnosis) and their degrees of clonal 
expansions as compared to the other six samples. Further determinations of those SchS 
patients likely to develop LPDs becomes trickier solely based on these datasets, although on 
comparison to the rest of the SchS patients, markedly reduced clonal expansions in samples 
15, 18 and 21 and the lack evidence suggesting LPLs upon BM histology, renders evolution 
to malignancy less probable. Nevertheless, evolution of a clone from any samples would not 











5.4.2.4 Chapter conclusions 
Using NGS technology and through bioinformatics analyses, the work in this chapter 
addresses the hypothesis that SchS is a clonal B cell disorder. The existence of a skewed 
CDR3 repertoire within each sample is highly suggestive of a clonal population of B cells. 
Though SchS exhibits abnormal CDR3 length distribution and preferential V, D and J segment 
usage and recombination, the absence of public CDR3 sequences could suggest that the 
monoclonal component produced by SchS is not directed at a sole antigen. The latter scenario 
is explored in the subsequent chapter through isolating the monoclonal component and 
exploring these SchS antibodies’ binding preferences. 
Taking the aforesaid perspectives into consideration, it is thus debatable as to whether SchS 
can be precisely defined as an oligoclonal or polyclonal disorder. Given the observation that 
20% of SchS patients go onto develop lymphoproliferative disease, it is credible to suggest 
that the evidence of clonality seen in SchS maybe representative of various stages of pre-
malignant transformation, co-existing with the ‘normal’ B cell repertoire. These pre-malignant 
B cell clones would then further require malignant transformation, an event that doesn’t occur 
in all SchS patients. Whether the aforementioned event is due to a genetic event (i.e. somatic 
mutation) or caused by an epigenetic defect remains to be investigated. Nevertheless, as 
carried out in other LPDs such as CLL, monitoring the expanded CDR3 clones over a 

















Chapter 6 Main Discussion  
The data and observations described are discussed in this chapter, with regards to the 
implications of these novel findings pertaining to the basic understanding of SchS 
pathogenesis. The wide breadth of investigations carried out in this work with a relatively 
significant number of SchS patients have extensively addressed ideas and notions described 
in the literature. The work presented in thesis has addressed the hypotheses below, with the 
rationale explained in detail within Section 1.9, Introduction. 
• SchS patients have mutations in the IL-1β /IL-18 molecular processing platform 
known as the NLRP3 inflammasome. 
• A proportion of SchS patients have the MYD88 L265P gain-of-function mutation. 
• Oligoclonal Haematopoiesis (OH) is a feature of SchS, evident through the presence 
of additional ‘passenger’ mutations associated with myelodysplastic syndromes 
(MDS).  
• Serum derived SchS IgM binds a common antigen. 
• SchS bears characteristics of a clonal B cell disorder. 
6.1 Main findings 
(1) NLRP3 activation-associated molecular markers (IL-18 and ASC specks) were 
found elevated in the serum of 19 SchS patients and whether NLRP3 mutations 
were a feature of SchS in a larger cohort of patients (n=32), was the next line 
of enquiry. Deep sequencing of this gene revealed no somatic variants, 
excluding the idea that such mutations would be responsible for SchS 
pathology.  
	
(2) The suggestion that the L265P MYD88 mutation would be present in SchS 
patients was initially postulated by De Koning et al in 2014 (20), and prior to the 
publication of this work in this thesis - this concept was not experimentally 
addressed. Nine out of 30 SchS patients tested were positive for this 
pathogenic mutation, emulating the percentage of those patients who go onto 





(3) The DNA from 30 SchS patients was subject to sequencing with a gene panel 
commonly used for the diagnosis of MDS using NGS. The results garnered from 
these explorations did not support the concept of CH in autoinflammatory 
disease, but rather underscored the incidence of age-related findings. An 
average of 1.3 somatic mutations are acquired per HSC every ten years, and 
the detection of HSC clones in those over 55 years is common (269). 
Considering the average age in the SchS and aNLRP3 patient cohorts was also 
55 years, there is a high likelihood that these outcomes are a consequence of 
ageing, rather than a mechanism pertaining to development of auto 
inflammatory disease.  
	
(4) The results of the array for all IgM samples demonstrated preponderance to 
nuclear located proteins such as histones, transcriptional regulators and 
splicing factors, however a common antigen was not detected amongst the 
three SchS patients.  
	
(5) Biased V, D and J segment usage and recombination followed by abnormally 
skewed CDR3 lengths is suggestive that the landscape of the B cell repertoire 
in SchS is indeed inclined to produce abnormal Igs. These findings are further 
extended through the assessment of expanded CDR3 aa sequences, with each 
sample demonstrative of CDR3 clonal expansion, though to varying degrees.  
	
 
6.2 Future Experiments  
6.2.1 Precise assessment of IL-1 and related cytokines 
As alluded to in the introduction section 1.2.7 and indeed demonstrated by the results in 
section 2.3, it is challenging to quantify levels of IL-1β partly due to its short half-life (88). One 
way to address this issue is to assess the levels of IL-1Ra or indeed the soluble receptor form 
of IL-1R1 as an indirect marker of IL-1β (90, 93). Whilst carrying out the aforementioned via 
several ELISAs would be one way to measure these markers in serum, qPCR would be a 




for example, would not only encompass those cytokines which largely remain endogenous – 
for example IL-1α, but also quantify those cytokines which are challenging to detect in serum 
(i.e. IL-1β). Other cytokines associated with SchS and autoinflammation (i.e. IL-18 and IL-18 
binding protein) could also be detected this way. For both described ELISA and qPCR 
experiments, obtaining samples before, after and during a flare would indicate the levels of 
the cytokine at different disease intervals.  
6.2.2 Screening for the MYD88 L265P mutation 
The results of the MYD88 L265P ASO PCR revealed that a third of the SchS cohort have this 
mutation. Interpretation of this feature as a precursor to developing WM, is substantiated by 
similar percentages of SchS patients developing such LPL’s. However, follow up of the MYD88 
positive subset of patients is necessary to validate this indication. Nevertheless, given the 
lengthy diagnosis period of SchS, averaging at five years, screening for this MYD88 mutation 
will certainly aid clinicians where SchS is suspected. Additionally, the presence of alternate 
activating MYD88 mutations in SchS is imperative to consider. High throughput sequencing of 
RNA revealed 8% of 155 ABC-DLBCL patients had one of the following somatic mutations: 
V217F, S219C, M232T, S243N or T294P (184). Subsequently, Treon et al and Varettoni et al 
discovered three out of the latter MYD88 variants present in approximately 5% of WM cases, 
who were negative for the L265P mutation upon primary screening (430, 431). Four of the 
mutants reside within the evolutionarily conserved ‘B-B loop’ of the TIR domain (shown to be 
important in TLR4/IL-1 mediated signalling), whereas the T294P mutation alters the conserved 
‘box-3’ region of the TIR domain, depicted to be also ‘important in IL-1 signalling’ (184). Given 
that such mutations are present in a relatively small proportion of patients with rare 
haematological malignancies, the proportion of SchS patients bearing these variants could be 
even lower. Even so, comprehensive analysis of the entire MYD88 gene may further reveal 
novel variants in addition to the ones described in literature, accounting the proinflammatory 
role of this protein in the context of autoinflammatory disease.   
 
 
6.2.3 The effect of IgM on SchS pathology 
SchS-IgM exposure to pyroptotic debris as a consequence of autoinflammation, could create 
feedforward loop of recognising self-antigenic structures causing further immune stimulation. 
One way to investigate the aforementioned suppositions could be through mimicking an in-
vivo pro-inflammatory environment through culturing SchS derived PBMCs and dosing in 




levels of proinflammatory cytokines (i.e. IL-6, IL-18) or via RT-PCR to determine if IgM 
application induces significant changes at the transcript level of inflammatory markers. 
Although not discriminatory in view of the binding preferences and the fact that IgM binds a 
wide range of epitopes, this approach would demonstrate the hypothesised, self-perpetuating 
inflammation. Certainly, anti-IL-1 treatment could break the supposed ‘cycle’ through reducing 
levels of IL-1, thus deregulating IL-6 and impeding further expansion of the B-cell clone. This 
is supported by the observation that IgM levels tend to remain steady during the course of 
disease in those SchS patients who do not develop LPDs (22, 26, 39).  
 
6.2.4 Follow up of VDJ usage and CDR3 aa expansion  
The clonal discrepancies seen among the SchS patients could be influenced by recent 
antigenic exposure or age-related immune decline, extensively reported in literature (329, 432, 
433).  Conversely, these findings may represent different stages of malignant transformation, 
with the aforesaid speculations necessitating longitudinal patient follow up. Through 
comparison of the data presented in Chapter 5 with analogous data sought in those who go 
on to develop LPD, would specifically reveal those VDJ gene segments preferentially used 
and show the expansion of particular CDR3 aa clones. Analysis of paired sample data, 
alongside IgH repertoire sequencing of sorted B-cells (i.e. naïve, memory, plasmablast, 
plasma), would precisely enable identification of the clonal origin of the malignantly 
transformed cells and hence implicate the cell type responsible for generation of the 
monoclonal gammopathy in SchS. For example, the IgM monoclonal component in MGUS 
has been identified to originate from CD20+ lymphoplasmacytic cells with the CD19+/CD20+ 
and CD25+ phenotype determined as the origin of WM (434, 435). Defining the same in SchS 
and subsequently quantifying BM infiltration of those particular cells is a supplementary means 
to monitor progression to LPDs. SchS patients showing a BM infiltration of >10% those cells, 
and/or demonstrate a mutation associated with haematological malignancy, are more 
susceptible to LPD development. This proposal is based on the follow up of five SchS patients 
who progressed to WM exhibiting over a 10% BM infiltrate of lymphocytes (436).  
 
6.3 Strengths and Limitations of this PhD project 
Access to a relatively large cohort of SchS patient samples formed the primary strength of this 
thesis, and in this regard all the investigations carried out are therefore ‘novel’. Each of the 




pathophysiology, with a capacity to impact both the clinical and scientific aspects of this rare 
indication.  
In a period where Whole Exome Sequencing and Whole Genome Sequencing are considered 
to be the ‘gold standard’ of genetic examinations, the cost, timing and applicability to this SchS 
cohort required deliberation. In view of the apparent heterogeneity of SchS, it is plausible to 
consider that screening the entire SchS exome or genome would demonstrate various 
mutations, a large proportion of which are unlikely to be SchS related. This body of work 
screened over 60 genes associated with autoinflammation, haematological malignancies and 
more specifically, MDS. Although extensive probing did not reveal a universal mutation, ruling 
out pathogenic variants within genes highly suspected of contributing to SchS pathogenesis 
is of great significance. For example, addressing the long standing stipulation that NLRP3 
mutations are causal of SchS, dismisses this notion in a relatively large group of patients and 
the focus of future genetic studies can be on other genes. 
SchS patients in general have a low percentage of monotypic B cells present within the BM, 
and this is likely to be reflected through a lower amount of circulating B cell clones. On this 
supposition, MYD88 L265P ‘mutation negative’ patients, may in fact be positive for the 
mutation, but could not be picked up through gDNA analysis. Nevertheless, the presence of 
the latter mutation in a subset of SchS patients is a novel finding, and screening for this variant 
can certainly corroborate a suspected diagnosis.    
The monoclonal component has not been the focus of previous SchS research to the extent 
and depth that this work has, despite many researchers theorising the generation and 
consequential effects of this Ig in SchS. The HuProt™ array targets 75% of the human protein 
coding genome, thus it is debateable as to whether the potential SchS target was in fact within 
the 25% of proteins not captured on this slide. Further, the assumption that the monoclonal 
component was in fact included within the isolation of total IgM cannot be ascertained, and 
thus the IgM isolated may not be fully representative of the SchS gammopathy. Nevertheless, 
the compelling evidence of skewed Ig repertoire sought through NGS of the IgH region, implies 
the presence of a monoclonal B-cell population. Highly expanded CDR3 aa sequences 
forming a substantial proportion of the total CDR3 repertoire was documented in each patient, 
though to different degrees. Although these findings may be suggestive of recent antigenic 
exposure or a feature of the ageing immune system, it is likely that the clonality detected is in 
part due to SchS combined with the transformation to haematological malignancy in a subset 








The work presented in this PhD thesis covered a broad range of well-regarded suppositions 
and theories based on previous experimental evidence and comparison to alike conditions in 
literature. The impact of these findings not only broadens the limited literature of this rare entity 
and but forms a point of reference for both clinicians and research scientists in the 
autoinflammatory disease field. Two publications were generated from this work thus far and 
each of the results chapters forms the foundation and further paves way for future research to 
be carried out. Continuing to establish both the genetic and molecular mechanisms causative 
of SchS as suggested will not only facilitate a streamlined diagnosis and but rapidly improve 





















Chapter 7                         Appendices 
7.1 Primer sequences 
7.1.1 Results Chapter 2 primer sequences  
Gene Primer 
name 















































Table 22: Primer sequences for NLRP3. 
Table 22 indicates the primer sequences used to generate PCR products for NLRP3. Primers 
were designed to cover the introns, exons, 5’ UTR and 3’ UTR, to encompass any mutations 















7.1.2 IgH sequencing primers 





IGHL 4 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCTGTGGTTCTTYCTBCTSCTGGTGG 
IGHL 5 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTCCTCCTRGCTRTTCTCCAAG 
IGHL 6 TCGTCGGCAGCGTCAGATCTGTATAAGAGACAGCTGTCTCCTTCCTCATCTTCCTGCC 
IGHJ GTCTGTGGGCTCGGAGATGTGTATAAGAGACAGCTTACCTGAGGAGACGGTGACC 
Table 23: List of primers used to amplify the IgH locus. 
Wobble bases follows the IUB code: S=C/G,  Y=C/T,  M=A/C,  R=A/G,  K=G/T,  W=A/T,  
B=C/G/T.  
	
7.2 Results Chapter 3 primer sequences 
7.2.1 ASO-PCR primer sequences for MYD88 
	
Reverse primer:                      5’ AGG AGG CAG GGC AGA AGT A  3’ 
Forward primer (Wild Type):   5’ GTG CCC ATC AGA AGC GCC T  3’ 













































Table 24: The panel of 28 MDS associated genes.	
Table 24 indicates the MDS associated genes included within the targeted sequencing panel, 
alongside the exon coverage and reference sequences. This sequencing work was carried 













7.3 Genes sequenced as part of the UCL panel 
This sequencing work was carried out at University College London for SchS patients 12-28 










Gene Gene Description Chromosomal location Transcript reference 
 AP1S3  adaptor-related protein complex 1, sigma 3 
subunit  
2q36.3  NM_001039569  
CARD14  caspase recruitment domain family, member 
14  
17q25  NM_024110  
IL10  Interleukin 10  1q31-q32  NM_000572  
IL10RA  Interleukin 10 receptor, alpha  11q23  NM_001558  
IL10RB  Interleukin 10 receptor, beta  21q22.11  NM_000628  
IL1RN  Interleukin 1 receptor antagonist  2q14.2  NM_173842  
IL36RN  Interleukin 36 receptor antagonist  2q14  NM_173170  
LPIN2  Lipin 2  18p  NM_014646  
LYN  Tyrosine-Protein Kinase  8q13  NM_002350  
MEFV  MEditerranean FeVer  16p13.3  NM_000243  
MVK  Mevalonate Kinase  12q24  NM_000431  
NLRC4  NLR family, CARD domain containing 4  2p22-p21  NM_021209  
NLRP12  NLR pyrin domain containing protein 12  19q13.42  NM_144687  
NLRP3  NLR pyrin domain containing protein 3  1q44  NM_001243133  
NLRP6  NLR family, pyrin domain containing 6  11p15  NM_138329  
NLRP7  NLR family, pyrin domain containing 7  19q13.42  NM_001127255  
NOD2  Nucleotide-binding oligomerization domain 2  16q12  NM_022162  
PLCG2  Phospholipase C, Gamma-2  16q24.1  NM_002661  
POMP  proteasome maturation protein  13q12.13  NM_015932  
PSMA3  proteasome (prosome, macropain) subunit, 
alpha type, 3  
14q23  NM_002788  
PSMB4  proteasome (prosome, macropain) subunit, 
beta type, 4  
1q21  NM_002796  
PSMB8  Proteasome Subunit, Beta-Type, 8  6p21.3  NM_148919  
PSMB9  proteasome (prosome, macropain) subunit, 
beta type, 9  
6p21.3  NM_002800  
PSTPIP1  Proline-Serine-Threonine Phosphatase 
Interacting Protein 1  
15q24-q25.1  NM_003978  
PYCARD  PYD and CARD domain containing  16p11.2  NM_013258  
RBCK1  Ranbp-Type and C3HC4-Type Zinc Finger-
Containing 1  
20p13  NM_031229  




7.4 Calculation of the frequency of CDR3 clones  
The following section details the CDR3 aa frequency calculations for the remaining 9 SchS 
patients corresponding to Section 5.3.5. 
 
7.4.1 10% B-cell assumption within gDNA 
Sample	14	
Total number of productive reads: 145,525 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.1 (10% assumption) = 3,400 B cells 
145,525/3400 = 43  (Equating to 43 reads per cell) 
Top CDR3 clone count: 9,460          9,460/43 =  220 
220 times this clone appears in a total of 3281 B cells* 
	
Sample	15	
Total number of productive reads: 131,436 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.1 (10% assumption) = 3,400 B cells 
131,436/3400 = 39  (Equating to 39 reads per cell) 
Top CDR3 clone count: 4,230          4,230/39 =  108 
108 times this clone appears in a total of 3215 B cells* 
	
Sample	16	
Total number of productive reads: 146,656 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.1 (10% assumption) = 3,400 B cells 
146,656/3400 = 43  (Equating to 43 reads per cell) 
Top CDR3 clone count: 12,498          12,498/43 =  291 









Total number of productive reads: 382,040 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.1 (10% assumption) = 3,400 B cells 
382,040/3400 = 96  (Equating to 96 reads per cell) 
Top CDR3 clone count: 12,236          12,236/96 =  258 
127 times this clone appears in a total of 3279 B cells* 
	
Sample	20	
Total number of productive reads: 133,271 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.1 (10% assumption) = 3,400 B cells 
133,271/3400 = 39  (Equating to 39 reads per cell) 
Top CDR3 clone count: 10,078          10,078/39 =  258 
258 times this clone appears in a total of 3322 B cells* 
	
Sample	21	
Total number of productive reads: 212,452 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.1 (10% assumption) = 3,400 B cells 
212,452/3400 = 62  (Equating to 62 reads per cell) 
Top CDR3 clone count: 48,205          48,205/62 =  778 
778 times this clone appears in a total of 3361 B cells* 
	
Sample	22	
Total number of productive reads: 568,651 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.1 (10% assumption) = 3,400 B cells 
568,651/3400 = 167  (Equating to 167 reads per cell) 
Top CDR3 clone count: 75,453          75,453/167 =  452 






Total number of productive reads: 415,622 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.1 (10% assumption) = 3,400 B cells 
415,622/3400 = 122 (Equating to 122 reads per cell) 
Top CDR3 clone count: 115,113          115,113/122 =  944 
944 times this clone appears in a total of 3282 B cells* 
	
Sample	25		
Total number of productive reads: 71,806 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.1 (10% assumption) = 3,400 B cells 
71,806/3400 = 21  (Equating to 21 reads per cell) 
Top CDR3 clone count: 13,404          13,404/21 = 638 
638 times this clone appears in a total of 3419 B cells* 
	
	
The theoretical number of B cells was estimated using the total number of productive reads 
and the assumption that 10% of the gDNA content comprised of B cells. This outlined 
estimation was applied to all 10 SchS patients. The calculations pertaining to sample 12 are 
detailed within the main body of text (Section 5.3.5).  
*The minor reduction in B cells was computed by the addition of all reads at a 1% assumption, 














7.4.2 1% B-cell assumption in gDNA 
	
Sample	14	
Total number of productive reads: 145,525 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.01 (1% assumption) = 340 B cells 
145,525/340 = 428  (Equating to 428 reads per cell) 
Top CDR3 clone count: 9,460          9,460/428 =  22 
22 times this clone appears in a total of 328 B cells* 
	
Sample	15	
Total number of productive reads: 131,436 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.01 (1% assumption) = 340 B cells 
131,436/340 = 387  (Equating to 387 reads per cell) 
Top CDR3 clone count: 4,230          4,230/387 =  11 
11 times this clone appears in a total of 321 B cells* 
	
Sample	16	
Total number of productive reads: 146,656 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.01 (1% assumption) = 340 B cells 
146,656/340 = 431  (Equating to 431 reads per cell) 
Top CDR3 clone count: 12,498          12,498/431 =  29 











Total number of productive reads: 328,040 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.01 (1% assumption) = 340 B cells 
328,040/340 = 964  (Equating to 964 reads per cell) 
Top CDR3 clone count: 12,236      12,236/964 =  13 
13 times this clone appears in a total of 328 B cells* 
	
Sample	20	
Total number of productive reads: 212,452 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.01 (1% assumption) = 340 B cells 
212,452/340 = 625  (Equating to 625 reads per cell) 
Top CDR3 clone count: 48,205          48,205/625 =  26 
77 times this clone appears in a total of 336 B cells* 
	
Sample	21	
Total number of productive reads: 216,294 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.01 (1% assumption) = 340 B cells 
216,294/340 = 636  (Equating to 636 reads per cell) 
Top CDR3 clone count: 4,873          4,873/636 =  8 
8 times this clone appears in a total of 329 B cells* 
	
Sample	22	
Total number of productive reads: 568,651 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.01 (1% assumption) = 340 B cells 
568,651/340 = 1672  (Equating to 1672 reads per cell) 
Top CDR3 clone count: 75,453          75,453/1672 =  26 






Total number of productive reads: 415,622 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.01 (1% assumption) = 340 B cells 
415,622/340 = 1222  (Equating to 1222 reads per cell) 
Top CDR3 clone count: 115,113          115,113/1222 =  94 
94 times this clone appears in a total of 328 B cells* 
	
Sample	25	
Total number of productive reads: 71,806 
200ng initial input = 200,000pg 
6pg/cell = 34,000 cells (approx.) 
34,000 * 0.01 (1% assumption) = 340 B cells 
71,806/340 = 211  (Equating to 211 reads per cell) 
Top CDR3 clone count: 13,404    13,404/211 =  64 
Answer: 64 times this clone appears in a total of 344 B cells* 
	
The theoretical number of B cells was estimated using the total number of productive reads 
and the assumption that 1% of the gDNA content comprised of B cells. This outlined estimation 
was applied to all 10 SchS patients. The calculations pertaining to sample 12 are detailed 
within the main body of text (Section 5.3.5).  
*The minor reduction in B cells was computed by the addition of all reads at a 1% assumption, 
however excluded those cells that had a read value of <1.  
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